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ABSTRACT
BCG is the only licensed vaccine against tuberculosis (TB), yet its protective 
efficacy is variable. Exposure to non-tuberculous mycobacteria (NTM) has been shown to 
render BCG less effective. It was therefore hypothesised that exposure to NTM in early life 
may attenuate the immunogenicity of BCG, and that regulatory T cells (Tregs) may 
contribute to this reduced response.
Neonates were recruited at birth (n = 103) and randomised to receive BCG vaccine 
at birth or at 414 months of age. Blood was collected at birth, 414- and 9- months of age and 
immune responses were assessed by flow cytometry and multiplex bead array.
Exposure to NTM prior to BCG vaccination elicited Thl and Th2 responses to 
PPD-tuberculin at 414 months, including IL-10 induction that was not observed in those 
vaccinated at birth. Higher IFNy production 414 months post vaccination was observed in 
children vaccinated at birth compared to 414 months of age. The results support the starting 
hypothesis and suggest that while FOXP3+ Tregs are not involved in the attenuated 
response, NTM induced IL-10-producing Tregs may be responsible for the reduced IFNy 
reactivity. Interestingly IL-13 was induced by BCG vaccination at both time points and 
was sustained until 9 months of age in those vaccinated at birth.
IFNy and IL-10 both correlated with tuberculin skin test (TST) reactivity. The data 
suggests that IFNy may initiate the response, but IL-10 controls the induration. It was also 
clear that higher ‘cut offs’ for the TST are more appropriate for defining possible M.tb 
infection in BCG vaccinated children in this environment.
Overall the results suggest that exposure to NTM attenuated the pro-inflammatory 
response when vaccination was delayed. Vaccination at birth induced a mixed Thl/Th2 
response at 414 months, but only the Th2 response was sustained at 9 months. Furthermore, 
IL-10 appears to play a critical role in regulating mycobacterial immunity.
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1.1 MYCOBACTERIUM TUBERCULOSIS
1.1.2 Epidemiology o f tuberculosis
Despite the introduction of vaccination against tuberculosis (TB) with a laboratory 
attenuated strain of M.bovis (Bacillus Calmette-Guerin vaccination (BCG)) in the 1920’s, 
transmission of Mycobacterium tuberculosis (M.tb), the causative organism of the disease 
has not yet been controlled. It is estimated that up to one third (2.2 billion) o f the world’s 
population may be infected with M.tb, (Sudre, ten Dam et al. 1992) and approximately 
10% of these cases will progress to clinical disease during their lifetime, resulting in an 
estimated annual death rate of 1.8 million worldwide. With the emergence of HIV 
infections and drug resistant M.tb, these figures are likely to increase.
1.1.3 Microbiology o f mycobacteria
M.tb is part of the genus Mycobacterium which are rod-shaped aerobic and non- 
motile bacteria (approximately 1 - 1 0  pm long) that are characteristically acid-alcohol fast, 
due to the high content of lipids comprised mainly of mycolic acid. Although considered 
Gram-positive bacteria with a peptidoglycan cell wall and lack of outer cell wall, Gram 
staining is negative due to the unique ‘waxy’ cell wall present in mycobacteria, and 
therefore this method cannot be used in diagnosis. The classical stain for mycobacteria is 
the Ziehl Neelsen stain with which mycobacteria stain bright red/pink (Shoub 1923). A 
natural division occurs between the slow growers (> 7 days per cell division) including 
M.tb, M. avium, M. bovis, M. marinum, M. africanum, M. kansasii, and M. intracellulare, 
and rapid growers (< 7 days per cell division) such as M. smegmatis and M. fortuitum. The 
pathogenicity of the various mycobacterial infections depends upon virulence factors that 
mediate survival inside the host. Those mycobacteria that cause tuberculosis form the M.tb 
complex and include M.tb, M. bovis, M. africanum and M. microti. Comparative genomics 
of the mycobacteria within the M.tb complex show that overlapping portions of the region 
of difference 1 (RD1) are absent from the M. bovis (BCG) attenuated strain (including
coding regions for early secretory antigen-6 (ESAT-6) and culture filtrate protein-10 (CFP- 
10)) suggesting that this region codes for important virulence factors (Mahairas, Sabo et al. 
1996; Behr and Small 1999; Behr, Wilson et al. 1999).
Non-tuberculous mycobacteria (NTM) cause neither TB nor leprosy, but they may 
cause pulmonary or disseminated disease similar to TB, particularly in the 
immunocompromised host (e.g. M. avium and M. marinum). In most parts o f the world TB 
is predominantly caused by M.tb, but in West Africa M. africanum causes almost half of 
the cases of pulmonary tuberculosis (Niobe-Eyangoh, Kuaban et al. 2003) and appears to 
have reduced virulence and T cell immunogenicity compared to M.tb (Mostowy, Onipede 
et al. 2004; de Jong, Hill et al. 2006). Recent studies have found 38% of all TB cases in 
The Gambia to be attributed to M. africanum, 63% of these were HIV-infected (de Jong, 
Hill et al. 2005). This preponderance of M. africanum associated TB disease in 
immunocompromised individuals suggests that M. africanum may be more like an 
opportunistic infection than M.tb, although disease severity is comparable (de Jong, Hill et 
al. 2005; de Jong, Hill et al. 2007).
1.1.4 Clinical pathology o f tuberculosis
Tuberculosis is an air-borne infection which is commonly transmitted through 
coughing, sneezing or spitting aerosol droplets containing the organism. Exposure in 10 - 
30% of contacts will lead to infection (Zhang 2008), and of those, 90% will become 
latently infected (LTBI) with the M.tb sitting dormant within macrophages (1995). The 
contained M.tb induce granuloma formation; a dynamic structure containing activated 
lymphocytes and continuously stimulated macrophages due to local tumour necrosis factor 
alpha (TNFa) production (Mohan, Scanga et al. 2001). Re-activation of M.tb occurs in 
approximately 10% of such latently infected individuals, often due to reduced 
immunocompetence from factors that include malnutrition, physical and mental stress, 
aging and immunosuppressive conditions (e.g. HIV) or therapies. Such individuals may
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progress quickly to symptomatic disease, with signs including persistent cough, weight 
loss and night sweats. The recommended standard treatment for M.tb is 2 months with 
rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E), followed by 4 months 
with RH alone. Unfortunately resistance to anti-tuberculosis drugs has become a major 
public health issue in recent years (CDC 2008). Multi-drug resistant TB (MDR-TB) is 
defined as resistance to R and H and extensively drug-resistant TB (XDR-TB) is resistance 
to 3 or more classes of second-line drugs (CDC 2008).
1.2 IMMUNE RESPONSE TO MYCOBACTERIA
1.2.1 Innate response
The immune response to mycobacteria involves both the innate and the adaptive 
arms of the immune system. Upon inhalation of M.tb the bacteria are phagocytosed, 
predominantly by alveolar macrophages, facilitated by a number of molecules including 
cholesterol (Gatfield and Pieters 2000) and mannose receptors that recognise the mannose- 
rich cell wall of the mycobacteria (Bonar, Chmiela et al. 2005). Interactions between the 
pathogen associated molecular patterns (PAMPs) found on the organism with pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs) on immune cells, initiate 
the innate immune response. Purified mycobacterial antigens preferentially interact with 
TLR2, possibly in combination with other TLRs. However, infection with whole bacilli 
evokes a more complex activation pattern involving at least TLR2 and TLR4 (Quesniaux, 
Fremond et al. 2004), although TLR1, 6, 8 and 9 have also been shown to be involved in 
M.tb recognition (Bulut, Faure et al. 2001; Bafica, Scanga et al. 2005; Davila, Hibberd et 
al. 2008). Control of infection is mediated by release of cytokines and chemokines that 
enhance recruitment of more leukocytes and activate phagocytosis of the mycobacteria, 
leading to engulfment within a phagosome. This phagosome fuses with a lysosome in the 
cell to form a phagolysosome containing microbicidal material including proteolytic 
enzymes, lysozyme and nitric acid. This combination of factors causes mycobacteria to be
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broken down, within the phagocytes and antigenic fragments of the pathogen are loaded 
onto the Major Histocompatibility Complex (MHC) class II molecules and presented to T 
cells at the surface of the macrophage. Infected macrophages and dendritic cells (DCs) 
secrete various cytokines including IL-12 which initiate the Thl immune response leading 
to increased IFNy production. Early and rapid production of IFNy from natural killer (NK) 
cells can initiate activation of macrophages. IFNy activated macrophages are thought to 
control the infection at the localised site, whilst phagocytic dendritic cells migrate to the 
lymph node in an IL-12p40 dependent manner (Cooper and Khader 2008) and present 
antigen to cells o f the adaptive immune system, polarising naive T cells towards a Thl 
response. In addition IFNy activated macrophages trigger TNFa production, increased 
antigen presentation, increased production of reactive nitrogen intermediates (RNI) such as 
nitric oxide (NO) and reactive-oxygen intermediates (ROI), all leading to effective killing 
of mycobacteria (Chan, Chan et al. 2001). NO is produced by macrophages in response to 
IFNy signalling from inducible nitric oxide synthase (iNOS) and has anti-mycobacterial 
properties in mice (Chan, Chan et al. 2001) but this is more controversial in humans. 
However, functional iNOS has been identified in the broncho alveolar lavage o f pulmonary 
TB patients (Nicholson, Bonecini-Almeida Mda et al. 1996), as has NO production from 
the exhaled air (Wang, Liu et al. 1998; Idh, Westman et al. 2008), suggesting that NO also 
plays a role in human disease.
IL-6 is also produced by macrophages and contributes to early M.tb immunity by 
promoting inflammation (Saunders, Frank et al. 2000) and Thl 7 T cell development in 
combination with transforming growth factor beta (TGFJ3) (Djoba Siawaya, Beyers et al. 
2009) (Awasthi and Kuchroo 2009). However IL-6 can also play an anti-inflammatory role 
by reducing the IFNy response from uninfected macrophages in mice (Nagabhushanam, 
Solache et al. 2003). The locally activated macrophages also produce the 
immunosuppressive cytokine IL-10, which contributes to reduced IL-12 production 
(Hickman, Chan et al. 2002). Thus, it is most likely that the balance between the virulence
18
of the pathogen and the quality and magnitude of the host response that determines disease 
susceptibility or resistance.
1.2.2 Adaptive response
Presentation on MHC class II molecules induces a CD4+ T cell response and 
polarisation towards a Thl, IFNy response as mentioned earlier. Enhanced microbicidal 
activity o f infected macrophages is predominantly mediated by this IFNy from CD4+ T 
cells (Flynn 2004). The role for CD4+ T cells in protective immunity to TB is highlighted 
by the susceptibility of CD4-gene depleted mice and HIV-infected individuals (Corbett and 
De Cock 1996; Caruso, Serbina et al. 1999; Flynn 2004). In addition CD4+ T cells appear 
to have M.tb-specific cytotoxic activity where restriction of M.tb growth is granule 
dependent suggesting CTL activity of CD4+ T cells may play a role in immunity to TB 
(Canaday, Wilkinson et al. 2001).
Other T cell populations can also be involved in the protective response including 
CD8+, CD 1-restricted T cells (invariant NKT cells) and gamma-delta (y8) T cells, the 
mechanisms of which are less clear (Kaufmann, Baumann et al. 2006).
An increasing number of studies have demonstrated the importance of CD8+ T cells 
in mycobacterial immunity through the production of protective cytokines such as IFNy 
and TNFa (Smith and Dockrell 2000; Kaufmann 2001; Kaufmann and McMichael 2005). 
CD8 T cells specific for epitopes in ESAT-6 and with cytolytic activity have been found in 
TB patients (Lalvani, Brookes et al. 1998). These CD8 T cells have also been found to 
localise to sites of infection (Caccamo, Meraviglia et al. 2006). Interestingly, studies in 
The Gambia have shown reduced perforin production from CD8+ and reduced cytotoxic T 
cell activity in TB patients (Smith, Klein et al. 2000) along with reduced IFNy and TNFa. 
The presence of IL-4 producing CD8+ T cells was only evident in the TB patients 
suggesting alteration in the Thl and Th2 cytokine balance in CD8+ T cells during TB 
disease (Smith, Klein et al. 2002). Although M.tb primarily resides in vacuoles, it has been
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proposed that antigens from M.tb reach the cytosol by escape of whole organism 
(McDonough, Kress et al. 1993), regurgitation of processed antigen (Pfeifer, Wick et al. 
1993), and/or movement of soluble proteins through pores within the membrane of TB 
phagosome (Mazzaccaro, Gedde et al. 1996; Cho, Mehra et al. 2000) which may explain 
the contribution of CD8 T cells in M.tb infection.
1.2.3 Cytokine responses
During M.tb infection and disease progression, signs of both activated and 
suppressive cytokine production are present highlighting the complexity of immunity to 
TB.
Thl cytokines
Human studies have shown that individuals with mutations in the genes that code 
for IFNy or the IFNy receptor (IFNGR) exhibit increased susceptibility to M.tb infection 
(Casanova, J et al, 2002)(Newport, Huxley et al. 1996) indicating the importance of this 
cytokine in anti-mycobacterial immunity.
However evidence in animals, and more recently in humans, suggest this may not 
be the case. Revaccination with BCG at 6 and 9 weeks in cattle induced increased IFNy 
and IL-2 cytokine responses to PPD, but these were associated with greater lung and 
lymph node tuberculosis lesions than those vaccinated once at birth although still less than 
the unvaccinated group (Buddie, Wedlock et al. 2003). Similarly a lack o f correlation 
between IFNy responses to PPD and protection against tuberculosis was found in the non­
human primate model (Langermans, Andersen et al. 2001). However mice studies have 
shown that limiting IFNy, or the repertoire of the IFNy-producing T cells, allows control of 
short term infection, but subsequent maintenance of control is lost suggesting that different 
protective mechanisms may be involved at different stages of infection (discussed in 
(Cooper and Khader 2008)). Recent studies have illustrated that many other cytokines have
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immunoregulatory roles in the control of infection (Dockrell 2007; Goldsack and Kirman 
2007). Goldsack et al presents evidence that memory CD4 T cells can protect against 
tuberculosis in the absence of IFNy and suggest IL-10 and regulatory T cells may be 
involved (Goldsack and Kirman 2007).
Thl 7 cytokine
IL-17 is a pro-inflammatory cytokine that is predominantly produced by Thl 7 
differentiated CD4+ T cells that develop in the presence of IL-23, although y8 T cells also 
produce IL-17 during mycobacterial infection (Lockhart, Green et al. 2006; Khader, Bell et 
al. 2007; Khader and Cooper 2008). TGFp together with IL-6 or IL-21 are required to 
initiate Thl 7 cells suggesting a link between the innate response and regulatory T cells 
(Awasthi and Kuchroo 2009). IL-17 is increased in IFNy deficient mice following 
infection with BCG, but these mice are unable to control infection suggesting that IL-17 is 
not required for protection (Cruz, Khader et al. 2006). In support of this, production of IL- 
17 was observed as a primary response to a known non-protective vaccine in mice, 
compared to a lack of IL-17 production to a protective vaccine (Romano, D'Souza et al.
2006). In contrast, IL-17 has been shown to have a role in the secondary response against 
TB in mice. Protection from a peptide-based vaccine was found to be dependent on IL-17 
production as part of a memory response, alongside a reduction in IFNy (Khader, Bell et al.
2007). Recently human studies have observed a reduction of IL-17 producing CD4+ T cells 
in the peripheral blood of TB patients compared to TB contacts further supporting the idea 
that IL-17 may play a role in protection against TB (Scriba, Kalsdorf et al. 2008; 
Sutherland, Adetifa et al. 2009). The concept of Thl and Thl 7 T cells both being induced 
by M.tb infection in response to IL-12p40 and IL-12p70 is discussed in the review by 
Cooper and Khader (Cooper and Khader 2008). The conflicting studies suggest that the 
timing of IL-17 and IFNy production e.g. as a primary or a memory response may be 
crucial to the type of immune response triggered and consequently the protective effect
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against TB.
Th2 cytokines
Th2 cytokines can play a negative role in M.tb infection (Seah, Scott et al. 2000). 
IL-4 can inhibit IFNy production in mice (Heinzel, Sadick et al. 1989) (Buccheri, Reljic et 
al. 2007). Indeed, IL-4'7' KO mice had substantially reduced infection in lungs and spleen 
for up to 8 weeks (Buccheri, Reljic et al. 2007). However, TB patients often exhibit both a 
Thl and a Th2 response to M.tb, which is not inconsistent with the classic Thl/Th2 
paradigm (Jung, Ryan et al. 2003) (Kidd 2003). IL-13 shares a receptor subunit with IL-4 
(IL-4Ra) and therefore the function of these cytokines is often linked. Indeed IL-13 
concentrations are increased in TB patients (Seah, Scott et al. 2000), and high levels are 
associated with a rapid response to TB treatment, suggesting a protective effect of IL-13 
(Djoba Siawaya, Beyers et al. 2009). The mechanism of action is not clear, but it may 
assist in preventing autophagic killing of M.tb in macrophages (Harris, De Haro et al.
2007).
Suppressive cytokines
One of the strongest inhibitors of IFNy is IL-10. In humans, elevated levels of IL- 
10 were observed in the serum of TB patients compared to contacts, and it was suggested 
that IL-10 may play a role in re-activation of TB (Verbon, Juffermans et al. 1999). IL-10 is 
produced from many cell types of both the innate and adaptive immune system, making it 
difficult to interpret the role of IL-10 in M.tb infection and disease. Increased IL-10 from 
macrophages is associated with an increased tendency to develop TB (Awomoyi, Marchant 
et al. 2002). Interestingly, T cell clones from broncho alveolar lavage fluid that expressed 
both IFNy and IL-10 have been observed, which might be important in balancing the 
immune response (Gerosa, Nisii et al. 1999). Interestingly human IL-10 was first cloned 
from an IFNy secreting T cell clone as cytokine synthesis inhibitory factor (CSIF) (Vieira,
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de Waal-Malefyt et al. 1991). Several studies have observed these Thl IL-10 secreting 
cells, and it has been suggested that IL-10 secreting antigen specific T cells may be 
activated later during infection after the initial pro-inflammatory IFNy response from the 
same cells (reviewed in (O’Garra and Vieira 2007)). M.tb can also induce production of the 
regulatory cytokine TGF{3 from macrophages, which in turn suppresses Thl responses 
during infection (Toossi, Young et al. 1995; Guyot-Revol, Innes et al. 2006). This may 
explain why IFNy production in PBMC cultures from TB patients can be enhanced by 
TGFJ3 inhibition (Hirsch, Ellner et al. 1997). TGFp induced in vitro following PPD 
stimulation can induce IL-10 production from monocytes and potentiate the 
downregulation of IFNy (Othieno, Hirsch et al. 1999).
Finally further studies have identified other cytokines that may play a role in the T 
cell mediated control of M.tb infection and disease including IL-27, IL-18 and IL-8 
(Yamada, Shijubo et al. 2000) (Wu, Huang et al. 2007), (Sutherland, Adetifa et al. 2009), 
reviewed in (Cooper and Khader 2008). However, the exact signature of biomarkers and 
the time such factors act to provide protection or susceptibility to disease remains to be 
fully elucidated.
1.3 ANIMAL MODELS OF M.TB
Host-pathogen interactions during M.tb infection are difficult to study in a human 
system, mainly due to difficulties accessing the site of infection and the complexity o f the 
disease process. The mouse is the most commonly used experimental animal model for 
many diseases including tuberculosis. The ability to access tissue sites of infection and the 
wide range of immunological reagents and transgenic animals available make the mouse 
ideal for mechanistic studies, although it is not necessarily the best model of M.tb. The 
mouse is not a natural host for M.tb and the course of infection is quite different to the 
human disease. Over the years a number of alternative animal models have been identified,
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all with advantages and disadvantages. The first stages of infection are similar in most 
models, but latency, granuloma formation, caseation of the granuloma, cavity formation 
and TB disease patterns vary (Figure 1.1). M.tb infection in mice does not lead to latency 
and granuloma formation, the guinea pig forms granulomas but does not enter a state of 
latency, and the rabbit harbours infected macrophages in granulomas leading to cavity 
formation but lack reagents and are expensive to keep (Capuano, Croix et al. 2003). Cattle 
are the natural host for a mycobacterial infection similar to TB (bovine tuberculosis) which 
develops with many of the key features of human TB. Calves are immunocompetent at 
birth and naturally sensitised to environmental antigens, which makes this model 
particularly useful for comparative human infant studies in geographical locations with 
high levels of NTM, however these models are expensive and the availability of reagents is 
limited (Buddie, Skinner et al. 2005). The zebrafish has provided a model that can be 
infected with M. marimim (a pathogen of ectoderms closely related to M.tb) leading to a 
similar course of infection and disease to human TB. Fish have a complex adaptive 
immune system akin to that of mammals and their transparency for the first three weeks of 
life means that it is possible to trace the migration of cells during development (Pozos and 
Ramakrishnan 2004). The non-human primate model of tuberculosis has also been used for 
many years, but the cost and biocontainment required have limited their use. Cynomolgus 
monkeys can be reproducibly infected with low doses of M.tb via a flexible bronchoscope 
leading to a disease very similar to that seen in humans including latent infection, 
granuloma and cavity formation (Capuano, Croix et al. 2003). With the advent of genomics 
and increasing bioinformatics expertise, mathematical models o f infection and disease 
have shown promise in furthering our understanding of the mechanisms of granuloma 
formation and TB disease (Morel, Ta'asan et al. 2006; Ray, Flynn et al. 2009). This 
approach could help to reduce the need for animal experimentation, and promote a more 
targeted approach to studying tuberculosis.
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Figure 1.1: Infection process o f Mycobacterium tuberculosis (M.tb). M.tb infection is 
initiated by transmission o f M.tb infected droplets by aerosol (I), 7 — 10 days later M.tb 
starts multiplying in macrophages (2), the lymphocytes are activated which activate 
macrophages and convert a tuberculin skin test to positive (3). Granulomas form that have 
a centre o f low pH and low oxygen which inhibits M.tb growth (4) and contains the M.tb in 
a state o f latency (5). The centre o f the granuloma can become necrotic and form the 
cheesy consistency described as caseation. Upon re-activation, M.tb multiplies in the 
centre o f the granuloma and leaks into the extracellular space, further multiplying and 
leading to cavity formation and dissemination o f disease (6). Diagrams obtained from 
(Janeway 2005).
1.4 IMMUNE EVASION BY M.TB
M.tb has co-evolved with its human host for thousands of years with the oldest 
human remains showing signs of M.tb infection being 9,000 years old (Hershkovitz, 
Donoghue et al. 2008). This has allowed ample time for M.tb to develop mechanisms to 
evade the immune response of the host (reviewed in (Flynn and Chan 2003)). These 
mechanisms are illustrated in Figure 1.2. As a pathogen that resides inside macrophages, 
the most obvious strategy has been to avoid destruction within the cell once it has entered, 
thereby allowing latency to be established. Murine studies have shown the importance of 
the nitric oxide synthase 2 (NOS2)-dependent pathway generating toxic RNIs as a method 
of controlling pathogens within macrophages. In iNOS /_ KO mice infection with M.tb is
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associated with a significantly higher risk of dissemination and mortality (reviewed in 
(Chan, Chan et al. 2001)). Removal of these RNIs using nitric oxide synthase inhibitor 
aminoguanidine after infection with a virulent strain o f M.tb resulted in susceptibility and 
reactivation of TB (Flynn, Scanga et al. 1998). Evasion of RNI toxicity has been shown in 
murine models to occur by the production of antioxidant products. In humans, it has been 
difficult to induce NO in many in vitro systems making it difficult to confirm the murine 
work. However, the presence of iNOS has been found in vivo in the human lung (Nathan 
2002) and alveolar macrophages (Nicholson, Bonecini-Almeida Mda et al. 1996; Wang, 
Liu et al. 1998) but it is unclear what RNI evasion strategies M.tb applies in humans. Both 
maturation of, and the environment within, the phagolysosome are altered by M.tb, 
affecting the phagosomal biogenesis and allowing the bacilli to avoid the normal 
antimicrobial effects (Russell 2001). Furthermore, IFNy induced MHC class II 
upregulation and thus presentation of antigen to the surface of macrophages is also 
inhibited by M.tb infection (Hmama, Gabathuler et al. 1998). This inhibition is controlled 
by a 19kD fraction of M.tb that acts via TLR2 pathway within the phagosome (Noss, Pai et 
al. 2001). However this 19kD protein can also induce Thl cytokine production associated 
with a good immune response. It is possible that these opposing effects occur at different 
stages of infection and that the inhibitory effect dominates during the chronic stages (Flynn 
and Chan 2003).
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Figure 1.2: A schematic summary o f mycobacterial infection o f macrophages.
Macrophages phagocytose mycobacteria inducing an innate response that includes TNFa, 
IL-12, IL-6 and IFNy production and recruitment o f other immune cells to the site o f  
infection. Mycobacteria are taken up into phagosomes that fuse with lysosomes forming a 
phagolysosome. The resulting M.tb epitopes are transported to the surface and loaded onto 
MHC class II molecules where they can initiate T cell activation. T cells then proliferate, 
produce cytokines and activate further macrophages. Induction o f suppressor cytokines act 
to balance the immune response and limit immunopathology. Mycobacterium tuberculosis 
(M.tb) uses various mechanisms to evade the pro-inflammatory immune response as 
illustrated in green. Blue arrows = activation, red arrows = inhibition, green arrows = 
M.tb evasion strategies. (Macrophage diagrams (Janeway 2005)).
1.5 PREVENTION OF TUBERCULOSIS
1.5.1 Bacillus Calmette Guerin (BCG) vaccine
BCG was first given as an oral vaccine for humans in 1921 to protect against 
tuberculosis. BCG consists of a live attenuated strain of Mycobacterium bovis that has been 
passaged a number of times over many years, but were originally maintained in Paris, 
France. The continual growth of these cultures has introduced various undefined genetic 
mutations and changed the activity and virulence of the vaccine to establish an attenuated 
form (reviewed in (Chen 2005)). In 1929, a tragic accident in Liibeck, Germany occurred 
when a virulent strain of TB was introduced into the vaccine and killed 29% of the 252 
children vaccinated (reviewed in (Chen 2005)). From this time onwards the oral vaccine 
was withdrawn from the market and replaced with the intradermal vaccination route still 
used today (Andersen and Doherty 2005). This method of administering BCG produced 
greater reliability and reproducibility than the oral vaccine although there may be 
differences in the responses. Oral vaccination induces both cellular and humoral mucosal 
responses (Monteiro-Maia, Ortigao-de-Sampaio et al. 2006) whereas this may not be the
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case with intradermal vaccination.
Distribution to several laboratories around the world has led to a number of 
different strains being maintained (reviewed in (Behr and Small 1999)) although today 
more than 90% of global BCG production is made up of either Russian BCG-1, Tokyo 
172-1, Danish 1331, Moreau RDJ or Pasteur 1173-P2 sub strain ‘seed lots’ maintained in 
several laboratories in lyophilised batches (Ho 2004).
BCG is administered according to WHO guidelines which differ according to 
geographical location. Several developed, low risk countries e.g. US and most of Europe 
do not vaccinate individuals with BCG unless they are part of a high risk population within 
the country. However, WHO recommends that in countries with a high risk o f TB, children 
should be vaccinated on first contact with a healthcare worker, most often at birth (WHO 
2004).
Protective effect o f BCG
The protective efficacy of BCG varies from 0-80%, which is highly associated with 
latitude (meta-analysis (Colditz, Berkey et al. 1995)). BCG efficacy against tuberculosis is 
poorer in vaccinated populations that live in rural areas closer to the equator than those 
further away or living in urban settings (Colditz, Berkey et al. 1995; Fine 1995). A high 
rate of protection (78%) was demonstrated in the UK amongst 14 to 15 year olds (Hart 
1967), whereas no protection against TB was observed in Malawian studies (1996). 
Nevertheless, although long term protection in adulthood may be poor, BCG is thought to 
provide good protective efficacy against extrapulmonary severe forms of TB in childhood 
(Sudre, ten Dam et al. 1992). Moreover, TB patients that have been previously vaccinated 
with BCG elicited healed localised pulmonary lesions, whereas unvaccinated TB patients 
had more disseminated lesions (Sutherland and Lindgren 1979). This would suggest that 
BCG reduces the incidence of disease, but does not prevent infection.
The largest trial of BCG efficacy took place in Chingleput, India in the 1970s, and
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showed very disappointing results (WHO 1979; 1980). The entire population of Chingleput 
of about 360,000 people were included in the trial. Two thirds were vaccinated with BCG 
(Danish and French) at two doses (standard 0.1 mg and low dose 0.01 mg) and the 
remaining third were not vaccinated. The incidence of infection was measured at baseline 
and at 2 follow up time points (6 months apart) and then at 2/4 year intervals. Although it 
was predicted that BCG would elicit 80% protection, after the fifth 2,/4-year follow up 
interval, there were similar numbers of TB cases among both the vaccinated and 
unvaccinated groups, although the incidence for both groups was lower than expected 
(Hitze 1980; Tripathy 1983). Several possible theories have been developed to explain 
these variable results which are reviewed in (Smith, Wiegeshaus et al. 2000). One theory 
that was proposed was that the high level of non-tuberculous mycobacteria (NTM) present 
in the environment may have provided a degree of protection in the unvaccinated group 
similar to that of BCG. Skin tests to PPD-B revealed that 95% of the population included 
in the trial were reactors to NTM suggesting there was no real placebo (1980).
Reasons for variability o f BCG protection
The reason for the variability of protection against TB across the world is still 
unclear but includes differences in the dose administered (Power, Wei et al. 1998), 
different strains of BCG (Lagranderie, Balazuc et al. 1996; Davids, Hanekom et al. 2006; 
Wu, Huang et al. 2007), the age at vaccination (Tripathy 1983) or methodological practices 
(Clemens, Chuong et al. 1983).
Effect o f NTM on BCG efficacy
However, one of the most widely accepted hypotheses is that natural immunity to 
NTM in the environment renders BCG less effective or masks its protective effect 
(Comstock and Palmer 1966; Rook, Bahr et al. 1981; Stanford, Shield et al. 1981; Smith, 
Wiegeshaus et al. 2000).
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A number of animal studies support this hypothesis: Mice exposed to M. avium 
complex prior to BCG vaccination showed inhibition of BCG bacterial growth in the lung 
and spleen, and inhibition of BCG specific immune responses by ex vivo IFNy ELISpot 
assay (Brandt, Feino Cunha et al. 2002). This led to the proposed mechanism that prior 
sensitisation to mycobacterial antigens may lead to rapid elimination of BCG before it can 
generate a protective immune response. Several murine and cattle studies also showed that 
pre-sensitisation with M. avium was associated with poor vaccine responses to BCG 
(Buddie, Wards et al. 2002; Young, Slobbe et al. 2007). Oral infection of mice with M. 
avium prior to BCG parenteral immunisation decreased IFNy secretion by splenic 
lymphocytes in response to overnight stimulation with PPD. This reduced IFNy response 
was evident when BCG was given at 16 weeks of age although only statistically significant 
after 24 weeks of pre-sensitisation. Interestingly pre-sensitisation with M. avium 16 and 24 
weeks prior to BCG vaccination increased IgGl and IgG2a PPD-specific antibody 
responses compared to the PBS sensitised group suggesting cross-reactive mycobacteria 
may imprint an inappropriate, type 2 response on the immune system which negatively 
influences subsequent responses to BCG vaccination (Young, Slobbe et al. 2007).
In contrast M. avium can prime the immune response of calves to BCG vaccination. 
Twelve weeks after M. avium sensitisation, cattle were vaccinated with BCG. Fourteen 
weeks after vaccination increased IFNy production in response to PPD-Z?ovw was observed 
in the sensitised group and appeared more rapidly than the BCG alone group, however the 
PPD-^ovw skin test reactivity was similar between the groups (Howard, Kwong et al.
2002). Similar findings in guinea pigs showed that BCG and MAI (M  avium- 
intracellulare) elicited similar levels of protection from low virulence strains of M.tb 
(Edwards, Goodrich et al. 1982). Interestingly, a study in cattle showed that 2/6 animals 
that had been pre-sensitised to M. avium, vaccinated with BCG 12 weeks later and then 
challenged with M. bovis at 24 weeks, had a positive tuberculin skin test (PPD-avium and 
bovis) at 36 weeks compared to 6/6 cattle that were not pre-sensitised but these animals
had fewer lesions and numbers of tissues containing viable M. bovis suggesting pre­
sensitisation with mycobacterial antigens primed the immune response and enhanced BCG 
protection from M.bovis (Thom, Howard et al. 2008).
In addition earlier guinea pig studies showed that exposure to NTM of various 
types (M. avium, M. kansasii and M. fortuitum) prior to BCG vaccination had no effect on 
survival after M.tb challenge (Palmer and Long 1966).
Human studies in Malawi suggested that in adults a good IFNy response to NTM 
was related to reduced BCG specific IFNy responses, and therefore most likely less 
protection against tuberculosis (Black, Dockrell et al. 2001). Infant studies in The Gambia 
showed that 22% of non-BCG vaccinated, non-TB diseased infants exhibited a positive 
tuberculin skin test (TST) of > 5 mm induration at 3 months (Ota, Goetghebuer et al. 
2006), suggesting priming by environmental NTM. Furthermore, good PPD-specific IFN-y 
responses were observed in vitro in BCG nai've 2 month old infants, albeit at significantly 
lower levels than those immunised with BCG at birth (Vekemans, Ota et al. 2004).
Effect o f age on BCG vaccination
As mentioned previously, in TB endemic areas WHO recommends that children 
should be vaccinated on first contact with a healthcare worker, most often at birth (2004). 
Despite the immaturity of the neonatal immune system, Weir et al have shown that 
vaccination at birth or during adolescence induces immunological memory to 
mycobacterial antigens 14 years after vaccination. However peripheral responses to PPD- 
tuberculin waned from 3 months to 12 months and from 12 months to 3 years post 
vaccination (Weir, Gorak-Stolinska et al. 2008). Strong Thl responses to PPD-tuberculin 
were also observed in Gambian infants vaccinated at birth that were similar to those seen 
in adults (Marchant, Goetghebuer et al. 1999; Vekemans, Amedei et al. 2001), and these 
remained present at 1 year although at a lower level than 2 months after vaccination 
(Marchant, Goetghebuer et al. 1999). Further details in relation to vaccination in early life
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will be discussed later.
BCG booster vaccination
Booster doses of BCG to augment the primary response have remained a 
contentious issue. A number of studies have failed to detect any protective effect of BCG 
revaccination (Sepulveda, Parcha et al. 1992; 1996; Chihota, Nyazema et al. 1998; Tala- 
Heikkila, Tuominen et al. 1998; Leung, Tam et al. 2001), although it has been shown to 
provide protection against leprosy (1996). It is assumed that the initial immune response 
prevents the booster vaccine to replicating in the host. However two studies from Eastern 
Europe conclude that revaccination with BCG may have some beneficial effects (Kubit, 
Czajka et al. 1983; Lugosi 1987). Interestingly, in cattle revaccination at 6 weeks 
following prior vaccination at birth reduced protection in calves, possibly by inducing pro- 
inflammatory immunopathology (Buddie, Wedlock et al. 2003). It may therefore be crucial 
to determine an appropriate time between vaccination and revaccination in order to 
optimise protection against TB. This may also be important when designing new vaccines 
using BCG as a vector (Kaufinann, Baumann et al. 2006).
1.5.2 Other vaccines fo r  prevention ofTB
The inconsistency of protection from BCG has led to further vaccines being 
developed that aim to replace the BCG or boost the BCG response. The leading TB 
vaccines are based on live mycobacterial vaccines largely by attenuating M.tb or modifying 
BCG, and subunit vaccines using a immunodominant viral vector or adjuvant to increase 
their immunogenicity (reviewed in (Andersen and Doherty 2005)).
One of the recombinant BCG vaccines expresses the listeriolysin O protein from 
Listeria monocytogenes (rBCGAUre:CHly+). The listeriolysin O protein damages the 
phagosomal membrane, allowing mycobacterial protein to be presented by MHC class I 
and permitting strong CD8+ T cells responses. This has exhibited better protection against 
virulent M.tb compared to BCG in the murine model (Conradt, Hess et al. 1999; Grode,
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Seiler et al. 2005). In September 2008, human Phase I trials in adults commenced in 
Germany.
Many of the vaccines being developed contain Ag85, an immunogenic antigen from 
M.tb. MVA-Ag85 is a live, recombinant, replication-deficient vaccinia Ankara virus, 
expressing Ag85. As BCG confers protection against disseminated disease in childhood (< 
10 years of life) removing it from novel vaccine strategies may not be appropriate. 
Therefore the BCG booster strategy has gained considerable interest in developing 
vaccines against TB. Phase 1 trials in mice of BCG prime followed by MVA-Ag85 boost 
resulted in stronger immunogenicity than BCG alone (McShane, Brookes et al. 2001). In 
addition, human Phase I studies found naturally acquired anti-mycobacterial immunity 
after vaccination with the same prime-boost strategy (McShane, Pathan et al. 2004). This 
vaccine is the most developed novel TB vaccine to date; it is currently in Phase Ha trials in 
a population of young infants in The Gambia (McShane, H and Ota, MO personal 
communication) and Phase lib trials of this vaccine have recently commenced (March 
2009) in South Africa with 2800 BCG vaccinated, 4 month old infants (McShane, H 
personal communication).
If BCG is to be used as a prime in many novel TB vaccine strategies it is important 
to understand its immunogenicity especially in a young population within a setting that is 
most likely to benefit from the new vaccine. As mentioned earlier, vaccination on a 
background of NTM exposure may influence vaccine efficacy. For this reason the testing 
of novel vaccines in a setting of high exposure to NTM is essential.
1.6 HYGIENE HYPOTHESIS
In a similar way that NTM may affect BCG vaccination it has been postulated that 
NTM may also play a role in the controversial ‘hygiene hypothesis’. Originally formulated 
by Strachan et al in 1989, it was proposed that a lower incidence of infection in early 
childhood could explain the rise in allergic diseases in the developed world and the lower
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incidence of allergy in developing countries with increased environmental microbial 
exposure (Strachan 1989). Rook et al proposed that exposure to mycobacteria with low 
pathogenicity, controlled by immunoregulatory mechanisms, may protect against later 
atopic disease (Rook, Hamelmann et al. 2007). This is supported by several studies 
showing an inverse relationship between atopic disorders and exposure to infectious 
pathogens in early life (Shaheen, Aaby et al. 1996; Matricardi 1997; Shirakawa, Enomoto 
et al. 1997; van den Biggelaar, van Ree et al. 2000). These studies include the effect of 
mycobacteria which can also be shown with BCG vaccination. Indeed, Aaby et al have 
shown that those with a BCG scar are less likely to have atopy than those without (Aaby, 
Shaheen et al. 2000). Defects in regulatory pathways in allergy and autoimmune diseases 
would support this idea. Suppression of allergen-induced eosinophilia in mice can be 
brought about by infection with M.tb (Erb, Holloway et al. 1998). In addition, vaccination 
with M. vaccae led to improved atopic dermatitis in children with moderate-to-severe 
disease (Arkwright and David 2001). The proposed mechanism behind this theory is based 
on the increased maturation of dendritic cells driving a suppressive Treg response 
(regulatory DCs), rather than a Thl or Th2 inflammatory response (Rook, Hamelmann et 
al. 2007). The possible regulatory mechanisms involved in the hygiene hypothesis are 
dicussed later in this chapter.
1.7 REGULATION OF IMMUNE RESPONSES
1.7.1 Regulatory T cells (Tregs)
Distinguishing ‘self from ‘non-self is tightly controlled in the thymus by negative 
selection, however self reactive T cells can escape this process requiring a second control 
mechanism. Suppressor T cells were first postulated in the 1970s (Gershon, Cohen et al. 
1972) as a mechanism to provide this tight regulation and prevent auto immunity. 
Difficulties with identifying and characterising these cells led to the demise of this area of 
research (Moller 1988) and it wasn’t until the mid-1990s that Tregs were identified as
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distinct populations (Sakaguchi, Sakaguchi et al. 1995). Most of the initial studies 
examined the role o f Tregs in autoimmunity, but later it became evident that Tregs were 
likely to be involved in all immune responses. A number of subsets of Treg populations are 
thought to exist, one of the most widely studied being those that possess the a-chain o f the 
IL-2 receptor (CD25) that are designated naturally occurring Tregs (nTregs) since they are 
derived from the thymus (Sakaguchi, Fukuma et al. 1985; Sakaguchi, Sakaguchi et al. 
1995). Adaptive or inducible Tregs (aTregs or iTregs) are peripherally induced in response 
to exogenous antigen, and are generally defined by their cytokine production (Groux, 
O’Garra et al. 1997).
Phenotype o f Tregs
Mouse studies indicate that the entire subset of CD4+CD25+ T cells have regulatory 
properties, but human Tregs are thought to be confined to the CD4+CD25hlgh subset which 
consists of ~ 5% of the total CD4+ T cell population, and frequently co-expresses other 
markers including intracellular CTLA-4, GITR, CD62L, neuropilin-1 and LAG-3 (Bruder, 
Probst-Kepper et al. 2004; Huang, Workman et al. 2004; Ochando, Yopp et al. 2005) 
(reviewed in (Wing, Fehervari et al. 2006)). To complicate matters CD25, and many o f the 
Treg markers described to date are also markers of T cell activation and therefore not 
specific to Tregs. FOXP3, a forkhead/winged-helix transcription factor is expressed in this 
population and natural mutations in this gene have been shown to cause uncontrolled 
activation o fT  cells and dysregulation of immune function in both mice (termed ‘Scurfy’ 
(Brunkow, Jeffery et al. 2001)) and humans (immune dysfunction, polyendocrinopathy, 
enteropathy, X-linked or IPEX (Bennett, Christie et al. 2001)). Nomenclature for FOXP3 
has been standardised to illustrate the human gene (FOXP3), the mouse gene {Foxp3) and 
protein expression from human and mouse (FOXP3) (Coffer and Burgering 2004). 
Expression of Foxp3 in transgenic mice and ectopic expression in human cells has been 
shown to induce regulatory activity (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003;
Fontenot, Rasmussen et al. 2005), and although the evidence suggests that expression of 
FOXP3 in any cell can confer suppressive activity, it has recently been shown to be 
upregulated upon activation (Gavin, Torgerson et al. 2006; Allan, Crome et al. 2007; 
Popmihajlov and Smith 2008) without inducing suppression (Morgan, van Bilsen et al. 
2005; Allan, Crome et al. 2007). However this is a transient effect, peaking within 24 - 48 
hours of polyclonal TCR stimulation in vitro (Gavin, Torgerson et al. 2006) (Morgan, van 
Bilsen et al. 2005), and returning to baseline levels by 5 - 10 days (Gavin, Torgerson et al. 
2006; Popmihajlov and Smith 2008). FOXP3 expression has also been identified in human 
CD8 T cells (Roncador, Brown et al. 2005) (Wang, Ioan-Facsinay et al. 2007) which also 
show suppressive activity (Bisikirska, Colgan et al. 2005; Morgan, van Bilsen et al.
2005)(Cosmi, L et al, 2003) and within CD4+CD25' T cells, possibly those committed to 
becoming Tregs (Morgan, van Bilsen et al. 2005). This evidence suggests that although 
FOXP3 is a good marker of suppressive Tregs, this marker cannot be relied upon to define 
Tregs. Combined gene expression microarray, flow cytometry and functional assays 
identified an inverse correlation between FOXP3 with the IL-7 receptor (CD 127) (Liu, 
Putnam et al. 2006). It was shown that CD4+CD127' T cells were as suppressive as the 
classic CD4+CD25high population, and at present CD4+CD25+FOXP3+CD127low is the most 
widely accepted phenotype for characterising nTregs.
Naturally occurring Tregs (nTregs)
Naturally occurring Tregs have the important function of preventing reactivity to 
both ‘self and ‘non-self antigens in an IL-2 dependent manner (Thornton, Donovan et al. 
2004). IL-2 is necessary for proliferation and full activation of the responder T cells, 
however the mechanism by which Tregs inhibit IL-2 production is not clear. The inhibitory 
effects of nTregs are thought to involve both direct cell-to-cell contact and indirect (via 
APC presentation) mechanisms in an antigen specific manner. Human CD4+CD25hl8h T 
cells exhibit suppression of proliferation of CD4+CD25’ T cells in direct cell contact-
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dependent manner or via the inhibition of DC function (e.g. via IL-10 or TGFp production) 
(Jonuleit, Schmitt et al. 2001; Ito, Hanabuchi et al. 2008; Vignali, Collison et al. 2008). 
Conflicting studies report on the involvement of IL-10 and TGFp in mediating the 
suppression by nTregs. Some studies have found blocking these cytokines did not affect 
the suppressive function of the nTreg. IL-10-deficient nTregs were found to be protective 
in the mice model of colitis, implying that IL-10 is not important in the anti-inflammatory 
activity o f nTregs in this model (reviewed in (Wing, Fehervari et al. 2006)). Although cell- 
to-cell contact is required for suppression, this may not involve APCs (antigen presenting 
cells) as regulation is apparent in APC free systems (Thornton and Shevach 2000). 
However it appears that DCs may be important for the homeostasis of nTregs. Suppression 
of nTregs is reversed by the stimulation of DCs with CpG via TLR9 which is thought to be 
partly dependent on IL-6 production (Pasare and Medzhitov 2003). Interestingly both 
human and murine nTregs have been shown to express granzyme A or B after activation 
and are able to kill other cells in a perforin-dependent way (Grossman, Verbsky et al. 
2004) although this is controversial and does not support the idea of reversible suppression 
of T cells. Once stimulated it is thought that nTregs can also have a bystander effect 
suppressing both CD4+ and CD8+ T cells responses non-specifically (Thornton and 
Shevach 2000).
In mice, adoptive transfer of CD4+ T cells depleted of CD25+ cells to athymic mice 
elicits a variety of autoimmune diseases, whereas co-transfer with CD4+CD25+ cells 
inhibited such disease development (Sakaguchi, Sakaguchi et al. 1995; Takahashi, 
Kuniyasu et al. 1998). Indeed the frequency and severity of autoimmune disease induction 
seems to correlate closely with the extent of the nTregs depletion (Ono, M et al, 2006).
Adaptive Tregs (aTregs or iTregs)
Adaptive Tregs are thought to be derived in the periphery from conventional T cells 
following antigen stimulation and are associated with production o f the suppressive
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cytokines IL-10 and TGFp (Trl and Th3 T cell subsets respectively) and a lack o f IL-2 
(Groux, O'Garra et al. 1997; Barrat, Cua et al. 2002; O'Garra, Vieira et al. 2004; Nicolson, 
O'Neill et al. 2006; Wakkach, Augier et al. 2008). Both Trl and Th3 T cells are thought to 
control specific autoimmune diseases in various murine models including colitis (Groux, 
O'Garra et al. 1997) and experimental autoimmune encephalitis (EAE) respectively 
(Weiner 2001). Interestingly, TGFp, in combination with IL-6, can induce Thl7 pro- 
inflammatory T cells with opposing effects to aTregs which may be important in the 
control of infection (Bettelli, Carrier et al. 2006). FOXP3 is generally associated with 
nTregs, but it can also be induced in conventional peripheral CD4+ T cells in situations o f 
low doses of antigen (Kretschmer, Apostolou et al. 2005) making the distinction between 
nTregs and aTregs difficult.
In addition to the Tregs described above, there is evidence for other regulatory T 
cells including CD8+ suppressor T cells that can secrete IL-10 or TGFp (Haynes, 
Vanderlugt et al. 2000; Garba, Pilcher et al. 2002), y5 T cells that suppress anti-tumour 
activity of CTLs and NK cells (Seo, Tokura et al. 1999), and NKT cells that secrete IL-10 
(Sonoda, Faunce et al. 2001).
1.8 ROLE OF TREGS DURING INFECTION
Controlling infection requires recognition of the pathogen and elimination by a 
series of controlled immune responses while limiting collateral damage from exuberant 
immune reactivity. Ideally, this would lead to immunity against subsequent challenge with 
the infection. At the same time micro-organisms would benefit from incomplete 
elimination for successful transmission. It is evident that Tregs play a significant 
regulatory role in control of the host pro-inflammatory response, thus limiting collateral 
damage, as mentioned in the previous sections. Many intracellular pathogens including 
leishmaniasis, malaria, HIV, TB and dengue fever (Belkaid, Piccirillo et al. 2002; Aandahl,
39
Michaelsson et al. 2004; Hisaeda, Maekawa et al. 2004; Mills 2004; Luhn, Simmons et al. 
2007; Scott-Browne, Shafiani et al. 2007) (reviewed in (Belkaid 2007)) have all been 
shown to be controlled by Tregs. Most of this work has been in mice, but more recent 
human studies suggest similar regulatory roles in human infections. Increased Tregs during 
infection is generally associated with suppressive cytokine production (IL-10 and TGFP), 
higher pathogen loads and persistence leading to chronic infection, whilst benefits for the 
host include reduced immunopathology from uncontrolled pro-inflammatory responses and 
prevention of autoimmunity (Boussiotis, Tsai et al. 2000; McGuirk, McCann et al. 2002; 
Couper, Blount et al. 2008).
In mice infected with herpes simplex virus (HSV), nTregs have been shown to 
protect against the development of virus-induced inflammatory lesions (Suvas, Azkur et al. 
2004). Chronic infection with Schistoma mansoni also illustrates the protective role of 
nTregs against immunopathology, as their removal increases damage to the liver (Hesse, 
Piccirillo et al. 2004). Tregs have been implicated in the immunological 
hyporesponsiveness associated with other chronic infections in humans including 
cytomegalovirus (CMV), hepatitis B virus (HBV), HIV, Chlamydia trachomatis, and TB 
(reviewed in (Belkaid 2007). The removal of which can induce protection from some 
pathogens. Plasmodium yoelii, a parasite strain responsible for lethal rodent malaria, is 
eradicated from the body after removal of nTregs (Hisaeda, Maekawa et al. 2004). In 
humans the removal of CD4+CD25+Tregs enhances in vitro proliferation and IFNy 
production in response to malaria antigens in blood from patients infected with 
Plasmodium falciparum (Walther, Tongren et al. 2005).
The role of Tregs in enhancing chronicity of infections is nicely illustrated in the 
Leishmania major murine model. Antigen specific nTregs (CD4+CD25+) accumulate in the 
dermis at sites of infection with L. major. These suppress IFNy production and the ability 
of effector T cells to eliminate the parasite from the host using IL-10-dependent and IL-10- 
independent mechanisms (Belkaid, Piccirillo et al. 2002). Re-infection at a distal site leads
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to immunity at the second site, but re-activation at the primary site. If anti-CD25 antibody 
is given intravenously prior to challenge, immunity is achieved in both sites, suggesting 
that re-activation is a result of the local immunosuppressive effect of Tregs at the original 
site (Mendez, Reckling et al. 2004). Functional Tregs (CD4+CD25+CTLA' 
4+FOXP3+GITRh ) were also found in the skin of human visceral leishmaniasis patients that 
were able to produce large amounts of IL-10 and TGFp, and suppress phytohaemagglutinin 
(PHA)-induced proliferation (Campanelli, Roselino et al. 2006).
In humans, HIV-specific nTregs from HIV infected individuals showed strong 
suppressive function in vitro that correlated with lower viraemia in plasma and higher 
CD4+ to CD8+ ratios (Kinter, Hennessey et al. 2004). In addition, individuals that are 
infected with hepatitis C virus (HCV) have a higher number of nTregs in the blood 
compared with uninfected individuals and depletion of these cells enhances antigen- 
specific CD8+ T cells responses in vitro (Sugimoto, Ikeda et al. 2003). The numbers of 
nTregs inversely correlate with liver damage suggesting the role they play in controlling 
inflammatory responses and liver damage (Bolacchi, Sinistro et al. 2006).
Naturally occurring Tregs can produce IL-10, as observed in the L. major model, 
but generally Trl aTregs are the source of IL-10. These develop from conventional T cells 
in certain conditions such as exposure to immature APCs, repeated exposure to antigen, or 
the presence of IL-10 itself. One of the earlier studies of antigen-specific IL-10-producing 
Trl cells, was in response to malaria antigens. Selected alternative peptide ligands (APL) 
of the immunodominant CD4 T cell epitope downregulated IFNy and proliferation, by 
preferential induction of IL-10 suggesting induction of Trl suppressor cells (Plebanski, 
Flanagan et al. 1999). Inducible antigen-specific Trl clones were generated in mice 
infected with B. pertussis (McGuirk, McCann et al. 2002), and isolated from humans with 
HCV (MacDonald, Duffy et al. 2002). The mouse study showed suppression o f Thl by 
Trl-cell clones specific for bacterial antigens, whereas the human study indirectly
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supported a role for IL-10 producing T cells by demonstrating increased IFNy production 
in vitro after addition of neutralising IL-10 antibodies.
FOXP3 can be induced by TGFp producing T cells, adding another level of 
complexity to the definitions of the Treg subsets. After experimental malaria infection of 
human volunteers, enhanced TGFp+ and FOXP3+Tregs were detected in the peripheral 
blood that correlated with faster parasite growth rates (Walther, Tongren et al. 2005). It has 
been proposed that the additional subset of induced FOXP3+ Tregs may be required in the 
gut to regulate between tolerance to commensal bacteria and immunity to invading 
pathogens (Belkaid 2007). This is supported by the observation that the gut is the main site 
where these converted cells have been found. After oral exposure to antigen (OVA), DCs 
from the lamina propria of the small intestine of lymphopenic mice were found to promote 
high levels of Treg conversion relative to lymphoid derived DCs. This was dependent on 
retinoic acid (RA; a vitamin A metabolite highly expressed in the GALT) in the presence 
of TGFp (Sun, Hall et al. 2007). This peripheral source of Tregs could be particularly 
important in long-term chronic conditions such as M.tb since thymic output is limited in an 
older age group and the nTreg supply is likely to decline.
1.8.1 Tregs and TB
Both nTregs and aTregs have a role in TB disease. IL-10 is involved in tuberculin 
skin test (TST) anergy, which is associated with poor prognosis by unknown mechanisms 
(Boussiotis, Tsai et al. 2000; Delgado, Tsai et al. 2002). IL-10 specific neutralising 
antibodies increase PPD-specific IFNy production by T cells from non-responders in vitro 
suggesting that Trl cells mediate T cell suppression in TB patients (Boussiotis, Tsai et al. 
2000). It is also clear that in mice foot pad swelling of a DTH response to PPD was 
reduced by abrogation of IL-10 (Nadler, Luo et al. 2003). TGFp has been shown to be 
secreted by M.tb infected macrophages (Othieno, Hirsch et al. 1999). Naturally occurring
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Tregs are also upregulated in patients with tuberculosis (Guyot-Revol, Innes et al. 2006; 
Ribeiro-Rodrigues, Resende Co et al. 2006; Chen, Zhou et al. 2007; Hougardy, Verscheure 
et al. 2007; Li, Lao et al. 2007) and depress immune responses to the protective heparin- 
binding haemagglutinin antigen (HBHA). Interestingly the latter study showed that this 
suppression was independent of IL-10 and TGFP (Hougardy, Place et al. 2007). 
Upregulated FOXP3 expression has also been associated with TB disease (Guyot-Revol, 
Innes et al. 2006; Burl, Hill et al. 2007). In one study M.tb latently infected subjects (PPD+, 
TST+, EC+) had a significantly lower FOXP3 mRNA levels than in both the controls 
(PPD+, TST', EC) and in the TB cases. It was speculated that the Tregs sequestered to the 
lungs during infection but active disease led to increased Tregs and migration in peripheral 
blood (Burl, Hill et al. 2007). This is supported by studies in mice and monkeys that have 
shown that Tregs proliferate and accumulate at sites of M.tb infection (Scott-Browne, 
Shafiani et al. 2007)(Green, A et al, personal communication).
Collectively these findings particularly support a role for IL-10 producing Trl T 
cells in the control and chronicity of mycobacterial infection and a possible role for 
FOXP3+Tregs.
1.9 VACCINATION AND TREGS
It is clear that regulatory T cells can control secondary responses to infections in 
both specific and non-specific manners. This would suggest that responses to vaccination 
could be affected by memory Tregs induced by vaccine specific or different microbes. In 
mice studies using a vaccine against L. monocytogenes, pre-existing nTregs restricted the 
magnitude of pathogen-specific CD8+ T cell responses upon secondary challenge with the 
bacterium or vaccine (Kursar, Bonhagen et al. 2002). Similarly depletion of nTregs using 
anti-CD25 antibody (resulted in 44 -  65% reduction in CD4+FOXP+ T cells) prior to 
vaccination with MVA-CSP malaria vaccine in mice enhanced IFNy responses, increased 
parasite control and more durable immunity (at least to 100 days when the effects of anti-
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CD25 would be eliminated) compared to vaccine alone (Moore, Gallimore et al. 2005). 
Interestingly, if vaccination induces a suboptimal response it can increase the likelihood of 
inducing Tregs, and on re-challenge these Tregs reduce the protective response. This has 
been clearly shown with the use of the Leishmania antigen LACK in mice vaccination 
trials. When used in conjunction with an adjuvant, protection was achieved, but the 
absence of adjuvant favoured the emergence of IL-10-producing regulatory T cells which 
predicted vaccine failure (Stober, Lange et al. 2005). However the induction o f the Tregs 
can also prevent immunopathology associated with vaccination. Thus, vaccination against 
B. Burgdorferi induces an osteoarthropathy which is reduced with the induction of nTregs 
(Nardelli, Burchill et al. 2004).
Early studies have found suppressor T cells induced by BCG vaccination in rats, 
that hamper efficient immunity upon revaccination but these were not defined as Tregs 
until later (Ha, Waksman et al. 1974). In addition, cell mediated immunity to BCG 
infection in mice is increased in IL-10 deficient mice, and these mice eliminate the bacteria 
more quickly than wild type mice (Jacobs, Fick et al. 2002). Furthermore, in mice, the 
level of Tregs prior to vaccination altered the Thl response to the BCG vaccine, but Tregs 
were not thought to be involved in protection from BCG vaccination (Quinn, Rich et al.
2008). Additional studies in mice (Quinn, McHugh et al. 2006; Li and Shen 2009) and 10 
week old human infants (Hanekom 2005) have shown an upregulation of FOXP3 Tregs but 
the role of Tregs in human BCG vaccination is not clear.
1.10 HYGIENE HYPOTHESIS AND TREGS
It has been postulated that Tregs play a role in the controversial ‘hygiene 
hypothesis’. Continuous exposure to harmless mycobacteria could lead to increased 
background levels of activated Tregs which have a non-specific bystander effect or 
dampen responses against ‘self such as in the gut. The increased numbers o f regulatory 
DCs lead to increased Tregs against ‘self, gut associated antigens and allergens
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downregulating autoimmunity, inflammatory bowel diseases and allergies (Rook, 
Hamelmann et al. 2007).
The interaction between dendritic cell and mycobacteria can occur via pathogen 
recognition receptors, such as the TLRs. Evidence for TLR modulation of allergy comes 
from experiments where administration of LPS (TLR4 agonist) in mice prior to allergen 
sensitisation suppressed IgE production, development of airway eosinophilia and Th2 
responses (Gerhold, Blumchen et al. 2002). In addition, polymorphisms of several TLR 
molecules have been associated with increased allergy (reviewed in (Gam and Renz 2007) 
and (Yang, Fong et al. 2006). Interestingly Tregs could also be modulated by PAMPs 
including those derived from M.tb (Caramalho, Lopes-Carvalho et al. 2003).
It is likely that cytokines play a role in polarising DCs and controlling allergy. 
Decreased IL-4 and IL-5 production from Th2 CD4+ T cells and increased IFNy from Thl 
T cells is associated with successful venom-specific immunotherapy (VIT) which induces 
tolerance to insect stings (Durham and Till 1998). It has also been found that IL-10 and/or 
TGFp Tregs are generated during the early stages of allergen-specific immunotherapy 
suggesting the involvement of Tregs in reducing allergy (Jutel, Akdis et al. 2003) 
discussed in (Jutel, Akdis et al. 2005)). The role of IL-10 has shown conflicting results 
with IL-10 polymorphisms found in those with asthma in addition to lower levels of IL-10 
in the bronchoalveolar lavage fluid (Borish, Aarons et al. 1996; Lyon, Lange et al. 2004). 
IL-10 is a potent suppressor of IgE and can skew the specific response from IgE to an IgG4 
dominated phenotype (Jutel, Akdis et al. 2005). However atopic dermatitis has been 
associated with increased IL-10 and IL-13 in the peripheral blood (Lee, Lee et al. 2000; 
Aleksza, Lukacs et al. 2002; Szegedi, Barath et al. 2009). Seneviratne et al showed that 
although IL-10 was induced by individuals with mild atopic dermatitis those with the more 
severe form had lower frequencies of IL-10 producing allergen-specific circulating CD4+ T 
cells compared to non atopic controls. This was accompanied by higher frequencies of 
TNFa, IL-4, IL-5 and IL-13 (Seneviratne, Jones et al. 2006). T cell involvement and in
particular the role of Th2 cytokines in atopic dermatitis are reviewed in Ogg, G (Ogg
2009).
BCG vaccination inhibits a de novo allergic inflammatory response in a mouse 
model of asthma, in association with increased CD4+CD25+ T cells and FOXP3 expression 
and increased IL-10 and TGFp expression (Li and Shen 2009), suggesting that Tregs 
induced by mycobacteria were responsible for suppression of this allergic disorder. 
Interestingly, IPEX patients that have dysfunctional FOXP3 expression are predisposed to 
dermatitis and food allergies linking the presence of Tregs to decreased allergy (Torgerson, 
Linane et al. 2007; Wan and Flavell 2007). BCG has also been shown to suppress Th2 
responses by altering the function of allergen-activated DCs to induce IFNy and IL-10 
producing Thl T cells (Yokoi, Amakawa et al. 2008). In the case of autoimmunity, a study 
in Argentina found that multiple sclerosis (MS) patients who developed parasite infections 
had fewer MS exacerbations than those that did not. Interestingly the parasite infected 
patients had an induction o f Tregs (CD4+CD25hlghFOXP3+) specific for myelin basic 
protein (MBP) (Correale and Farez 2007).
The age of exposure to mycobacteria appears to be significant in its ability to 
reduce atopy, since early life or even prenatal exposure result in the most pronounced 
effects. In a murine model, LPS applied to pregnant mice reduced the allergic response to 
OVA in the offspring with reduced levels of IgE, IgGl and IL-5 and IL-13 Th2 cytokines 
(Blumer, Herz et al. 2005). There are limited humans studies, but examination o f intestinal 
flora of children growing up in different allergy risk areas has shown different bacteria 
colonising the gut in the first year of life (Majamaa and Isolauri 1997). Administration of 
Lactobacillus rhamnosus GG (LGG)-containing probiotic formula given to neonates was 
shown to reduce the development of cow’s milk allergy (Majamaa and Isolauri 1997).
Although there is accumulating evidence to support the hygiene hypothesis, other 
studies fail to show these associations and suggest that the differences are due to host 
effects rather than causal effects between infection and atopy. Obhara and Bardin discuss
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the body of evidence relating to BCG vaccination and atopy in human studies. Their 
analysis found that 10 out of 23 published epidemiological studies showed an inverse 
relationship between BCG and atopic disease, but no relationship with geographical 
location (Obihara and Bardin 2008). In The Gambia no relationship between tuberculin 
skin test positivity (a measure of either pathogenic or non-pathogenic mycobacterial 
exposure or BCG vaccination in these children) and atopy (measured by response to at 
least one common allergen) was found (Ota, van der Sande et al. 2003). By contrast 
children living in more rural areas of the Gambia were more likely to be atopic (43% 
positive for at least one allergen tested) than in the urban areas (22%) (Ota, van der Sande 
et al. 2003). It was suggested that intense exposure to dust in these areas might lead to high 
exposure to the most common allergen causing asthma, the house dust mite. Important 
factors that may explain differences in the outcomes between these studies include 
heterogeneity in study design, variability in immunity to BCG, influence of other 
mycobacteria including dose and persistence of NTM, and simultaneous BCG and allergen 
exposure (Obihara and Bardin 2008).
Taken together Tregs (both naturally occurring and adaptive) are increasingly 
described to be participating in most immune responses in variable proportions to either 
the advantage of the host or pathogen. It is likely that the magnitude, and the timing of 
Treg induction are crucial in determining their benefit or otherwise to the host.
1.11 INFANT IMMUNOLOGY
Studying the development of infant immunity in humans is difficult for 
experimental, practical and ethical reasons and therefore many studies are based on the 
more easily available cord blood or detailed mouse studies. Immune development in mice 
and humans is similar in the sequence of events however the kinetics are quite different; in 
humans immunocompetent T cells are developed by mid-gestation and in mice maturity of
47
T cells occurs postnatally (Fadel and Sarzotti 2000). The neonatal period in humans is 
restricted to the first 28 days of life, after which it is defined as an infant; whereas for mice 
this period is less well defined and is described as the first 1-7 days of life (Fadel and 
Sarzotti 2000; Siegrist 2001). Since the 1980’s scientists have worked on designing mouse 
models o f the human immune system, often termed the ‘humanised mouse’. Although 
there are now many sophisticated humanised mouse models available (Legrand, Weijer et 
al. 2006) they still do not provide a realistic in vivo representation of immune development 
in humans, where environmental and genetic factors often play an important role. With this 
in mind, alongside the high levels of infant mortality worldwide, and the increasing 
number of vaccines that the infant’s immune system needs to deal with, it is imperative to 
study immune responses in human populations, particularly in high disease burden 
settings.
1.10.1 Maternal transfer o f immunity
During the first few months of life maternal antibodies that have transferred from 
the placenta during gestation protect the infant from micro-organisms to which the mother 
has immunological memory. However lymphocytes are not transferred in this way and 
therefore infants are susceptible to infectious diseases that require T cell mediated 
protection, in particular intracellular pathogens.
There is very little known about what antigens cross the placental barrier, but 
malaria studies have isolated parasites in cord blood and malaria specific IgM antibodies, 
an Ig iso type that does not cross the placenta (Malhotra, Ouma et al. 1997; King, Malhotra 
et al. 2002; Brustoski, Kramer et al. 2005; Brustoski, Moller et al. 2006; Malhotra, Mungai 
et al. 2006). Therefore it is not inconceivable that mycobacterial antigens may also cross 
the placental barrier, as indicated in a Kenyan study that examined in utero exposure to 
helminth and mycobacterial antigens (Malhotra, Ouma et al. 1997). In this study, cord 
blood from 30% of neonates responded to PPD after 3 days of culture producing 70 —
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2,000 pg/ml of IFNy. Helminth specific responses were also found in cord blood 
suggesting prenatal exposure to helminths and mycobacteria may lead to tolerance or 
altered foetal immunity (Malhotra, Ouma et al. 1997). Transplacental or in utero vertical 
transmission has also been demonstrated in various animal models of mycobacterial 
infection (Sweeney, Whitlock et al. 1992; Judge, Kyriazakis et al. 2006; Alinovi, Wu et al. 
2009; Singh, Sohal et al. 2009), although it is possible that the placental environment is 
quite different in cattle, goats and rabbits compared to humans.
Breast feeding can reduce the frequency and severity of gastrointestinal and 
respiratory infections in infants mainly due to the transfer of maternal humoral immunity 
in breast milk. Breast feeding can also enhance cell mediated responses to the mitogen 
PHA and tetanus toxoid up to 6 weeks of life (Stephens, Brenner et al. 1986). Interestingly, 
BCG responses were enhanced in breastfed infants vaccinated at birth, but not those 
vaccinated later than 1 month of life (Pabst, Godel et al. 1989). The extent of cell-mediated 
immunity transmitted through breast milk is unclear and several older studies give 
conflicting results. One study found PPD specific T cells in breast milk but no responses to 
PPD in cord blood suggesting the mycobacterial antigens from a PPD+ mother did not 
cross the placental barrier (Schlesinger and Covelli 1977), whereas others have found 
responses to PPD in cord blood of children exposed to PPD positive mothers, but no 
difference between those that were breast fed and those that were not (Keller, Rodgriguez 
et al. 1987) implying transplacental transmission of mycobacterial antigens but not via 
breast milk.
1.10.2 Tolerance
Increased susceptibility of neonates to infections has been proposed to be a 
consequence o f an immature immune system and induction of neonatal tolerance 
(Billingham, Brent et al. 1953). Mice injected with alloantigens at birth are rendered 
tolerant, but later in life the same encounter stimulates a strong Thl immune response
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(Billingham, Brent et al. 1953).
The process of T cell selection by clonal deletion occurs in the thymus to avoid 
reaction to ‘self. Those T cells with high affinity binding to ‘self antigens are removed by 
negative selection, while those with low affinity binding to antigens are eliminated by 
positive selection. The remaining T cells are released into the periphery and express a 
diverse repertoire of T cell receptors (TCRs) to foreign antigens (Burnet 1957; Sprent 
1995). Following this principle, antigens introduced early in life activate their specific T 
cells, causing them to get activated at a time that the host immune system is eliminating 
self-reacting cells, therefore these activated T cells are deleted without a deposit of 
memory. When such a host encounters the same antigen there is an anergic tolerogenic 
response. For example, infection of neonatal mice with lymphocytic choriomeningitis virus 
(LCMV) results in tolerance to infection (Evans, Borrow et al. 1994). A decreased ability 
to respond to certain stimuli in early life was supported by many studies, but in the late 
1990’s it became clear that neonates (both mice and humans) had the ability to respond to 
specific stimuli at a magnitude comparable to adults, but with a great deal of variability 
ranging from non-responsiveness to fully mature function. This appears to depend on many 
factors including quantity of functional immune cells present, type o f stimulus, antigenic 
dose and environment (Forsthuber, Yip et al. 1996; Adkins and Du 1998) (Marchant, 
Goetghebuer et al. 1999; Chipeta, Komada et al. 2000) (reviewed in (Adkins, Leclerc et al. 
2004)).
1.10.3 Cord blood studies
A large extent of what is known about early life immunology in humans has come 
from cord blood studies since large volumes are easily available and collection is non- 
invasive. Cord blood is often studied as a source of antigen naive T cells (CD45RA+/RO' 
/CD62L+) but this may not be as robust as once thought. Results from comparative studies 
between cord blood and adult peripheral blood are often conflicting and make it difficult to
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understand the true differences. Although the majority of T and B cells in cord blood are 
CD45RA+ (Szabolcs, Park et al. 2003), Byrne et al found that at least 25% of T cells from 
the cord blood of premature foetuses were CD45RO/RA" on both CD4+ and CD8+ T cells. 
The CD4+ population frequently expressed CD25+ (IL-2R alpha) and were able to 
proliferate in response to exogenous IL-2, however, in contrast to adults, they were 
unresponsive to mitogenic anti-CD2 or anti-CD3 antibodies suggesting anergic properties 
(Byrne, Stankovic et al. 1994). This compared to another study which showed that, 48 
hours after cord blood stimulation with anti-CD3 antibody, T celis expressed CD25 and 
proliferated in an IL-2 dependent manner. By 72 hours the cord blood T cells showed 
extensive apoptosis compared to adult cells, accompanied by increased CD95L expression 
although not mediated by the FasL pathway (Canto, Rodriguez-Sanchez et al. 2003).
This increased apoptosis along with increased proliferation compared to adults has 
been shown in several other studies of cord blood lymphocytes (Tu, Cheung et al. 2000; 
Yang, Hsu et al. 2001; Canto, Rodriguez-Sanchez et al. 2003; Szabolcs, Park et al. 2003; 
Kessel, Yehudai et al. 2006). Szabolcs et al found that the proliferating T cells still 
possessed a naive phenotype (CD45RA+/RO‘, CD69', CD25' and HLA-DR’), with an 
increased absolute number of T, B and NK cells in cord blood. CD8+CD57+CD28‘ 
‘suppressor’, CD8+CD45RA+CD27‘ ‘cytotoxic’ and the skin homing marker, cutaneous 
lymphocyte-associated antigen (CLA) were all absent among the T cells in cord blood 
(Szabolcs, Park et al. 2003). However, Keever et al found reduced numbers of NK cells 
and lower proliferative, stimulatory and cytotoxic activity for cord blood mononuclear 
cells compared to adult PBMC (Keever 1993). The progression of naive T cells to effector 
cells is dependent on the survival of antigen specific T cells and their resistance to 
apoptosis. This process of T cell maturation in cord blood has been linked to insulin-like 
growth factor 1 (IGF-1) which enhances the PHA-induced CD45RO+ T cells and reduces 
their susceptibility to apoptosis through IL-6 production (Tu, Cheung et al. 2000) (Law, Tu 
et al. 2008).
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1.12 IMMUNITY TO INFECTIONS IN EARLY LIFE
In human disease, malaria infected children less than 5 years of age have 
diminished Thl and Th2 malaria-specific responses compared to adults (Xainli, Baisor et 
al. 2002). However a study in Kenya showed similar responses to thrombospondin-related 
adhesive protein of Plasmodium falciparum (PfTRAP) peptide epitopes in both adults and 
children (Flanagan, Mwangi et al. 2003). In addition, adult level Thl responses can be 
induced by BCG vaccination in neonates (Marchant, Goetghebuer et al. 1999; Vekemans, 
Amedei et al. 2001; Hussey, Watkins et al. 2002). Thl and Th2 T responses to polyclonal 
TCR activation have also shown comparable profiles between cord blood and adults 
including IFNy, IL-12, TNFa and IL-10 production.
L I 1.1 Defects in adaptive responses in early life
Increased susceptibility to infection in neonates has been linked to a Th2 biased 
response and reduced cytokine production in response to inflammatory stimuli, rather than 
the inability of lymphocytes to proliferate (Krampera, Tavecchia et al. 2000; Smart and 
Kemp 2001). Production of IL-12 in neonates has been shown to be defective, a cytokine 
that plays a central role in Thl differentiation and production of IFNy (Goriely, Vincart et 
al. 2001). Another study found changes in transcriptional regulation of the IFNy promoter 
caused reduced IFNy production from CD4 T cells, but not CD8 T cells, in neonatal naive 
cells (White, Watt et al. 2002). Despite the T cell tolerance and anergy described in 
neonates characterised by Th2 development and lack of cytotoxic T cells (CTL), strong 
CTL function has been detected in human infants with the congenital CMV infection, 
demonstrating that mature CTL activity is possible in early life (Marchant, Appay et al. 
2003). Interesting studies in mice have shown that T cells from neonatal mice that are 
susceptible to Pneumocystis carnii-induced pneumonia can resolve infection when 
transferred into adult mice, suggesting the defects are not inherent within the T cell but
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may be related to the cytokine milieu (Qureshi and Garvy 2001). The mechanism of the 
Th2 skewing observed in many neonatal responses may be explained by increased 
susceptibility of neonatal memory T cells to apoptosis after re-exposure to antigen (Li, Lee 
et al. 2004).
Differences between neonates and adults have been shown for B cell function 
(reviewed in (Adkins, Leclerc et al. 2004)). Neonatal antibody responses are delayed in 
onset, reach lower peak levels, are o f shorter duration, differ in IgG2 distribution in 
humans and are of lower affinity and reduced heterogeneity than adult responses. In 
humans, the reduced antibody responses are thought to be partially due to the presence of 
maternal antibodies, and may contribute to the higher vaccine failure rates observed in 
young infants. This reduced antibody function is not associated with intrinsic B cell 
defects, but is likely to be due to limited development of the B cell compartments and/ or 
colonisation of plasma cells in the bone marrow (Adkins, Leclerc et al. 2004).
1.11.2 Defects in innate responses early in life
Less is known about the neonatal innate immune response, but several studies have 
shown that neonatal dendritic cells have an inability to deliver signals required for the 
polarisation of immune responses towards a Thl pro-inflammatory protective response 
(Trivedi, HayGlass et al. 1997; Delespesse, Yang et al. 1998). IL-12 derived from DCs 
plays a role in both the innate and the adaptive response. It has been observed that 
neonatal dendritic cells do not respond well to TLRs, leading to defective production of IL- 
12 (Levy, Zarember et al. 2004; Krumbiegel, Zepp et al. 2007). However, it is interesting 
to note that TLR8 and the dimer TLR7/8 can induce a mature response in cord blood with 
production of TNFa and IL-12/IL-23 as well upregulation of CD40 by neonatal DCs 
(reviewed in (Levy 2007). Increased B cell production of IL-10 has also been associated 
with reduced IL-12 production from dendritic cells, and may contribute to this defect (Sun,
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Deriaud et al. 2005).
It is also evident that neonates have a reduced number of granulocyte and monocyte 
progenitor cells which can lead to a reduction in neutrophil numbers during stress 
conditions. The neutrophils have also been shown to be functionally defective with an 
inability to migrate to sites o f inflammation and contribute to an overall ‘normal’ immune 
response (Carr, R 2000). Defects in neonatal immune cells may also be controlled by the 
physiological environment. Human neonatal cord blood mononuclear cells contain 
increased concentrations o f cyclic adenosine monophosphate (cAMP) compared to adults 
which can lead to an inhibition of IFNy and IL-12 while enhancement of cytokines such as 
IL-6, IL-10 and IL-23 (Schnurr, Toy et al. 2005). By contrast, certain cytokines such as IL- 
6, IL-10 and IL-23 have all been shown to be produced in greater quantities from neonatal 
monocytes and antigen presenting cells (APCs) than in adults (Angelone, Wessels et al.
2006) (Chelvarajan, Collins et al. 2004; Vanden Eijnden, Goriely et al. 2006).
It is therefore evident that neonatal responses in cord blood are different to those of 
adults, often leading to poorer CD4 and CD8 T cell function as a result of suboptimal 
antigen presenting cell-T cell interactions. However in certain conditions adult-like T cell 
responses can be induced thus overcoming these deficiencies.
1.13 VACCINATION IN EARLY LIFE
Due to the above deficiencies in the maturity of the immune system, several doses 
of vaccines are often needed to be given to young children to achieve protective levels of 
antibodies. The earlier in life infants are vaccinated, the poorer and more short-lived their 
antibody responses are, irrespective of the protection from maternal antibodies (reviewed 
in (Siegrist 2001)). However, vaccinating later in childhood exposes the child to a window 
of susceptibility to childhood infections at a time when the child is most vulnerable. 
Induction of significant primary IgG responses to vaccines can occur at >2 months of age,
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but persistence and adult-like levels are normally not possible until >12 months of age. 
Furthermore, the protein and polysaccharide based vaccines are generally unable to induce 
protective responses until >18 months of age (Siegrist 2001). Lower IFNy responses are 
associated with higher antigen specific T cell derived Th2 responses, weaker induction of 
IgG2 antibodies and limited cytotoxic T cells following early life immunisation, however 
most of this work is in mice (reviewed in (Siegrist 2001)). Despite these shortcomings, it 
is still important to prime the immune response at an early age. Oral polio vaccine (OPV) 
given at birth elicits a weak primary response in humans, but an increase in antibody levels 
to the second dose compared with unprimed infants (Dong, Hu et al. 1986). Interestingly in 
mice, neonatal Thl responses are generally transient with a largely Th2 secondary memory 
responses. It has been suggested that these initial Thl T cells are more susceptible to 
apoptosis (Singh, Hahn et al. 1996; Adkins and Du 1998).
Despite this, Thl responses to PPD similar to those seen in adults were observed in 
response to BCG vaccination in Gambian infants at birth (Marchant, Goetghebuer et al. 
1999; Vekemans, Amedei et al. 2001), and these remained present at 1 year although at a 
lower level than 2 months after vaccination (Marchant, Goetghebuer et al. 1999). This is in 
contrast to unvaccinated individuals whose primary responses to PPD were predominantly 
Th2 biased (Marchant, Goetghebuer et al. 1999; Vekemans, Amedei et al. 2001). In 
addition, BCG vaccination also induces a cytotoxic CD8 response in neonates that, 
although not as strong as the CD4 response, may also contribute to protection of BCG 
(Hussey, Watkins et al. 2002; Murray, Mansoor et al. 2006). Recent studies in South 
Africa showed in vitro IL-12, IL-10 and IFNy production in response to BCG was 
predominantly from innate cells at birth, including monocytes and NK cells, but was T cell 
derived by 13 weeks after BCG vaccination suggesting an innate response may play a role 
in protection against mycobacterial infections in early life (Watkins, Semple et al. 2008).
The extent to which maternal antibodies influence vaccine responses is not clear 
with some vaccines being inhibited, but others showing no influence at all, but induction o f
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T cell responses largely remain unaffected by these passively transferred antibodies 
(reviewed in (Siegrist 2003).
1.14 TREGS IN EARLY LIFE IMMUNITY
It has been long been known that neonatal thymectomy in mice leads to an 
increased incidence of autoimmune disease which can be prevented by infusion of adult 
Tregs (Suri-Payer, Amar et al. 1998). T cells with regulatory or suppressive phenotypes 
(CD4+CD25hlgh) have been identified during foetal development (Byrne, Stankovic et al. 
1994; Cupedo, Nagasawa et al. 2005; Darrasse-Jeze, Klatzmann et al. 2006; Michaelsson, 
Mold et al. 2006) and are thought to be essential in early life as part of immune tolerance 
to self antigens. Interestingly CD4+CD25hlgh Tregs appear to be detected at greater 
frequencies during gestation than at birth suggesting a role in intrauterine immune control 
(Takahata, Nomura et al. 2004). Interestingly a recent study showed that the transfer of 
maternal cells across the placenta induced CD4+CD25hlghFOXP3+ Tregs that suppressed 
foetal anti-matemal immunity, and persisted until at least early childhood (Mold, 
Michaelsson et al. 2008).
There are conflicting studies regarding the levels of Tregs in cord blood which may 
in part be due to the definitions used and assays performed. Many studies have suggested 
umbilical cord blood (UCB) has a greater percentage of CD4+CD25hlgh (5.1%) cells than 
adults (1.4%)(Wing, Ekmark et al. 2002) but this is in contrast to several other studies 
where similar numbers of CD4+CD25+Tregs (or CD4+CD127lowCD25+) were observed in 
cord blood (Takahata, Nomura et al. 2004; Santner-Nanan, Seddiki et al. 2008). However 
there is generally agreement that cord blood Tregs are of a more nai've phenotype 
(CD45RA+) compared to adults (Wing, Ekmark et al. 2002; Takahata, Nomura et al. 2004). 
The phenotype of cord blood CD4+CD25++ Tregs from Wing et aV s study were 
predominantly CD69', CD62Lbright, CD38bright, CD152+ (CTLA-4) and CD122+, with half 
the population being CD45RA+. In contrast only 10% of adult Tregs were CD45RA+. It
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was proposed that naturally occurring Tregs leave the thymus in a nai've state and become 
activated in the periphery (Wing, Ekmark et al. 2002).
Functional Tregs have been isolated in the neonate (Ng, Duggan et al. 2001; Wing, 
Ekmark et al. 2002; Takahata, Nomura et al. 2004; Godfrey, Spoden et al. 2005), where 
their suppressive function is equivalent to the suppressive activity o f adult CD4+CD25+ 
Tregs. It is most likely that in addition to controlling responses to self, these play a key role 
in the development of immune responses to foreign antigens and pathogens.
In addition to CD4+ Tregs, recent reports implicate key roles for CD8+ Tregs in 
neonatal life. CD8 Tregs have been found to down regulate Th2-induced pathologies, 
escaping neonatal tolerisation (Field, Caccavelli et al. 2003). The role of CD8+ Tregs in 
response to vaccines is not yet known.
Control of the immune response is vital for the maintenance of health. Regulatory T 
cells are likely to be involved in many aspects of this control including responses to 
infections. It is likely that similar processes are involved in memory responses to 
vaccination and it is therefore important to consider the contribution of Tregs to protection 
by vaccination, especially in young children who receive numerous vaccines in early life 
and may have different immune responses than adults.
1.15 HYPOTHESIS
It was proposed that exposure to NTM early in life induces regulatory T cells that 
attenuate responses to BCG vaccination, and that this might account for the poorer 
immunogenicity of BCG vaccine in countries with high levels of NTM in the environment, 
as illustrated in Figure 1.3.
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Figure 1.3: Proposed model o f BCG vaccination with respect to non-tuberculous 
mycobacteria (NTM) exposure. In areas o f high exposure to NTM memory T cells specific 
for mycobacterial antigens are induced particularly regulatory T cells that would control 
the response to NTM specific antigens. On vaccination with BCG, that contains many 
similar antigens to NTM, a reduction in the pro-inflammatory (IFNy) protective response 
o f the vaccine is observed in areas with previous high exposure to NTM compared to that 
from a low exposed setting. It is hypothesised that is this is due to the level o f 
mycobacterial specific Tregs that are present prior to vaccination. Blue cells represent 
effector memory T cells and green/yellow cells represent memory Tregs.
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CHAPTER 2 
Materials and Methods
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2.1 STUDY DESIGN
The study was approved by the MRC Scientific Co-ordinating Committee (SCC), 
the Gambian/MRC Research Ethics Committee and the London School of Hygiene and 
Tropical Medicine Research Ethics Committee.
Neonates were recruited at birth from the Sukuta Hospital with parental consent, 
and randomised into two groups according to BCG vaccination schedule;
-  Group 1 were vaccinated with BCG at birth (or within 1 week)
-  Group 2 were BCG vaccinated at 4Y2 months of age
Live, attenuated BCG vaccine (BCG Moscow strain (Mostowy, Tsolaki et al.
2003), Serum Institute of India Ltd, India, donated by UNICEF) was reconstituted using 
the accompanying vial of sodium chloride as per manufacturer’s instructions and 50 pL 
was injected intradermally into the deltoid region of the left arm (each 0.1 mL contained 1 
- 33 x 105 CFU) (Figure 2.1 A). This BCG Moscow strain was typed by Dr Peter Keller, 
Institute of Medical Microbiology, IMM, Zurich, Switzerland. According to phylogenic 
analyses BCG Russia is an ancient strain most closely related to parental M.bovis (Keller, 
Bottger et al. 2008).
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BFigure 2.1: Group 1 study participant being vaccinated with BCG (A) and being weighed 
as part o f the monthly follow up (B)
All other vaccines were administered according to the National Expanded 
Programme of Immunisation (EPI) schedule (Table 2.1) by MRC field worker nurses in 
order to ensure venesection for this study occurred at least 2 weeks post vaccination.
At birth 1 month 2 months 3 months 4 months 9 months >12 months
BCG
Hepatitis B Hepatitis B Hepatitis B
OPV OPV OPV OPV OPV (or
later)
DTwP DTwP DTwP
Hib Hib Hib
Measles
Yellow 
fever
BCG = Bacillus Guerin Calmette 
OPV = oral polio vaccine
DTwP = Diphtheria, tetanus, whole cell pertussis combined vaccine 
H ib =  Haemophilis influenza type B
Table 2.1: Extended Programme o f Immunisation (EPI) recommended schedule fo r
OPV (18 m)
DTwP 
Hib (16 m)
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vaccination o f Gambian infants
The randomisation was stratified for every 20 subjects. HIV status of the 
participants was not assessed; previous reports from The Gambia have found 2.4% HIV 
infection in adults (aged 15 — 49) and an estimated 1,200 children (aged 0 —14 years, 0.1% 
of population) living with HIV (UNICEF 2005) suggesting that it is unlikely that any of 
the children in this study would be HIV+. The study subjects were healthy babies, matched 
by age and socio-economic background, predominantly Mandinka in ethnicity and equal 
numbers were recruited through wet and dry seasons from June 2006 to August 2007.
Exclusion criteria included:
1. Birth weight < 2.5kg
2. Twins (to avoid genetic bias)
3. Any symptoms of intercurrent infection
4. Exposure to TB within their household or close contact with a TB case at 
time of recruitment
5. Any likelihood of long term travel out of the area within the 9 months of the 
study period.
As first contact with pregnant mothers is often on arrival at the maternity clinic 
during labour, verbal consent was taken in order to collect the cord blood at birth. Written 
consent was then obtained after birth when the fieldworker was able to discuss the details 
of the study with the mother. Only after written consent was obtained, were the cord blood 
samples processed in the laboratory. If the mother declined to participate in the study then 
the cord blood samples were destroyed at the clinic.
Blood and urine samples were collected at birth, 414- and 9- months of age. 
Preliminary analyses demonstrated that optimal results from laboratory assays required that
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the blood arrived within 6 hours of collection (data not shown). Every subject was 
followed up within the first week of life and then every month for the entire study. At each 
month, a TB questionnaire was completed to assess TB exposure of the subjects, and a 
routine health and morbidity questionnaire was completed to record anthropometric data 
(Figure 2.IB). At 9 months of age all subjects automatically became part o f the Sukuta 
birth cohort and are currently being followed up, on a regular basis to obtain 
anthropometric and clinical data, for 4 years o f life.
A copy of the information sheet provided to the mothers (or translated by the 
fieldworkers for the mothers), the consent form and the TB information sheet and 
questionnaire are all included as Appendices (Appendix I - IV).
2.2 TUBERCULIN SKIN TEST (TST)
Reactivity to the TST was assessed at 4/4 months of age in all subjects. 0.1 mL of 2 
T.U. (tuberculin units) RT23 SSI (Statens Serum Institute, Denmark) was injected 
intradermally into the mid flexor surface of the left forearm of the subject by a trained 
clinician or fieldworker. A definite white bleb was raised at the needle point, about 10 mm 
in diameter, which disappeared within 10 minutes. The induration was measured 48 - 72 
hours later by two independent fieldworkers. A positive induration was recorded as 
recommended by SSI; the average length and width of the raised area of induration 
(evaluated by rolling the point of a pen across the arm and marking when it reaches 
resistance).
In The Gambia, it was assumed that a TST of 5 - 10 mm at 4/4 months of age 
would be due to:
1. BCG vaccination, or
2. Exposure to NTM
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Exposure to M.tb was suspected if the TST >10 mm. These children were followed up 
intensively to assess TB exposure, thus it was expected that exposure would be minimal.
If TB exposure was suspected from the skin test results or the TB questionnaire, a 
clinician would visit the compound o f the subject and assess any likely exposure to a TB 
case within the compound. A skin test was also carried out on all members of the 
compound. Within the first 414 months o f life, any subject from the delayed vaccine group, 
thought to be exposed to TB was withdrawn from the study, screened for clinical evidence 
of TB and immediately given BCG vaccination if appropriate. Any subject or member of 
their compound, suspected to have TB, was referred to the local TB clinic for further 
analysis and treatment if required.
As an extension to this study, further ethics approval was granted to perform an 
additional TST at 20 - 28 months o f age (Appendices V and VI). Interim analysis will be 
presented within this thesis. When visiting the children at this time point a T-shirt designed 
by a colleague (Dr. Matthew Cotten) was donated to each child to thank them for 
participating in the study (Figure 2.2).
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Figure 2.2: Design for T-shirts given to all participants and sta ff involved in the study to 
thank them for their contributions (copyright Dr. Matthew Cotten)
2.3 SAMPLE COLLECTION
2.3.1 Cord blood collection
Immediately following delivery, before the placenta is separated, the umbilical cord 
was cleaned with alcohol and cotton and let to dry. A sterile prepared needle and syringe 
containing 7.5 Units of heparin per mL blood (sodium salt from porcine intestinal mucosa, 
Sigma-Aldrich, Poole, UK) was used to puncture a vein in the cord. Between 1 0 -5 0  mL 
of foetal cord blood was collected by a trained nurse or fieldworker and mixed well before 
being transferred into a sterile 50 mL conical tube and stored into the fridge prior to 
transportation to the laboratories in Fajara (within 6 hrs of collection).
2.3.2 4/2- and 9-month blood collection
Venous blood samples (1 mL/kg (max 5 mL)) were collected by trained 
fieldworkers from infants at 414-, and 9- months using a 21 gauge needle and inserted into 
the back of the hand. Blood was collected into a 5 mL bijou tube containing heparin at 7.5 
Units per mL blood (Figure 2.3). Group 1 (vaccinated at birth) and Group 2 (vaccinated at 
414 months) had the same venipuncture schedules.
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Figure 2.3: Venous blood being collectedfrom a 9 month old child
2.3.3 Urine collection
A urine sample was collected within the first few days of life into a urine bag 
(Urinocol® Cedex, France) fitted between the baby’s legs. The urine was transferred into a 
15 mL universal container and used to diagnose CMV infection.
At 4V2- and 9- months a urine sample was collected from the infant prior to blood 
collection and transported to the MRC on the same day. 1 mL of urine was stored at -20°C 
for later analysis for CMV infection.
2.4 CULTURE CONDITIONS
Whole blood samples were used for all ex vivo and in vitro work in order to 
optimise the small volumes of blood collected. To aid in the logistics and practicalities of 
this study, various protocols were tested including freezing of the blood cells using novel 
protocols used in field studies in South Africa (Hanekom, Hughes et al. 2004). However 
FOXP3 expression was found to be very sensitive to freezing methods and therefore fresh 
blood was used for the entire study. From each blood sample:
1. 100 pL was spun at 10,000 rpm for 5 mins and the plasma layer was aspirated 
and stored at -20°C
2. 250 pL was used to calculate a full blood count on a CA620-20 Balder 
parameter system (Boule Medonic, Stockholm, Sweden)
3. 100 pL was used to phenotype the cellular profile of the Tregs ex vivo by flow 
cytometry (600 pi was needed from one donor in each experiment to perform 
the flow cytometry compensations on the FACSCalibur (BD Biosciences))
4. 500 pL whole blood was cultured for 5 days (optimal time to measure IL-10 
and TGFp production from T cells and maximum time for sufficient cell 
survival without the aid of growth cytokines) with each of the following
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antigens:
a) Purified peptide derivative o f tuberculin (PPD, 25pg/mL; SSI, 
Denmark),
b) Live BCG (2 — 66 x 104 CFU/ mL, Serum Institute of India Ltd, India),
c) ESAT-6/CFP-10 fusion protein (EC, lOpg/mL; Klein, M, Leiden),
d) Staphylococcal enterotoxin B (SEB, 5 jig/mL; Sigma Aldrich, UK)
e) Unstimulated control
f) Unstimulated flow cytometry control (after culture combined this 
control well from each sample for flow cytometry compensations)
Twenty-four hours later the cultures were diluted 1:5 with RPMI medium 
containing 2% penicillin/streptomycin (10,000 U/mL, Sigma Aldrich, UK) and 1% L- 
glutamine (Sigma Aldrich, UK). Timing of dilution was optimised to reduce the volume of 
antigen used without compromising the survival of cells (Figure 2.4).
The superantigen SEB was chosen as the positive control since the cellular flow 
cytometry profile of the lymphocytes after 5 days of stimulation was similar to the 
unstimulated whole blood sample and therefore required fewer changes to the analysis of 
the flow cytometry plots. Any samples that did not respond to SEB were eliminated from 
the analysis with any of the antigens tested. PPD is a mixture of antigens derived from 
M.tb. Concentrations of PPD and SEB used were optimised from previous infant studies in 
our laboratory. Responses to PPD could therefore indicate TB disease or latent infection. 
However it is expected that there is cross reactivity with antigens in the BCG vaccine and 
NTM. The EC fusion protein consists of two antigens that are relatively M.tb specific. It 
was a kind gift from Dr Michel Klein, Leiden, The Netherlands and used at the 
recommended concentration from previous ELISpot assays. BCG and most NTM do not 
contain these antigens although there are exceptions (M. leprae, M. kansasii, M. marinum, 
M. smegatus, M. ulcerans) and therefore some cross reactivity may occur if these NTM are 
in the environment in The Gambia. The specific environmental mycobacteria common in
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The Gambia include M. intracellulare, M. avium and M  vaccae (Corrah 1994). Skin test 
antigens were used for this study but these are not available for human use at the current 
time. In vitro testing for all these specific antigens was beyond the scope of this study 
given the small volume of blood available. The BCG antigen was reconstituted in 
phosphate buffered serum (PBS) as directed for use as a vaccine, from the same vaccine 
batch as that used for vaccination of the study subjects. The concentration of the BCG was 
titrated by lymphoproliferation assay. BCG caused inhibition at the higher concentrations. 
2 pL per 100 pL cultures was found to be optimal and used for this study. This corresponds 
to a final concentration of 2 -  66 x 104 CFU/ mL.
After 5 days of culture with specific antigens:
1. 100 pL of supernatant was collected and stored at -20°C at day 5 of culture to 
quantify the production of cytokines.
2. 100 pL of cell suspension was collected at the same time point, spun at 10,000 
rpm for 5 mins and the pellet resuspended in 350 pi RLT lysis buffer containing 
RNase inhibitors (QIAGEN, Germany) for RNA extraction and stored at -70°C 
to study expression profiles at a later date.
3. The remaining cells were divided into three for phenotype intracellular analysis 
using 3 panels of antibodies (Table 2.2).
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2.5 CELL PHENOTYPING
The selection o f cell surface and intracellular antibodies utilised, ex vivo and after 5
• BD Pharmingen, Cedex, France
o CD4 (PE, mouse IgGl clone SK3), CD4 (APC, mouse IgGl clone 
SK3), CD8 (PerCP, mouse IgGl clone SKI), CD25 (FITC, mouse 
IgGl clone M-A251), IL-10 (PE, rat IgGl, clone RM4-5), Ki-67 
(FITC, mouse IgGl clone B56/MOPC-21)
• e-Biosciences, San Diego, US
o FOXP3 antibody (APC, rat IgG2a clone PCH101)
• IQ Products, Groningen, Netherlands
o TGF(3 (PE, mouse IgGl clone TB21)
days of culture are shown in Figure 2.5 and Table 2.2 and the details are listed below:
CD25 
activation 
marker/ 
Treg marker CD4 helper 
T cell marker
TGF{3
CD8 cytotoxic 
T cell marker
FOXP3
Ki-67
Figure 2.5: Phenotypic markers for flow cytometry analysis
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Experiment FITC
(pL)
PE
(pL)
PerCP
(pL)
APC
(pL)
Ex vivo and in vitro CD25 (2) CD4 (2.5) CD8 (5) *FOXP3 (5)
In vitro *K i-67  (5) *IL -1 0  (10) CD8 (5) CD4 (3)
In vitro CD3 (3) *TG Fp (5) CD8 (5) CD4 (3)
F ITC -  fluorescein isothiocyanate, PE -  phycoerythrin, PerCP - perid inin chlorophyll protein,
APC -  allophycocyanin 
* intracellular staining
( )  denote antibody volumes used per 100 pL 
Table 2.2: Flow cytometry antibody panels
Antibody titrations and isotype controls were assessed in cord blood to optimise the 
flow cytometry staining methods after 5 days of culture.
In humans, the average peak of expression of the activation marker, CD25 (IL-2R) 
after stimulation with SEB is 6 days with 80% lymphocytes expressing the marker 
(Caruso, Licenziati et al. 1997) and therefore the percentage of CD4 T cells that expressed 
CD25 was chosen to represent activated T cells after 5 days o f culture in our study.
There is still no clear definition of naturally occurring Tregs. Many of the markers 
that are expressed on a suppressive T cell are also expressed during activation o f T cells 
(e.g. HLA-DR, CTLA-4, GITR, LAG-3,). Studies in autoimmunity, reviewed in 
(Sakaguchi, Sakaguchi et al. 2001) and, more recently, infectious diseases, (reviewed in 
(Mills 2004)) have hailed FOXP3 as being the most likely candidate to identify Tregs 
within the CD4CD25^ compartment although it remains true that FOXP3 is also 
transiently upregulated upon activation of human T cells (Morgan, van Bilsen et al. 2005; 
Allan, Crome et al. 2007). During optimisation experiments upregulation of FOXP3 was 
found after 1 day of culture which reduced by 5 days, supporting an initial increase in 
expression upon activation but by 5 days expression of FOXP3 was more likely to be 
associated with true regulatory T cell activity. Human FOXP3 expression predominates in 
CD4 T cells that express high levels of CD25 and it has been suggested that human Tregs
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can be defined as CD4+CD25hlgh T cells (Baecher-Allan, Brown et al. 2003). However this 
definition remains controversial and is difficult to define by flow cytometry (see Appendix 
VII for Treg definition optimisations), thus we chose the definition of a Treg as the 
percentage of CD4+ T cells expressing CD25 and FOXP3. During the study period another 
marker was identified that has helped define Tregs. FOXP3+ T cells that downregulate the 
IL-7 receptor (CD 127) show highly suppressive properties (Liu, Putnam et al. 2006) and 
thus CD127low has been accepted, in combination with FOXP3, as a marker of Tregs. It 
was not possible to include this antibody to our panel for this study but work in our 
laboratory has shown that 94% of ex vivo CD4+CD25+FOXP3+ T cells in cord blood have 
downregulated expression of CD127 (Flanagan, K, personal communication). It is 
interesting to note that higher levels of CD 127 are expressed on cord blood CD4+ and 
CD8+ T cells, compared to adults and this may falsely reduce the number of Tregs 
identified using this method in cord blood (Hassan and Reen 2001; Schonland, Zimmer et 
al. 2003). When other intracellular markers were tested using the recommended FOXP3 
intra-nuclear staining protocol there was a high background response, therefore 
intracellular IL-10, Ki-67 and TGFJ3 were assessed using separate intracellular staining 
methods.
IL-10 and TGFp are associated with inducible Tregs and levels peaked after 5 days 
of culture, thus determining an optimal culture time.
As the volume of blood was limited, Ki-67, an intracellular marker of cell division, 
was used as a functional proliferation read out rather than performing separate lymphocyte 
proliferation assays by thymidine incorporation, bromodeoxyurindine (BrdU) or 
carboxyfluorescin diacetate succinimidyl ester (CFSE) staining.
Consistency within the analysis of the flow cytometry data was gained by utilising 
a predefined template for the gating strategies on Flow Jo (Treestar Inc, Oregon, US) and 
not deviating from this for all samples and all time points beyond that needed for subtle 
variations in sample characteristics. CD4+ and CD8+ antibodies were used in all three
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panels for flow cytometry and therefore the consistency of the percentages of cells with 
these markers indicated the level of inter-assay variability. The percentage of CD4+ and 
CD8+ T cells within the lymphocyte population was found to be highly consistent across 
all panels at all time points (data not shown). With respect to the CD4+ population, 
different CD4+ antibody clones and different fluorochromes were used within the FOXP3 
and the IL-10/TGFp panels. A comparison of CD4+ T cell values between panels was also 
consistent suggesting inter-assay variability was minimal (data not shown).
2.5.1 Cell surface staining
Red blood cells in whole blood were lysed 1:10 with 1 x red blood cell lysing 
buffer (diluted from 10 x buffer in PBS, BD Biosciences) for 7 mins. The in vitro samples 
were first collected from the wells of the tissue culture plate and spun at 2000 rpm for 10 
mins to pellet the cells before adding the lysis buffer. After 7 mins PBS was added up to 15 
mL to dilute the lysis buffer and avoid damage to the cells. The cells were spun at 2000 
rpm for 10 mins then washed (spun at 2000 rpm for 5 mins) with FACS buffer (0.5% BSA,
0.1% EDTA, 0.1% sodium azide in PBS) before being resuspended into 100 pL FACS 
buffer and stained with the cell surface antibodies shown in Table 2.2 for 30 mins at 4°C in 
the dark. The cells were then washed twice in FACS buffer before permeabilisation for 
intracellular staining.
For each experiment, unstimulated control cells for the compensation stains were 
pooled and processed as above before being separated into 5 tubes (100 pL in each tube) as 
below:
1. Unstained (to set up the voltage parameters)
2. CD3 (FITC, mouse IgGl clone UCHT1, BD Pharmingen)
3. CD4 (PE, mouse IgGl cloneSK3, BD Pharmingen)
4. CD3 (PerCP, mouse IgGl clone SK7, BD Pharmingen)
5. CD3 (APC, mouse IgGl clone UCHT1, BD Pharmingen)
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Each antibody used was previously optimised using isotype controls to assess background 
staining. Electronic compensation was required for every experiment to minimise spectral 
overlap detected by the photomultipliers of the FACSCalibur which is dependent on the 
sample and assay conditions.
2.5.2 Intracellular staining (ICS)
FOXP3 protocol
200 pL FOXP3 permeabilisation reagent (made on same day 1:3 with diluent 
provided) (e-Bioscience) was added and incubated at 4 C for 20 mins in the dark. The cells 
were then washed once in FACS buffer and then twice in 1 x FOXP3 permeabilisation 
buffer (diluted from 10 x stock in distilled water, e-Bioscience). 10% rat serum (e- 
Bioscience) was added to the cells for 15 mins at 4°C in the dark to block any non-specific 
binding of the FOXP3 antibody before 5 pL of FOXP3-APC was added for 30 mins at 4°C 
in the dark. The cells were then washed three times with FOXP3 permeabilisation buffer 
before resuspending in 150 pL fix buffer (1% formalin in PBS).
BD protocol
200 pL Cytofix/cytoperm (BD Bioscience, France) was added and incubated at 4°C 
for 20 mins in the dark. The cells were then washed in 1 x BD Permeabilisation buffer 
(diluted from 10 x stock in distilled water; BD Bioscience) and then incubated in the same 
buffer for 10 mins at 4 C in the dark. 10 pL of IL-10 and 5 pL o f Ki-67 antibodies were 
added and incubated for 30 mins at 4 C. TGFp was added after 10 mins for a total 
incubation of 20 min for this antibody. The cells were then washed three times with BD 
permeabilisation buffer before resuspending in 150 pL fix buffer (1% formalin).
When there were large numbers of samples, 96 well plates were used for staining
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and were transferred to 5 mL round bottom tubes (BD Falcon, Cedex, France) prior to 
running on the FACSCalibur (BD Biosciences). The maximum numbers of events 
collected from each sample were equivalent to 5,000 -  50,000 lymphocytes depending on 
the age of the subject and the culture conditions.
2.6 CYTOMETRIC BEAD ARRAY
Supernatants collected at day 5 were thawed and spun at 1500 rpm for 2 mins to 
pellet any debris and avoid needle blockage of the Bio-Plex 200 Suspension Array system 
(Bio-Rad, Hercules, California, US). 50 pL of selected samples were transferred to a 96 
well plate in preparation for the assay. All samples stimulated with SEB were diluted 1:2 
with media containing 10% serum (simulating the whole blood culture milieu) to detect 
cytokines within the range of the standard curve.
A 3-plex system to analyse IFNy, 1L-10 and IL-13 cytokine production (Thl 
cytokine kit, Bio-Rad) was used to analyse samples collected at birth and at 9 months, and 
a 6-plex system containing antibodies to IFNy, IL-10, IL-13, IL-6, IL-7 and IL-17 (Thl 
cytokine kit, Bio-Rad) was used to determine cytokine production at 414 months o f age.
Briefly, the lyophilised standard was reconstituted with 500 pL RPMI media 
containing 10% human serum, gently vortexed and incubated on ice for 30 mins. Serial 
dilutions of 1:4 were made according to manufacturer’s instructions with above media to 
create 8 standards for the low PMT setting which allows for a broad range standard curve. 
During all steps of the assay, the reagent solutions in the 96 well plate were removed by 
vacuum filtration using Aurum™ Vacuum manifold with 1-2 Hg pressure (Bio-Rad), and 
excess liquid was blotted with a lint free paper towel. The filter plate (Bio-Plex reagent kit, 
Bio-Rad) was prewetted with 100 pL assay buffer (Bio-Plex reagent kit, Bio-Rad). The 
conjugated microsphere beads were vigorously vortexed for 20 - 30 secs before being 
diluted with assay buffer (as per manufacturer’s instructions), and 50 pL was added to each 
well of the plate. The buffer was removed by vacuum filtration. The plate was then washed
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twice with 100 pL wash buffer (Bio-Plex reagent kit, Bio-Rad) after which 50 pi standards 
in duplicate and 50 pL single samples in were added to the plate. The plate was then sealed 
with sealing tape and incubated by shaking at 1,100 rpm for 30 secs followed by 300 rpm 
for 1 hour at room temperature in the dark. During the incubation the biotinylated detection 
antibody (Bio-Plex reagent kit, Bio-Rad) was diluted as per manufacturer’s instructions 
and kept in the dark at room temperature until use. The plate was washed three times with 
wash buffer as described previously and 25 pL of detection antibody was vortexed gently 
and added to each well, the plate was sealed with sealing tape and incubated by shaking at 
l,100rpm for 30 secs followed by 300rpm for 30 mins in the dark. The streptavidin-PE 
reporter antibody (Bio-Plex reagent kit, Bio-Rad) was diluted as per manufacturer’s 
instructions, vortexed rigorously and after another 3 washes with wash buffer, 50 pL was 
added to each well of the plate and the plate was sealed and incubated for 10 mins (shaking 
at l,100rpm for 30 secs followed by 300 rpm). The plate was finally washed three times 
with wash buffer and then each well was resuspended with 125 pi o f assay buffer, shaken 
for 30 secs at l,100rpm before reading the plate on the Bio-Plex 200 Suspension Array 
system (Bio-Rad).
Standard curve outliers were eliminated by identifying samples where the 
coefficient of variance (%CV) > 10% and observed/expected x 100 (obs/exp*100) was 
outside the range of 100 +/- 20. Any sample that recorded an error during the run 
(predominantly due to high aggregations of beads) was repeated. Calibration of the 
instrument was performed before every experiment using CAL2 calibration kit (Bio-Rad) 
with low RP1 target values (used for broad range standard curve).
2.7 CMV DIAGNOSIS
2.7.1 CMV DNA extraction
CMV viral DNA was extracted from 140 pL urine using the QIAmp viral RNA kit 
(QIAGEN, Hilden, Germany) as recommended by QIAGEN for nucleic acid extractions
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from non-cellular material. Urine from a known CMV infected subject was used as a 
positive control and PBS was used as a negative control.
Carrier RNA was utilised to increase the yield from the silica columns. It was 
prepared fresh, reconstituting in AVE buffer and diluting in AVL buffer as per 
manufacturer’s instructions. 560 pL of prepared RNA was added to 1.5 mL tubes (this 
equated to 5.6 pg yeast tRNA per sample). 140 pL sample urine was added to the carrier 
RNA and vortexed for 15 secs and incubated at room temperature for 10 mins. 560 pL of 
100% ethanol was added to each tube, vortexed for 15 secs and 630 pL of the sample was 
applied to a QIAamp Mini spin column before being spun at 8,000 rpm for 1 min. This was 
repeated to bind the entire DNA to the silica columns. The spin columns were washed with 
500 pL buffer AWI at 8,000 rpm for 1 min, then secondly with 500 pL buffer AW2 at
14,000 rpm for 3 mins. As an extra step, the column was spun at 14,000 rpm for 1 min 
without any buffer to remove any residual alcohol. The DNA was then eluted in two steps 
using 40 pL of AVE buffer for each step and stored at -20C .
Measurement of the yield of CMV DNA would be confounded by the carrier RNA 
eluted in the process, but purity of the sample was calculated on the Nanodrop (Thermo 
Scientific, Wilmington, Delaware, US) based on absorption values at 280 nm (protein), 
230 nm (detection of contaminating organics/ proteins), 270 nm (detection of phenol 
contaminates) using the following criteria: 260 nm / 280 nm >1.8, 260nm / 230 nm >1.8 
and 260 nm / 270 nm -1.2. If any sample was outside these limitations then the extraction 
was repeated.
2.7.2 CMV nested PCR
In the first round of PCR, 10 pL DNA was amplified using Hot Star Plus Taq 
polymerase kit (QIAGEN) following manufacturer’s instructions in a 25 pi total volume 
and with 0.1 pM CMV primers (WP1 forward -  5’ GTA CTC GCC CTC GTT TTC GGG 
TC 3’ and WP2 reverse -  5’ GTC TAT TGT GTC GAG TAT CTA CTC AG 3’). These
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primers amplified part of the membrane-associated protein UL50 gene of the human 
herpesvirus 5 (laboratory strain AD 169) which is highly homologous to the wild type 
human herpesvirus 5 Merlin strain. The CMV strain from The Gambia had not been 
sequenced but a BLASTn comparison of the primer sequences to genomic DNA from the 
NCBI database elicited a 100% homology to the laboratory strain and 98% homology to 
the wild type strain suggesting that it was likely the primers would amplify the Gambian 
strain. Extracted controls, mentioned above and a PCR negative control (10 pL of nuclease 
free water instead of sample) were amplified alongside the samples. PCR conditions were:
• 94°C, 4 mins — 1 cycle
• 94°C, 30 secs, 50°C 30 secs, 72°C 30 secs -  4 cycles
• 94°C, 30 secs, 57°C 30 secs, 72°C 30 secs -  31 cycles
• 72°C, 7 mins — 1 cycle
In the second round of PCR, 2 pL first round DNA product was amplified using 
Hot Star Plus PCR kit (QIAGEN) following manufacturers’ instructions in a 20 pi total 
volume and using 0.1 pM CMV primers (WP3 forward -  5’ TCC GAA GGC GAT GAG 
CTC GAT GT 3’ and WP4 reverse -  5’ CGA GTA TCT ACT CAG CTA CTG GGA 3’) 
that amplified within the first PCR product. PCR amplification conditions were same as 
above for the first round PCR.
10 pL second round PCR product was added to 2 pL of 6 x loading buffer 
(Promega, Madison, US) and ran on a 2% agarose gel (low melting point agarose, Sigma 
Aldrich, Poole, UK) in 1 x TAE buffer (50 x stock -  242 g Tris, 100 mL 0.5M EDTA, pH 
8.0, 57.1 mL glacial acetic acid made up to 1 L with water) at 100 volts alongside 1 kb 
molecular weight marker (Promega, Madison, US).
2.8 DATA COLLECTION AND VERIFICATION
Anthropometric information (at birth and at monthly follow ups), TB questionnaire,
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case report forms (CRF) forms, vaccine records, drop out forms, full blood count results 
and storage location for samples were all double entered onto a central Access database 
and original forms filed in one locked location. Results from flow cytometry, CBA and 
PCR were recorded on Excel databases.
Flow cytometric data was analysed using a template previously created during 
optimisations in Flow Jo software (Treestar, Oregon, US) with minor sample specific 
modifications. Cytokine concentrations below the level of detection (indicated as OOR in 
Bioplex software) were calculated as zero in the analysis. All values that were greater than 
the highest range within the standard curve were repeated by first diluting 1:2 with media. 
Data points/samples were eliminated if any o f the following problems arose:
1. EPI vaccine less than 7 days prior to blood collection
2. Cord blood was clotted
3. Cultures were contaminated
4. Flow cytometry antibodies did not work optimally
5. The positive control (SEB) did not induce a response in vitro
6. Samples with acquisition of less than 1,000 cells (in the case of an 
unstimulated well having less than 1,000 cells, all antigen stimulations from 
the same sample were removed from the analysis)
7. Technical problems with the FACSCalibur causing problems with 
acquisition of data
Outliers were always included in the data analysis unless mentioned otherwise.
2.9 STATISTICAL ANALYSIS
A test of Gaussian distribution was initially performed using the DAgostino - 
Pearson normality test (omnibus K2). For most values the data was not normally 
distributed and therefore non-parametric testing was used throughout.
Cross sectional comparisons between groups at each time point were assessed using
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a non-parametric 2-sided Mann-Whitney U test at 95% significance that tests differences in 
median values but also the distribution of the data (location and shape). This test is 
described with respect to medical literature by Hart, 2001 in a revision o f analysis from 
BMJ articles (Hart 2001). All paired analysis (i.e. unstimulated compared to stimulated 
samples or longitudinal data) was analysed using non-parametric 2-sided Wilcoxon 
matched paired test at a 95% significance level which analyses related samples by 
comparing the ranks of the differences, regardless of the sign o f the difference and 
ignoring all zero differences.
Correlations were analysed using Spearmans non-parametric correlation coefficient 
as opposed to linear regression as X and Y are both variables that were measured.
The categorical data assessing gender differences were recorded as contingency 
tables and analysed using Fisher’s Exact test for small sample sizes.
Bonferroni corrections were used according to the numbers of parameters assessed 
and the number of times a dataset was analysed. Corrected and uncorrected data were 
reported.
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CHAPTER 3 
Cohort Characteristics
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3.1 THE GAMBIA
The Gambia is the smallest country in Africa situated at the furthest Western point 
of the continent surrounded by Senegal (Figure 3.1).
Sukuta
Figure 3.1: Map o f Gambia and location o f Sukuta field site
The country is approximately 300 km long and 40 km wide, with approximately 
3,700 km of roads (80% unpaved, (CIA 2008)) and a population of 1.74 million (CIA 
2008). The River Gambia, the origin of which lies in Guinea Conakry, runs from East to 
West through the entire country and is 8 km wide at its widest point. At 13° latitude, The 
Gambia experiences a tropical climate that consists of a wet season (June -  October) and a 
dry season (November -  May). The Gambia has no confirmed mineral resource deposits
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and has a limited agricultural base although 75% of the population depends on crops and 
livestock for its livelihood (CIA 2008). Although Gambia has a history of many successful 
small scale industries including ground nut export and fishing, its most lucrative industry is 
tourism, with approximately 200,000 tourists, mainly from Europe, visiting Gambia every 
year to experience Gambia’s natural beauty, tropical birds, sandy beaches and winter sun. 
The gross domestic product per capita (GDP PPP) in 2008 was estimated to be $1,200 
compared to the UK estimation in 2008 of $37,400 (CIA 2008). The majority religion is 
Islam (90%) while the remaining includes Christians (8%) and those of indigenous beliefs 
(CIA 2008).
3.2 CHILD HEALTH IN THE GAMBIA
Reducing child mortality by two-thirds is one of the Millennium Goals to be 
achieved by 2015. Globally, about 29,000 children under the age of 5 die every day (21 
every minute) from preventable causes (UNICEF 2009). Life expectancy in The Gambia is 
54.95 years of age (male 53.06 and female 56.9 years) (UNICEF 2006). The birth rate is 
one of the highest in the world at 38.36 births per 1,000 population (CIA 2008) but there is 
a high mortality rate, especially in under 5 year olds (113 per 1,000 children) (UNICEF 
2006). However, The Gambia has been one of the fastest improvers in under-five mortality 
rates among developing countries (UNICEF 2006). A study in the rural upper river regions 
showed acute lower respiratory tract infections (ALRTI) were the most frequent cause of 
death in children under 5 years of age. Other major causes were malaria, acute gastro­
enteritis and chronic diarrhoea with malnutrition. During the neonatal period (< 28 days of 
life) children were more susceptible to ALRTIs, whereas malaria and chronic diarrhoea 
were more frequent causes of mortality from 1 - 5  years of age (De Francisco, Hall et al. 
1993). From 1949 to 1997 the probability of dying in The Gambia was highest for 1- 5 
year old children (66 per 1,000) compared to neonates (15 per 1,000) and infants (1 month 
to 1 year) (36 per 1,000) (Rayco-Solon, Moore et al. 2004). Mortality used to be greatest in
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the ‘hungry’ season (July — November), although this seasonality of deaths was lost from 
1985 onwards (Rayco-Solon, Moore et al. 2004). This is thought to be due to the more 
efficient implementation and availability of basic health measures. The neonatal mortality 
rate of 15 per 1,000 was low compared to earlier reports of 39 per 1,000 (Leach, McArdle 
et al. 1999) and the UNICEF figure of 46 per 1,000 (UNICEF 2000). Leach et al showed 
that infections were responsible for 57% of the neonatal deaths (Leach, McArdle et al. 
1999). Infectious diseases have been reduced by the implementation of the EPI in 1979 
which has been very successful with up to 90% of infants throughout the country being 
vaccinated with the recommended vaccines (see Table 2.1)(WHO 2008). Receiving all 
recommended vaccinations before the age of 9 months has had a positive effect on 
preventing under-5 child mortality in The Gambia (Rutherford, Dockerty et al. 2009).
It is estimated that the incidence of TB disease in The Gambia is 603 per 100,000 
(Hill, Jackson-Sillah et al. 2008). A recent surveillance o f TB incidence from the greater 
Banjul area of The Gambia revealed Sukuta as a ‘hot spot’ for TB cases. However 80% of 
the detected cases occurred in the 1 5 - 4 9  year age group and only 1.6% in < 1 year olds 
which is the age of the children in our study (Touray, K personal communication).
3.3 SUKUTA FIELD SITE
Sukuta is a semi-rural community about 15 minutes drive from the main MRC field 
station at Fajara (Figure 3.1). The field site is based at Sukuta Government Hospital run by 
a prominent local figure called ‘Aunt Sally’, a senior nurse who is dedicated to the running 
of the hospital.
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Figure 3.2: Sukuta field team and infant immunology lab staff. From left to right; back
row - Momodou Cox, Prof. Hilton Whittle, Momodou Bah, Saidou Sowe, Ebrima Touray, 
second row - Suleyman Colley, Buba Darbo, Public Health Officer at Sukuta Health 
Centre, Janco Camara, Saiho Bob, Dr. Owolabi Olumuyiwa, Sargo Sanneh, Karamou 
Manneh, Omar Badjie, third row - Fatou Noho Konteh, Jankey Ya Jagne, Isatou 
Drammeh, Lady Chilel Sanyang, Aunty Sally, Dr. Jane Adetifa, Musa Sambou, Saikou 
Mendy, Jammo Sowe, bottom row crouching - Jainaba Njie-Jobe, Sarah Burl, Dr. Katie 
Flanagan, Ebu Bah.
Within the compound of the clinic is a smaller clinic dedicated to MRC studies, 
which was established by Prof. Hilton Whittle, Dr. Amaud Marchant and Dr. Marianne van 
der Sande in 2001 to study CMV infection. Since this time many studies have been carried 
out and a birth cohort has been established. The site is now used to study infections that 
affect infants in early life and to investigate responses to infant vaccines (current and 
novel). There is one MRC clinician, Dr. Jane Adetifa and 13 MRC field workers, 5 with 
nursing qualifications (Figure 3.2) based at the field site. Each fieldworker has a 
motorcycle to travel within the 40 km catchment area to visit study participants throughout
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the dry and wet seasons.
3.4 STUDY SET UP
According to International Conference of Harmonisation/ WHO Good Laboratory 
Practice (ICH-GCP) guidelines (www.ich.org) any clinical intervention study in human 
subjects must be set up as a clinical study. Although BCG is an already licensed vaccine, 
changing the usual schedule could introduce risk to a human subject and therefore it was 
thought advisable to set up the study using the MRC GCP guidelines that are based on the 
principles of the ICH GCP guidelines. After 50 subjects had been recruited the study was 
monitored internally by the clinical trial monitor with no major underlying problems.
3.5 STUDY DROP OUT ANALYSIS
103 babies were recruited into the study at birth. The final dropout rate was 15.6% 
which was below the original estimated rate of 20%. Of the 103 subjects recruited, 91 were 
followed up at 414 months (88.3%) and 87 by 9 months (84.4%). Table 3.1 illustrates the 
details of the ‘drop outs’ of the study.
REASONS FOR DROP OUT 0 - 4% m 414 - 9 m at 9 m
Died 3 0 0
TB exposed 1 0 o
TB disease 0 0 0
Withdrew consent 2 0 1
Travelled 0 1 2
Protocol deviation 6 0 0
TOTAL 12 1 3
Table 3.1: Reasons study participants dropped out of study over the 9 months o f the study
Three babies died within the first month of life (2/3 were within 2 days of birth).
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One of these was diagnosed as having sepsis but the remaining two had general fever and 
breathing difficulties that were undiagnosed before death. This would approximate to a 
neonatal mortality rate (NMR) of 30 per 1,000 live births (official Gambia NMR is 46 per
1,000 live births (UNICEF 2000)). In 2006, the NMR of England, Wales and Northern 
Ireland was 3.4 per 1,000 live births (CEMACH 2006). Thus, this study suggests a 10-fold 
higher NMR in Sukuta than in a Western setting, although the sample size was too small to 
extrapolate this to a nationwide statistic and there was a selection bias of recruitment birth 
weight > 2.5kg (in 2007, 6% of births in Sukuta were < 2.5kg).
3.6 DOCUMENTATION
The CRFs and source documents used in this study are summarised in Table 3.2. An 
access database was created to hold the data generated by the 2731 forms completed.
Forms entered into database Number collected
Recruitment form at birth 103
First visit form 95
Monthly follow up form 726
TB questionnaire 1101
Infant Welfare Card (IWC) vaccine details 103
Case Report Forms (CRF) for bleeding and TST 177
Drop out forms 16
Results from Medonic cell analyser 101
Storage location forms for all laboratory samples 309
TOTAL 2731
Table 3.2: Number offorms collected fo r  the duration o f the study
A recruitment form for each subject recorded details of the parents and birth of the 
child. A first visit form is filled out to record the child's given name and details within the 
first month of life (traditionally children in The Gambia are given a name by the father of
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the child at a naming ceremony which is usually within the first 2 weeks of life). From 
month 2 until month 9 each child was followed up on a monthly basis and a general health 
form and a TB exposure questionnaire were completed. On average, >75% of monthly 
follow up forms were completed, the absent forms being mainly due to the family 
travelling at time required for follow up. Each child that dropped out o f the study was 
recorded, with detailed reasons as listed above in Table 3.1. A CRF was recorded for each 
blood collection and TST administered, along with details of the personnel involved with 
collection of blood or measurement of the TST.
3.7 VACCINE SCHEDULE
Each mother of the study participants was advised to bring their child to the MRC 
field site at Sukuta for their child’s EPI vaccines so that a record could be maintained of 
each vaccine administered. This information was recorded on the child's Infant Welfare 
Card (IWC; a form that is given to every newly bom child in The Gambia and records 
vaccines administered in addition to height and weight). MRC field staff recorded the 
vaccines given, on a database and a schedule of follow up was set up to maintain the 
appropriate vaccine schedules for each child. Although this intense follow up was 
implemented there were still cases of blood collection at 4%- or 9- months o f age that 
occurred less than 1 week post vaccine administration. It is not known what effect vaccines 
have on in vitro responses to other antigens, thus these individuals were removed from the 
final analysis.
3.8 OVERALL COHORT CHARACTERISTICS
Fifty males and 53 female newborn babies were recmited into the study. In Group 1 
27/53 (50.9%) were female and in Group 2 26/50 (52.0%) were female suggesting no sex 
bias in the randomisations of the groups. All babies were cephalic spontaneous vaginal 
deliveries without complications. According to the criteria of the study the weight of the
child recruited at birth had to be at least 2.5 kg. Two babies with a birth weight below 2.5 
kg were mistakenly recruited at birth but immediately dropped out as indicated as protocol 
deviation in Table 3.1, and these values were eliminated from the length and weight values 
presented in Table 3.3.
Characteristic
Gender (%) Male Female
50 53
Ethnicity (%) Mother Father
• Mandinka 67 64
• Fula 10 18
• Wolof 8 7
• Other 15 11
No. of Pregnancies (range)
• Total including 3 .8 (1 -1 0 )
miscarriages
• Live deliveries 3.6 (1 -9 )
Mother’s median age (range) 26 (1 8 -4 5 )
Lived in Sukuta (%)
• < 2 yrs 6 (6.0%)
• 2 - 10 yrs 31 (30.3%)
• >10 years 23 (22.5%)
• always 42 (41.2%)
Birth weight (average kg) 3.2 (2 .5 -4 .2 )
Birth length (average cm) 49.5 (46 -52 .1 )
Table 3.3: Cohort characteristics
Sixty five percent of mothers had lived in the community for greater than 10 years 
with nearly half of all mothers being permanent residents for their entire life (41.2%)(Table 
3.3). This suggests the study participants were from a stable population within Sukuta and 
would have similar social pressures over the time of the study. Mandinka was the 
prominent ethnic group with 67% of mothers and 64% of fathers from this group. The 
second most prominent group was Fula and Wolof was third with only 8% of mothers and 
7% of fathers from this group (Table 3.3). This proportion is more consistent with rural
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areas of The Gambia rather than the urban areas of Banjul and Fajara (where MRC's main 
unit is based) that are predominantly Wolof speaking. Sukuta is therefore termed semi-rural 
(or peri-urban) as it is close to an urban area but has a setting and community more usually 
seen in rural areas. These statistics are similar to previous larger studies in Sukuta (Miles, 
Sande et al. 2008).
All mothers breastfed their children for the duration of the study (9 months) with 
daily supplements of water, porridge, rice, coos (couscous) or custard starting from 
approximately 3 months. The majority of children were taking some solid supplements, by 
9 months of life.
The median number of pregnancies, including miscarriages of the mothers of the 
study subjects was 3.8 with a range of 1 to 10 but numbers of live births was 3.6 with a 
range of 1 to 9. The median age of the mothers was 26, which is equivalent to the overall 
birth cohort in Sukuta which has a median age of 25 (n = 703) (Hossin, S personal 
communication).
Overall it was found that the characteristics of this study cohort were similar to 
previous studies in Sukuta and therefore suggest this group of children are representative 
of the Sukuta community.
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CHAPTER 4 
Ex vivo immune cell populations and
phenotypes
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4.1 INTRODUCTION
Studying the development of infant immunity in humans is difficult for 
experimental, practical and ethical reasons and therefore many studies are based on more 
easily available cord blood or detailed newborn mouse studies. Immune cells in cord 
blood, however, are predominantly naive and have different characteristics and dynamics 
than later in life (Keever 1993; Ciccimarra 1994; Roncarolo, Bigler et al. 1994; Zola, 
Fusco et al. 1995; Fadel and Sarzotti 2000; Szabolcs, Park et al. 2003) and therefore there 
is a need to study responses after birth in order to understand how the infant immune 
system matures particularly in response to pathogens and vaccines encountered in early 
life. Additional factors such as geographical location (Das, Bhanushali et al. 2008) and 
genetic background (Newport, Goetghebuer et al. 2004) also influence immune 
development in early life.
Antibody mediated immune responses are supplemented by circulating 
transplacentally acquired maternal antibodies which wane by 6-9 months of age, in 
addition to antibodies received through breast feeding, and these aid in protecting the 
infant from infections to which the mother has developed immunity. There is limited 
evidence of the contribution of maternal memory T cells to newborn immunity, and 
therefore they remain susceptible to those infections that are cleared by a cell mediated 
response, such as intracellular infections.
Immune cell populations in whole blood can be determined using a cell analyser. 
Normal ranges have been established as ‘reference ranges’ and deviation outside of these 
limits may indicate disease (Table 4.1).
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Concentration in blood 
(x 109 cells /L)
Percentage 
of blood (%)
Size
(pm)
Erythrocytes Male Female 
4400-5900 3800-5200
-50 6 - 8
Platelets 150-440 N D Irregular
White blood cells (leukocytes) 4 - 11 -50 7 - 2 0
• Granulocytes % ofWBC
o Basophils 0-0 . 2 0 - 1 9 - 1 2
o Eosinophils 0 - 0.45 1 -3 1 0 - 1 4
o Neutrophils 2.1 -7.2 55-65 9 - 1 2
• Lymphocytes 1.5-4.0 20- 40 7 - 2 0
• Monocytes 0.2-0.8 4 - 1 0 1 5 - 2 0
• NK cells 0.004-0.02 1 -5 7 - 2 0
ND = not determined
Table 4.1: Normal composition o f peripheral blood in adult Caucasians
Various studies have shown that age (Lugada, Mermin et al. 2004; Adetifa, Hill et 
al. 2008; Sirdah, Tarazi et al. 2008), sex (Bain 1996; Jackson, Carter et al. 2001; Rushton, 
Dover et al. 2001; Lugada, Mermin et al. 2004; Adetifa, Hill et al. 2008) and ethnic origin 
(Alur, Devapatla et al. 2000; Cheng, Chan et al. 2004; Lugada, Mermin et al. 2004; Robins 
and Blum 2007; Adetifa, Hill et al. 2008; Saathoff, Schneider et al. 2008; Sanz-Pelaez, 
Angel-Moreno et al. 2008; Sirdah, Tarazi et al. 2008) can lead to a change in the expected 
normal range. There are little data on what is an appropriate normal range for an African 
infant population, but studies based in various African settings have shown increased 
haemoglobin (Hb), packed cell volume (PCV), mean cell haemoglobin (MCH) and 
numbers of red blood cells (RBC) in cord blood from normal healthy neonates (Mukiibi, 
Mtimavalye et al. 1995; Mukiibi, Nkrumah et al. 1995; Dapper and Didia 2006; 
Christensen, Jopling et al. 2008). Sex differences are thought to only appear after puberty, 
where females have lower haemoglobin and red blood cell counts but higher neutrophil 
counts (Bain 1996; Jackson, Carter et al. 2001; Rushton, Dover et al. 2001; Lugada, 
Mermin et al. 2004; Adetifa, Hill et al. 2008). Sex differences prior to puberty have not
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been well described.
Paediatric studies o f lymphocyte subsets have described differences according to 
age, many of these occurred over the first year of life (Shearer, Rosenblatt et al. 2003). 
Changes in ex vivo (straight from collection, prior to in vitro stimulation) lymphocyte 
subsets can occur in response to infections (chronic or acute), stress, hormonal changes and 
even circadian rhythms (Laurence 1993). Very few studies describe the phenotype of 
circulating T cells in infants related to vaccination but rather focus on in vitro antigen 
specific responses. It might be expected that immediately after vaccination there would be 
a difference in the peripheral lymphocyte subsets as documented by Eibl et al after tetanus 
toxoid vaccination (Eibl, Mannhalter et al. 1984) but Berrington et al did not find this to be 
the case. Percentages of CD3+ T cells that were CD4+, CD8+ and CD4+CD25+ at 6 -  8 
weeks of age, prior to immunisations were similar to 7 months post infant vaccinations 
(Berrington, Barge et al. 2005).
Suppressive Tregs in human cord blood have been defined as CD4+CD25+ or 
CD4+CD25hlgh (Ng, Duggan et al. 2001; Wing, Ekmark et al. 2002; Berrington, Barge et al. 
2005; Godfrey, Spoden et al. 2005) (Byrne, Stankovic et al. 1994) (Cupedo, Nagasawa et 
al. 2005). There are conflicting opinions as to whether these Tregs are naive (CD45RA+) 
(Takahata, Nomura et al. 2004) or are primed in utero and possess a memory phenotype in 
the cord blood (Paganelli, Cherchi et al. 1994; Brustoski, Moller et al. 2006; Holm, 
Svensson et al. 2006; Santner-Nanan, Seddiki et al. 2008) (Izcue and Powrie 2005). Wing 
et al describe the phenotype CD4+CD25+ as being activated/memory T cells and 
CD4+CD25++ as being Tregs with a predominantly na'ive phenotype (Wing, Ekmark et al.
2002). Interestingly, the proportion of these Tregs appeared to decrease during gestation to 
adult-like levels at birth (Takahata, Nomura et al. 2004; Michaelsson, Mold et al. 2006). 
More recently the use of CD 127 and FOXP3 has further defined cord blood Tregs as 
CD4+CD25+FOXP3+CD127low (Figueroa-Tentori, Querol et al. 2008) and these constitute
approximately 6% of circulating lymphocytes, the majority having a memory phenotype 
(CD45RO+) (Santner-Nanan, Seddiki et al. 2008).
This chapter describes the numbers and phenotype of circulating blood cell 
populations (in particular, Tregs) without stimulation (ex vivo) in early life (at birth, 414- 
and 9- months of age) and examines if BCG vaccination alters the proportions of these 
populations.
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4.2 RESULTS
4.2.1 Differences in blood cell indices within the first 9 months o f life
Whole blood cell counts were measured using a Medonic cell analyser described in 
Chapter 2: Materials and Methods. The cell counts were not performed for every sample 
due to the limited quantities o f whole blood. Platelets were omitted from the analysis due 
to increased adhesion and clumping of platelets making the counts unreliable. A larger 
increase in platelet adherence than normal red cells has been found previously in human 
newborn cord blood (Aarts, Bolhuis et al. 1983). The results were compared to indices 
based on children aged between 12 months and 10 years from Kilifi, Kenya (Kenya 
Medical Research Institute/ Wellcome Trust Research programme), and the Gambia where 
available (Adetifa, Hill et al. 2008) and cord blood indices from an older Zimbabwean 
study (Mukiibi, Nkrumah et al. 1995).
It was evident that cord blood immune cells had a different profile to cells during 
infancy. Cord blood indices were frequently out of the ranges described for children > 12  
months of age but were within the range reported from cord blood studies in Zimbabwe 
(Figure 4.1 and Table 4.2). Cord blood contained significantly higher levels of 
haemoglobin than infants (p < 0.0001). However, using appropriate reference ranges for 
age, 28% of children were anaemic at birth and 12% of infants were anaemic at both 4/4- 
and 9- months (Figure 4.1 A and Table 4.2). The number of red blood cells in cord blood 
fell within the expected range but were reduced compared to 9 month old infants (Figure 
4.IB) and, on average, were greater in mass (PCV/Haematocrit), size (MCV) and 
haemoglobin concentration (MCHC, MCH) than infants (Table 4.2).
The significantly higher WBC counts in cord blood compared to infants (Figure 
4.1C) did not correspond to the proportions of lymphocytes which showed the opposite 
pattern and were lower in cord blood compared to 414 months (p = 0.0010) and 9 months 
of age (p = 0.0003) (Figure 4. ID).
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At 4 V2 months, The WBC count values appear to define two distinct populations of 
children with values below the median (although all within expected range) and above the 
normal range (Figure 4.1C). These two populations were not related to BCG vaccination 
status. Indeed, when the results were separated according to BCG vaccine schedule, no 
significant differences were found for any of the indices at any of the time points.
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Figure 4.1: Medonic blood counts. (A) haemoglobin, (B) red blood cells, (C) white blood 
cells and (D) lymphocytes were determined from 250 pi whole blood using a cell analyser. 
Cord blood n = 13 - 16, 4/> months n = 13 - 25, 9 months n = 39 - 59. Black bar represents 
median value and the blue shaded region represents the acceptable range o f values from 
Kilifi, Kenya for children 12 months — 10 years; the median value o f the range is 
represented by a blue line. The yellow shaded region represents the cord blood ranges the 
pink line represents the median value from Zimbabwe. Mann Whitney U test was applied to 
compare differences across ages at 5% significance, * represents adjusted values after 
correcting for multiple testing that were not significant.
Cord blood Reference for 
cord blood*
4Vz months 9 months Reference 
(1 2 m -  lOyrs)
Haemoglobin (Hb) g /dL 13.6
(7 .8 -15 .4)
15.2
(13.5-19.4)
10.2 
(7.1 -  12.8)
9.7
(5 .5 -27 .2)
10.7 (8.2 -  12.7)| 
8 .7 -1 3 .4 +
White blood cell (WBC) 
x 103/fd
10.75 
(5 .3 -  16.9)
13.8 
(4 .6 -  132.8)
9.0
(4 .8 -22 .2 )
9.1
(4 .0 -  15.6)
6.9 (3 .9 -  12.5 )1 
4 .9 -  14.3*
Lymphocytes % 41.3
(23.6-86.5)
ND 66.6
(48 .6-79 .2)
64.9
(36 .7-83 .4)
48.31 
(28.1 -6 8 .7 )
Red blood cell (RBC) x 106 
/pi
4.03
(3 .22-5 .43)
ND 4.35
(3 .43-5 .73)
4.52
(2 .23-6 .43)
4.41
(3 .6 -5 .7 )
Packed cell volume (PCV)
%
40.45
(23.7-47.3)
47.3
(38.6-60.3)
30.7
(9 .5 -38)
30.30
(17 -75 .4 )
32.6H
(26 .8 -3 8 .1 )
Mean cell volume (MCV) 
fL
101.6
(71.6-116.9)
107.8 
(88 .8- 134.3)
73.5
(51 .4 -80 .7)
67.6
(49.2-86.1)
74 (56 .3-88 .7 )1  
63.4 - 86.3*
Mean cell Haemoglobin 
concentration (MCHC) g 
/dL
33.55 
(32.1 -3 4 .5 )
32.9
(30.3-38.3)
31.8 
(29.3 - 35)
31.65 
(20.3 -  34.8)
32.91 
(30.0 -  34.9)
Mean cell Haemoglobin 
(MCH) pg
34.27
(23.6-36.4)
31.9
(25.2-45.2)
23.80
(16 .5-27 .7)
21.28
(13.6 -64 .2 )
24.71
(17 .0 -2 9 .7 )
* Based on study in Zimbabwe, 1995 (Mukiibi, JM eta l 1995)
1 Based on ranges from Kilifi, Kenya (12 months -  10 years, Kenya Medical Research Institute/ Wellcome Trust Research programme) 
\ Based on Gambian study (Adetita, IMO et al, 2008) (6 months -  6 years)
ND = not determined
Table 4.2: Medonic blood counts. Median and ranges o f all blood indices from 250 pL 
whole blood analysed by a cell analyser alongside the normal acceptable ranges in Kilifi 
for children 12 months -  10 years and cord blood ranges from Zimbabwe. Cord blood n = 
13 - 16, 4/2 months n = 13 - 25, 9 months n = 39 -  59.
98
4.2.2 Gender differences in blood cell indices
Analysis by gender revealed no significant differences for any of the indices at 
birth, but a number of differences emerged at subsequent time points. Many of these 
differences were lost in the 4lA month age group after correcting for multiple testing, but 
clear differences persisted at 9 months if age. Females had higher levels of haemoglobin, 
PCV, MCV and MCH than males (Table 4.3); albeit at still significantly lower levels than 
in cord blood (p = 0.0001). At 414- and 9- months of age collectively, 80% (8/10) of 
anaemic infants were male. However at birth this was not the case since 75% (3/4) of 
anaemic neonates were female (Figure 4.2).
At birth 414 months 9 months
M F P
value
M F P
value
M F P
value
Haemoglobin (Hb) g /dL 14.4 13.4 0.3856 9.5 10.5 *0.0115 9.2 9.95 0.0040
White blood cell (W BQ  
x 1(/ /(al
10.7 10.8 0.4629 8.55 9.5 0.7814 9.0 9.6 0.6075
Lymphocytes % 45.3 40.8 0.4140 72.9 61.1 0.0786 52.25 64 0.720
Red blood cell (RBC) x
i o 6/p i
4.01 4.03 0.7332 4.34 4.42 0.4212 4.54 4.435 0.3060
Packed cell volume 
(PCV) %
43.2 40.2 0.4278 29.45 33.35 *0.015 29.1 31.80 *0.0065
Mean cell volume (MCV) 
fL
89.3 102 0.2573 64.75 75 *0.0051 64.1 70.15 <0.0001
Mean cell Haemoglobin 
concentration (MCHC) 
g/dL
33.2 33.60 0.4222 31.4 32.2 0.2117 31.95 31.45 0.9442
Mean cell Haemoglobin 
(MCH) pg
29.06 34.3 0.6064 20.54 24.44 *0.0158 20.21 22.28 0.0005
*Not significant after Bont'erroni correction, blue text denotes greater values in females
Table 4.3: Gender differences in blood cell counts. Median and ranges o f all blood 
indices from 250 pL whole blood analysed by a cell analyser and divided into groups 
according to gender. Differences between sexes were calculated using Mann Whitney non- 
parametric test at 5% significance. * represents values that were not significant after
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adjustment for multiple testing. Cord blood; male n = 5, female n = 9-11, 4/t months; male 
n = 5-10, female n = 8-15, 9 months; male n = 16-28, female n — 23-30.
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Figure 4.2: Gender differences in haemoglobin levels in each age group. Haemoglobin 
levels were determined from 250 pL whole blood using a cell analyser. Cord blood M: n = 
5, F: n = 9, 4 /  months M: n = 10, F: n = 15, 9 months M: n = 28, F: n = 30. Black bar
represents median value and the blue shaded region represents the acceptable range o f 
values from Kilifi, Kenya for children 12 months — 10 years. The yellow shaded region 
represents the cord blood ranges from Zimbabwe. Mann Whitney U test was applied to 
compare differences across ages at 5% significance, * represents values that were not 
significant after adjustment for multiple testing.
4.2.3 Differences in ex vivo cell phenotypes within the first 9 months o f  life
Immune cells from whole blood without stimulation (ex vivo) were phenotyped at 
birth (cord blood), 414- and 9- months o f age using flow cytometry with a panel o f 
antibodies that defined activated T cells (CD4 CD25 ) and Tregs (CD4 CD25 FOXP3 ) as 
described in Chapter 2: Material and Methods.
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Infants were randomised at birth to receive BCG or not. There was no reason to 
expect differences between the two groups in cord blood prior to BCG vaccination in either 
group. This was true for the absolute whole blood counts, the CD4+/CD8+ T cell 
populations and the FOXP3+ Tregs. However there were significantly more CD4 CD25 
activated T cells (p = 0.0463) in cord blood from Group 2 than Group 1 although this was 
not sustained after adjustment for multiple testing (Figure 4.3A - C).
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Group 2 p  value
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CD4 (%) 38.37 37.57 0.8813
CD8 (%) 19.31 22.83 0.0984
CD4(CD25) (%) 5.58 6.89 *0.0463
CD4(CD25FOXP3) (%) 0.92 1.14 0.2805
*not significant after Bonferroni correction, If total acquired events was 500,000 for each sample
Figure 4.3: Ex vivo cord blood responses. 100 jul cord blood was phenotyped ex vivo with 
antibodies to CD4, CD8, CD25, FOXP3 and compared between Group 1 (vaccinated at 
birth) and Group 2 (vaccinated at 4/2 months o f age). (A) Activated T cells (CD4+CD25+ ’ 
(B) Tregs (CD4+CD25+ FOXP3+>, and (C) summary table o f parameters compared. Mann
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Whitney U test was used to analyse the data at 5% significance. Median value is 
represented by a black line, n = 42 in each group, * represents values that were not 
significant after adjustment fo r  multiple testing.
Ex vivo immune cell populations were similar between Group 1 and Group 2 at 4'/4- 
and 9- months of age (Figure 4.4A-D) and when comparing T cells 4!4 months post BCG 
vaccination (i.e. 414 months in Group 1 compared to 9 months in Group 2)(data not 
shown). However, differences were found when the data was analysed longitudinally.
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Figure 4.4: Ex vivo T cell populations at 4V2- and 9- months o f age. 100 jul cord blood 
was phenotyped with antibodies to CD4, CD8, CD25, and FOXP3. (A) Activated T cells at 
4/2  months o f  age, (B) Tregs at 4 Z2 months o f age, (C) activated T cells at 9 months o f  age
and (D) Tregs at 9 months o f age. A Mann Whitney U test was used to analyse the data at 
5% significance. Median value is represented by a black line. 4 /2 months Group 1 n = 48, 
Group 2 n = 39; 9 months Group 1 n = 45, Group 2 n — 40, * represents values that were 
not significant after adjustment fo r  multiple testing.
From 100 pi blood, 500,000 events were acquired on the FACSCalibur for each 
sample. The absolute number of cord blood lymphocytes present for every 500,000 events 
obtained were significantly lower (median 141,839) than those acquired at 4Vi- (median 
165,594, p = 0.0056) and 9- months (median 169,312, p = 0.0001) (Figure 4.5A). This 
corresponded with the results obtained on the automatic cell analyser (Figure 4.5B). The 
non-lymphoid populations observed at all ages is likely to consist of macrophages and 
granulocytes which have greater size and/or granularity (Figure 4.5C) although these cell 
populations were not analysed in this study.
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Figure 4.5: Lymphocyte numbers ex vivo in young infants. 100 pi whole blood was
phenotyped by flow  cytometry immediately after collection. (A) absolute lymphocyte 
numbers in whole blood compared across ages, n = 81. (B) the percentage o f lymphocytes 
in whole blood compared across ages using a cell analyser, at birth and 4/2 months n = 13 
and 9 months n = 39. The back bar represents the median value. A Mann Whitney U test 
was used to analyse the data at 5% significance. (C) representative flow  cytometry plot ex 
vivo at 4/2 months showing lymphocyte population (black oval) and the non-lymphoid 
population (pink oval). In cord blood there are a greater number o f dead cells (illustrated 
in the region o f the red oval).
Paired longitudinal analysis of ex vivo immune populations was performed for all 
individuals grouped together regardless of BCG vaccination status for whom there was 
data for all three time points (Group 1 n = 44, Group 2 n = 37). The percentage of activated 
T cells increased from birth to AVi months and remained stable at 9 months, while there 
was a non-significant trend for reduced Tregs over time (Figure 4.6A and B).
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Figure 4.6: Longitudinal analysis on ex vivo phenotypes in all subjects. 100 pi whole 
blood at each time point was phenotyped with antibodies to CD4, CD8, CD25, and 
FOXP3. (A) CD4+CD25+ T cells, n = 81, (B) CD4+CD25+ FOXP3 T cells, n = 77. A 
Wilcoxon non-parametric paired test was used to analyse the data at 5% significance. 
Median value is represented by a black line.
When analysing longitudinal changes by vaccine groups, differences in the ex vivo 
phenotype emerged. Compared to cord blood, individuals vaccinated at birth (Group 1) had 
increased activated T cells at 414 months (p = 0.0013) that was not observed in BCG naive 
infants (Group 2) (Figure 4.7A and B). There were no differences in Group 2 414 months 
post BCG vaccine (assessed at 9 months of age) compared to cord blood or at 414 months 
of age (Figure 4.7B and D).
Ex vivo CD4 T cells, CD8^ T cells (Table 4.4) and FOXP3 Tregs (Figure 4.7C and 
D) were similar over the 9 months and were not altered by BCG vaccination.
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Figure 4.7: Longitudinal analysis on ex vivo phenotypes according to groups. 100pi
whole blood at each time point was phenotyped with antibodies to CD4, CD8, CD25, 
FOXP3. Data was separated into groups according to BCG vaccine schedule; Group I — 
vaccinated at birth, Group 2 = vaccinated at 4 V2 months. (A) Group 1 CD4 CD25 T 
cells, n = 44 (B) Group 2 CD4+CD25+ T cells, n = 37, (C) Group 1 CD4 CD25+ FOXP3+ 
T cells, n = 42 (D) Group 2 CD4 CD25 FOXP3 T cells, n = 35. A Wilcoxon non- 
parametric paired test was used to analyse the data at 5% significance. Median value is 
represented by a black line.
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At birth 4 /2  months 9 months
Birth vs 
414 m
Birth vs 
9 m
414 m vs 
9 m
lymphocytes 141,839 165,594 169,312 0.0056 0.0001 0.2852
CD4 (%) 38.79 35.87 38.07 0.0779 0.1356 0.3610
CD8 (%) 20.93 17.37 17.25 *0.0102 0.0893 0.8815
CD4(CD25) (%) 5.79 7.74 7.7 0.0003 0.0018 0.8506
CD4(CD25FOXP3) (%) 1.00 0.865 0.54 0.9914 0.1199 0.2267
Table 4.4: T cell populations at different age groups. 100 jul whole blood at each time 
point was phenotyped with antibodies to CD4, CD8, CD25, FOXP3, cord blood n = 74, 
4 V2 months n = 80, 9 months n = 82. A Wilcoxon non-parametric paired test was used to 
analyse the data longitudinally at 5% significance, blue text indicates values greater than 
the earlier time point. *represents values that were not significant after adjustment fo r  
multiple testing.
The reliability of FOXP3 as a marker of human Tregs has been a matter of concern 
since it can also be transiently upregulated upon activation of T cells (Gavin, Torgerson et 
al. 2006; Allan, Crome et al. 2007; Popmihajlov and Smith 2008) although this induction 
consistently peaked at 1 - 3 days of culture and reduced to baseline levels by 5 - 10 days. 
This would suggest Treg populations observed in this study after 5 days stimulation were 
likely to be ‘true' Tregs (see Chapter 2: Materials and Methods and Appendix VII).
In light o f these results a strong correlation between activated and regulatory T cells 
at 9 months of age was found in both vaccine groups (Table 4.5A and B). A weaker 
correlation also existed between activated T cells and Tregs in cord blood and at 
months although this was not significant after adjusting for multiple testing, and was not 
apparent when analysing by vaccination group.
It was hypothesised that increased regulatory T cells induced by exposure to 
environmental mycobacteria within the first 4 'A months of life may attenuate the response
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to BCG. When vaccinated at birth, the proportion of Tregs prior to vaccination was 
positively correlated to the levels of activated T cells (p < 0.0001, r = 0.5821) and Tregs at 
9 months (p < 0.0001, r = 0.6150) but not at 414 months (Table 4.5A and Figure 4.8). For 
Group 2 (vaccinated at 414 months) there was, similarly, no correlation at 4/4 months post 
vaccine (p = 0.3419, r = 0.1708)(Table 4.5B). The response at 9 months post vaccine in 
Group 2, i.e. 13!4 months of age was not measured in this study.
A
GROUP 1 Tregs at birth Tregs at 4Vi m Tregs at 9 m
Activated T cells at birth 0.2613 0.3742 0.6883
Activated T cells at 4Vi m 0.7968 0.0651 0.7871
Activated T cells at 9 m <0.0001 0.2542 0.0001
Tregs at birth 0.0583 < 0 .0 0 0 1
Tregs at 4'A m 0 .1732
Tregs at 9 m
B
GROUP 2 Tregs at birth Tregs at 4'A m Tregs at 9 m
Activated T cells at birth *0.0311 0.6498 0.7494
Activated T cells at 4% m 0.7054 0.4508 0.8466
Activated T cells at 9 m 0.4543 0.3419 0.0028
Tregs at birth 0.3038 0.6424
Tregs at 4Yi m 0 .7387
Tregs at 9 m
Table 4.5: Correlations between CD4 CD25+ activated T cells and CD4 CD25 FOXP3 
Tregs. 100 pi whole blood at each time point was phenotyped with antibodies to CD4, 
CD25, FOXP3. Comparisons between activated T cells (CD4 CD25) and Tregs 
(CD4 CD25 FOXP3 ) in (A) Group 1 (vaccinated at birth) and (B) Group 2 (vaccinated at 
4/2  months o f age) were examined using Spearman’s correlation coefficient. Values
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represented are p  values. Blue text = significant values at 5% significance. * represents 
values that were no longer significant after Bonferroni. Activated T cells; Group 1 n = 44, 
Group 2 n =37, Tregs: Group 1 n = 42, Group 2 n = 35.
201 %CD4+CD25+FOXP3+ at 9 m
i CD4+CD25+ at 9 m
%CD4+CD25+FOXP3+ 
at birth
Figure 4.8: Correlation between regulatory T cells at birth and T cell subsets at 9 
months in Group 1. 100 p i whole blood at each time point was phenotyped with antibodies 
to CD4, CD25, FOXP3. Comparisons between Tregs (CD4 CD25 FOXP3 ) at birth and 
activated T cells (CD4 CD25 ), n = 44 and Tregs n = 42 at 9 months o f age in Group 1, 
were examined using Spearman’s correlation coefficient.
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4.3 DISCUSSION
The reference ranges used for this study were based on values from African 
populations since Western ranges are not appropriate; for example, the World Health 
Organisation (WHO) reports anaemia in adults as <13 g/dL for men and <12 g/dL for 
women (<11 g/dL pregnant women) (WHO and CDC 2007), whereas these levels are 
within the normal range for an African adult population. The results of the study will 
contribute to a database of pooled results from Gambian infants to establish appropriate 
reference ranges in this study population.
As has been documented previously the blood cell indices changed significantly in 
the first 9 months of life. Cord blood indices were markedly different to those observed at 
4/4- and 9- months of age. Higher levels of Hb, PCV, MCV and MCH alongside reduced 
RBCs suggest that the red blood cells in cord blood are larger, denser and contain more 
haemoglobin per cell compared to infants. This may reflect the larger number of nucleated- 
RBC precursors (NRBC) present in cord blood. Within a few months of life these are 
enucleated by the liver and disappear from the peripheral circulation (Rolfo, Maconi et al. 
2007). Foetal Hb is both structurally and functionally different to adult Hb and may 
partially account for markedly higher levels in cord blood. However, because of their size 
and the ability for these NRBCs to resist lysis they may also be counted as white blood 
cells in the automatic cell analyser, thus leading to a falsely high white blood cell count. 
Indeed, recent automated counting methods that can distinguish these cells from normal 
white blood cells have demonstrated that approximately 3% (0 -  11.6%) of WBC in cord 
blood are in fact NRBC (Rolfo, Maconi et al. 2007). This may well explain the higher 
numbers of cells classified as WBCs in cord blood in this study and the higher reference 
ranges for WBCs in cord blood (Figure 4.1 and Table 4.2). The lymphocyte population 
showed the opposite trend to WBC and was lowest at birth increasing with age. Thus 
lymphocytes cannot account for the higher WBC count at birth. Increased WBC often 
accompanies infections but none of these children exhibited signs of infection when
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assessed at birth. Subclinical infections such as CMV or Epstein-Barr virus (EBV) can be 
acquired very young (including congenitally) in this population and are often 
asymptomatic (Miles, van der Sande et al. 2007) and may contribute to this finding, 
however all those with high WBC values at birth were not infected with CMV (data not 
shown).
Many studies have shown gender differences in blood cell indices in adults, but 
there are conflicting views as to whether the differences are physiological or are due to 
hormonal changes in women (Jackson, Carter et al. 2001; Rushton, Dover et al. 2001).The 
higher levels of Hb, MCV and MCH observed in 9 month old females compared to males 
in this study, is in contrast to patterns observed in adult studies where males have the 
higher blood cell indices suggesting some gender differences may not be related to sex 
hormones. It was also found that 80% of anaemic infants at 4Vi- and 9- months of age were 
boys. In support of our findings, Meinzen-Derr et al found that in a Mexican cohort, 65% 
of anaemic children at 9 months of age (Hb < 10g/ dL) were boys (Meinzen-Derr, Guerrero 
et al. 2006). Interestingly this study also showed that infants who are exclusively breast-fed 
for >6 months of age in developing countries may be at an increased risk of infant anaemia 
(Meinzen-Derr, Guerrero et al. 2006). In addition, extrapolated data from a study in 
Gambia found that the higher range of Hb for females up to 15 years of age than males but 
this reversed from 15 years to adult ranges where males have the higher ranges (Adetifa, 
Hill et al. 2008). There are reports that various vaccine regimes in early life can influence 
morbidity and mortality in a gender related fashion (Aaby, Jensen et al. 2003; Gariy, Jensen 
et al. 2004; Veirum, Sodemann et al. 2005; Aaby, Ibrahim et al. 2006; Aaby, Biai et al.
2007), further supporting gender effects at the pre-pubertal stage in life. Further gender 
related immune cell activity will be discussed in Chapter 7.
Unlike mice, human T cell production occurs during gestation and therefore at birth
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a diverse repertoire of T cells are present, although 90% of these are thought to have a 
naive phenotype (CD45RA+) (Adkins, Leclerc et al. 2004). This study analysed, by flow 
cytometry ex vivo lymphocytes expressing the markers CD4, CD8, CD25 and FOXP3.
Flow cytometry confirmed lower lymphocyte levels in cord blood compared to the 
other ages as seen with the cell analyser results. This agrees with published studies 
suggesting that they exhibit a higher degree of apoptosis compared to adults (Szabolcs, 
Park et al. 2003; Thornton, Upham et al. 2004; Kessel, Yehudai et al. 2006). CD4+ and 
CD8+ T cell frequencies within the lymphocyte population were comparable across all 
three age groups although they were reduced compared to the UK but similar to those 
observed from studies in India, Botswana and China (Das, Bhanushali et al. 2008). This 
further highlights the importance of geographical location in determining the ‘normal’ 
range for immune cell subsets.
One of the main aims of the study was to analyse the effect of delaying BCG 
vaccination on immune development. It was hypothesised that exposure to NTM in the 
absence of BCG vaccination might lead to the induction of Tregs. Certainly there was no 
difference in ex vivo Tregs at 414 months of age between BCG vaccinated (Group 1) and 
BCG naive (Group 2) infants suggesting Treg induction in the peripheral circulation was 
not affected by the presence or absence o f BCG vaccination. Antigen specific responses 
will be discussed in later chapters.
By contrast CD4+CD25+ T cell frequencies did increase significantly from birth in 
the vaccinated group, but not in the BCG naive group. However there was no difference 
between groups when comparing responses at 414 months of age which may be due to the 
lower activated T cells in the group vaccinated at birth (Group 1).
The strong positive correlation between Tregs prior to vaccination at birth and both 
activated T cell and Treg frequencies at 9 months of age is difficult to explain but suggest a 
relationship does exist between immune status at the time of receiving BCG and the ex 
vivo immune ‘set point’ 9 months later. However this effect was not strong enough to lead
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to statistical differences between Tregs or activated T cells in this Group 1 (vaccinated at 
birth) and those vaccinated 4}A months later.
Ex vivo responses may be confounded by several things including timing of 
previous vaccines, illness or external factors. These confounders were minimal in our study 
as the two groups were under the same environmental pressures and blood was not 
collected from children who exhibited signs of intercurrent infection. As mentioned 
previously, chronic asymptomatic infections such as CMV, EBV or colonisation by 
helminth parasites could all lead to changes in circulating T cells. In this community, 
previous studies have estimated 90% of children are infected with CMV by 12 months of 
age (Miles, van der Sande et al. 2007). CMV infection status of the children in this study 
will be discussed in chapter 7. Helminths, however seem to be less common in Gambia 
than expected. Nyan et al found 17% and 8.2% helminth infection in adults from urban and 
rural locations, respectively (Nyan, Walraven et al. 2001). More recent studies have shown 
very low levels, between 0 -  3% in adult populations from both low and high malaria 
exposed regions suggesting helminth infection is unlikely to be a confounding factor 
(Finney 2009).
Overall, cord blood exhibits different ranges for blood cell indices compared to 
infants at 4%- and 9- months which may largely be due to NRBCs present in cord blood 
but the differences observed in T cell populations were less obvious. Circulating activated 
T cells increased with age and possibly after BCG vaccination at birth. It was also 
concluded that the level of Tregs prior to BCG vaccination may relate to the frequencies o f 
circulating activated T cells and Tregs present 9 months later.
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CHAPTER 5
Exposure to environmental mycobacteria 
influences immunogenicity of BCG
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5.1 INTRODUCTION
In countries that are high risk for TB, BCG is recommended to be given at birth, on 
first contact with healthcare workers, or at least within the first year of life, although there 
is little immunological evidence that confirms when best protection is achieved. BCG at 
birth induces quantitatively and qualitatively similar Thl responses to vaccination as an 
adult, although many other vaccines (HBV, OPV, measles) given early in life induce Th2 
responses (reviewed in (Marchant and Goldman 2005)). The BCG induced Thl response is 
thought to be due to mycobacteria being potent activators of dendritic cells (Henderson, 
Watkins et al. 1997; Ausiello, Fedele et al. 2002). However, there is evidence that 
presentation of antigens is less efficient in neonates (reviewed in (Fadel and Sarzotti 2000) 
and (Siegrist 2001)) and, although TLR expression patterns on neonatal innate cells are 
similar to adults, they have reduced function (reviewed in (Levy 2007)).
5.1.1 Role o f cytokines in BCG immunogenicity
Immune correlates of protection against TB have mainly focused on T cell 
production of IFNy (Ellner, Hirsch et al. 2000). The importance of this cytokine can be 
demonstrated in those individuals with polymorphisms of IFNy or those with IFNGR 
deficiency. Patients with both dominant and recessive deficiencies in IFNyRl and STAT1 
have increased mycobacterial susceptibility and in the case of recessive STAT1 mutations, 
disseminated BCG disease can develop after BCG vaccination (reviewed in (Rosenzweig 
and Holland 2005)). Induction of IFNy is associated with IL-12 production and therefore it 
is not surprising that deficiencies in IL-12 can also exhibit themselves in susceptibilities to 
mycobacterial infection and impairment of memory T cell functions (Cleary, Tu et al. 
2003).
BCG induces a strong Thl response, in particular the production of IFNy, but can 
also induce other cytokines that may affect the protective response. A Th2 response is often 
evident alongside the Thl cytokine production in response to BCG, the dynamics of which
115
may be important in the maintenance and subsequent protection levels that are achieved. 
Sander et al showed that 1 —2 days after in vitro stimulation with live BCG the response is 
dominated by low IFNy and TNFa production. By 4 -  5 days there was a marked 
production of Thl lymphokines with 6% IFNy4, 4% TNFa4 and 2% IL-24 producing T 
cells. Late in the reaction, at 10 — 12 days, a Th2 response with increased IL-4, IL-5 and 
IL-10 was detected while the synthesis of Thl cytokines declined (Sander, Skansen-Saphir 
et al. 1995). The protective effect of BCG-induced IFNy has also come into question 
recently. Using 3 different in vitro bacterial inhibition assays, M.tb lysate or live BCG 
growth inhibition did not correlate with IFNy production from BCG stimulated 5 day 
cultures (Hoft, Worku et al. 2002). In addition a recent human study in South Africa 
showed that a significant number of BCG induced CD4 T cells failed to express IFNy, but 
expressed TNFa and IL-2 (Soares, Scriba et al. 2008). These studies suggest that BCG- 
induced IFNy may not be sufficient to study BCG protective responses. As reported in 
studies of TB both in mice and humans (reviewed in Chapter 1) the lack o f IFNy does not 
always correspond to lack of protection suggesting a signature comprising of a number of 
cytokines may be more informative as a correlate of protection. IL-17 is a pro- 
inflammatory cytokine that is predominantly produced by Thl 7 differentiated CD4+ T cells 
in the presence of IL-23, (Lockhart, Green et al. 2006; Khader, Bell et al. 2007; Khader 
and Cooper 2008). TGFp together with IL-6 or IL-21, independently o f IL-23 can also 
initiate this production suggesting a link with the innate response (Awasthi and Kuchroo 
2009). Interestingly, without IL-6 production, TGFp initiates development of adaptive Th3 
Tregs and therefore these cell types may be closely regulated acting optimally to control 
infection (Weaver, Harrington et al. 2006). Tuberculosis patients have shown reduced 
levels of CD44 production of IL-17 suggesting Thl 7 may be protective against TB (Scriba, 
Kalsdorf et al. 2008; Sutherland, Adetifa et al. 2009). It has been proposed that BCG 
vaccination induces IL-17-producing CD44 T cells that populate the lungs and, after 
challenge, trigger the production of chemokines that recruit CD44 T cells producing IFNy
which ultimately restrict bacterial growth (Khader, Bell et al. 2007). However IL-17 is 
increased in IFNy deficient mice following infection with BCG and these mice were 
unable to control the infection suggesting that IL-17 is not protective or that interaction 
with IFNy is required for IL-17 function (Cruz, Khader et al. 2006). IL-23 plays a role in 
generating IL-17 producing T cells and in the absence of IL-23, BCG vaccination of mice 
did not induce an accelerated memory response suggesting IL-23 may be required as part 
of the priming o f a secondary response rather than during the initial effector priming 
(Khader, Bell et al. 2007).
It has long been recognised that suppressor responses can also be induced by BCG 
(Bennett, Rao et al. 1978; Schrier, Allen et al. 1980) but more recently nTregs (Jaron, 
Maranghi et al. 2008) and IL-10 production (possibly by aTregs) have been shown to play 
a role, both in animal models (Jacobs, Fick et al. 2002; Barlan, Bahceciler et al. 2006; 
Morel, Badell et al. 2008; Li and Shen 2009) and in humans (Hanekom 2005; Sendide, 
Deghmane et al. 2005; Madura Larsen, Benn et al. 2007; Mendez-Samperio, Trejo et al.
2008). As mentioned above, the dynamics of cytokine induction following BCG 
vaccination has been shown to vary according to cytokine in in vitro studies, and this may 
correspond to the development of anti-mycobacterial immunity. Thus, Nabeshima et al 
showed that the IFNy response to PPD in adults vaccinated with BCG, peaked at 8 weeks 
and declined by 12 weeks, whereas IL-10 levels peaked at 2 weeks and declined to the 
lowest point 8 weeks after stimulation (Nabeshima, Murata et al. 2005).
5.1.2 Innate response to BCG
More recently it has been recognised that, in mice BCG can infect cells of the 
innate immune system (neutrophils, DCs and NK cells) often through TLRs leading to a 
polarised adaptive response indicating that mechanisms which upset these early 
interactions could alter T cell immunity to BCG vaccination (Esin, Batoni et al. 2004; 
Feinberg, Fieschi et al. 2004; Madura Larsen, Benn et al. 2007; Naoe, Ogawa et al. 2007;
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Marcenaro, Ferranti et al. 2008; Morel, Badell et al. 2008). It is likely that the majority of 
IFNy responses early in infection are produced by NK cells (Esin, Batoni et al. 2004; 
Feinberg, Fieschi et al. 2004; Marcenaro, Ferranti et al. 2008). Receptor NKp44 was 
induced after 3 and 4 days of in vitro stimulation with live BCG suggesting BCG directly 
interacts with NK cells (Esin, Batoni et al. 2008). In addition complement has also been 
shown to play a role in BCG immunogenicity. Complement C5a (anaphylatoxin), secreted 
by mycobacteria-infected macrophages, regulates IL-12p70 production. DCs from mice 
that lacked C5a secreted less IL-12p70 and more IL-10 in response to BCG, which led to 
reduced IFNy production from CD4+ and CD8+ T cells (Moulton, Mashruwala et al. 2007).
5.1.3 Role o f Tregs in BCG immunogenicity
Recent interest in regulatory T cells has led to the idea that Tregs (both nTregs and 
aTregs) may play a role in the anti-mycobacterial immunity. One investigation examined 
whether nTregs suppress the development of protective immunity to BCG in mice. 
Inactivating CD4+CD25+ Tregs prior to BCG vaccination increased the numbers of IFNy 
producing CD4+ and CD8+ T cells from the draining lymph nodes at 14 days post 
vaccination but surprisingly, protection was not affected (Quinn, Rich et al. 2008). The 
authors proposed this may have been due to an induction of aTregs in the periphery and/or 
IL-10 production but also support the increasing evidence that IFNy is not the sole 
cytokine responsible for protection.
5.1.4 BCG immunogenicity in humans
Human studies of infant BCG vaccination have shown varying degrees o f IFNy 
responses which seem to be dependent on the timing of vaccination, as reported in cattle 
studies (Buddie, Wedlock et al. 2003). Marchant et al found that delaying the BCG 
vaccination to 2 months induced a trend for lower PPD stimulated IFNy production 2 
months later compared to vaccination at birth although this was not significantly different.
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Overnight IFNy responses to PPD-tuberculin (PPD-T) persisted to 12 months of age in all 
vaccine groups (vaccination at birth, 2- and 4- months of age) although lower than initial T 
cells responses, suggesting memory T cells were activated (Marchant, Goetghebuer et al. 
1999). In contrast to this work, delaying the BCG vaccine to 10 weeks o f age and assessing 
10 weeks later, showed a trend for a greater induction of both IFNy and IL-10 production 
in response to heat killed BCG after 5 days stimulation compared to 10 weeks post 
vaccination at birth although this, also was not statistically significantly. In addition the 
sample size was small (n = 6 -  11) and therefore there is a high probability of this trend 
occurring by chance (Hussey, Watkins et al. 2002).
5.1.5 NTM effect on BCG immunogenicity
It has been suggested that the variation in BCG efficacy across different geographic 
locations (Rodrigues, Diwan et al. 1993; Colditz, Brewer et al. 1994; Colditz, Berkey et al. 
1995) is due to attenuated responses following exposure to NTM (the contribution of 
which varies across the globe) (Palmer and Long 1966; ten Dam 1984; Fine, Sterne et al.
1994). Epidemiological studies have illustrated greater efficacy of BCG in neonates 
vaccinated before prior NTM exposure (Colditz, Brewer et al. 1994; Colditz, Berkey et al.
1995) (Tidjani, Amedome et al. 1986; Lanckriet, Levy-Bruhl et al. 1995) and in vaccine 
trials where TST positive individuals have been excluded (Hart and Sutherland 1977). 
Areas with high exposure to NTM, like Southern India, where isolates of M. avium- 
intracellulare-scrofulaceum (MAIS) are commonly found in water and dust (Kamala, 
Paramasivan et al. 1994), BCG is particularly ineffective (Fine 1995). Animal studies have 
also provided support for this hypothesis. The original work was performed in guinea pigs 
sensitised with M. fortuitum, M. avium and M. kansasii prior to BCG vaccination. Palmer 
and Long suggested that environmental (non-tuberculous) mycobacteria (NTM) exposure 
primed the immune response providing a level of protection that then masks the protective 
response from BCG vaccination (Palmer and Long 1966). A second theory suggests that
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exposure to NTM blocks the BCG growth and protection. Mice and guinea pigs pre­
sensitized with M. avium or with cocktails of M. avium, M. vaccae, and M. scrofulaceum 
develop anti-mycobacterial responses that control the multiplication of BCG, thereby 
reducing its protective efficacy against TB (Kamala, Paramasivan et al. 1996; Brandt, 
Feino Cunha et al. 2002). The blocking of BCG immunogenicity by M. avium has been 
observed in mice and cattle by several research groups (Brandt, Feino Cunha et al. 2002; 
Young, Slobbe et al. 2007).
Cattle studies have also been useful in the understanding of the immunogenicity of 
BCG; they are the natural host for M. bovis and the clinical disease processes are very 
similar to humans. It also provides a model of natural sensitisation of NTM which can be 
exploited to consider its effect on BCG vaccination. Calves have minimal responsiveness 
to NTM antigens at birth but by 6 -  9 weeks of age most are responding to PPDs prepared 
from M. avium and M. bovis and some to ESAT-6/ CFP-10 antigens in a overnight whole 
blood IFNy assay (Buddie, Wedlock et al. 2003). Delaying BCG vaccination to 6 weeks of 
age compared to at birth induced similar IFNy responses, but less proliferation in response 
to PPD, although the level of protection conferred was similar (Buddie, Wedlock et al.
2003). Interestingly revaccination at 6 weeks after prior vaccination at birth reduced 
protection in calves possibly by inducing pro-inflammatory immunopathology (Buddie, 
Wedlock et al. 2003). However when comparing this study to an earlier study from the 
same group, vaccination at birth or 6 weeks of age was better at protecting calves from 
disease compared to vaccination at 5 - 8 months of age (Buddie, Wards et al. 2002). This 
suggests that the dynamics of NTM exposure at different ages is different and therefore the 
age of vaccination is important in the relationship between the response to NTM antigens 
and protection by BCG. Theories of how NTM may affect BCG immunogenicity are 
discussed later but briefly it is thought that exposure to mycobacterial antigens similar to 
that of BCG masks or inhibits the response to BCG.
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The mechanism by which pre-sensitisation with NTM reduces the protective 
capacity of BCG may be due to priming of the host immune system against mycobacterial 
antigens shared with BCG, and that recall o f this immune response upon vaccination results 
in accelerated clearance of BCG and hence decreased protective immunity against TB. 
Another possibility is that early exposure to cross-reactive mycobacteria may imprint an 
inappropriate Th2 or regulatory T cell response which negatively influences the response to 
BCG (Rook, Bahr et al. 1981; Stanford, Shield et al. 1981; Young, Slobbe et al. 2007). 
However, when mice were pre-sensitised with a more phlogenetically distant mycobacteria 
such as M. vaccae, the protective efficacy was enhanced, suggesting that strain variation 
and genetic relatedness of the mycobacteria can affect immune responses to BCG 
(Demangel, Gamier et al. 2005). Thus prior exposure to certain mycobacteria can prime 
the immune response to mycobacterial antigens and boost the BCG affect but only when it 
can override the immunological control imparted by sensitisation with these strains 
(Demangel, Gamier et al. 2005). The blocking or masking of BCG protection by NTM has 
been shown in several other animal studies (Weiszfeiler and Karasseva 1981; Edwards, 
Goodrich et al. 1982; Brown, Brown et al. 1985; Orme and Collins 1986; Kamala, 
Paramasivan et al. 1996; Howard, Kwong et al. 2002).
There are relatively few human studies; most based on the comparisons of 
populations of high NTM exposure e.g. Malawi, to low exposed areas e.g. UK (Farhat, 
Greenaway et al. 2006; Weir, Black et al. 2006). Black et al showed in Malawi that IFNy 
production to PPD following BCG was greater in those individuals with low initial 
responsiveness to MAIS antigens (Black, Dockrell et al. 2001). These pre-vaccination 
cytokine responses, from the supernatant of 6 day whole blood assays, were dependent on 
the type of NTM, where more individuals responded to the MAIS antigens than to other 
NTM antigens, such as M. fortuitum (Black, Dockrell et al. 2001) supporting previous skin 
test studies in the same population (Fine, Floyd et al. 2001). This finding also suggests 
that, in Malawi the predominant NTM in the environment may be responsible for the low
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protective levels of BCG found in this location. In a separate study by the same group 61% 
of BCG naive adults in Malawi were responders to PPD (> 62 pg/mL) compared to 22% in 
the UK suggesting there is less NTM exposure in the UK than in Malawi. The magnitude 
of response from before, to 1 year post-vaccination was higher in the UK than Malawi 
which corresponds to the level o f protection observed in these countries (Black, Weir et al. 
2002).
In a comprehensive review of the literature, Stanford and Rook et al proposed a 
two-pathway theory postulating that BCG vaccination can trigger either a protective or an 
antagonistic immune reaction based on the mycobacterial source of pre-vaccination 
sensitivity (Rook, Bahr et al. 1981; Stanford, Shield et al. 1981).
5.1.6 Non-specific effects o f  BCG
There are increasing, but still controversial reports that BCG vaccination may 
influence the maturation of the immune system non-specifically and have impacts on 
health later in life. It is clear that when administered at birth, BCG protects against leprosy, 
meningitis and extrapulmonary forms of TB (Antas and Castello-Branco 2008) but there is 
also evidence that BCG protects against various inflammatory or autoimmune diseases 
such as allergy, asthma, Crohn’s disease, insulin-dependent diabetes mellitus and specific 
cancers (epidemiological review in (Rousseau, Parent et al. 2008). The non-specific 
immunostimulatory effects of BCG have been widely documented as a treatment for 
bladder cancer (Bohle, A et al, 2003, Suttmann, H et al, 2004, Chen, X et al, 2007). BCG 
has been shown to induce neutrophils to release TNF-related apoptosis-inducing ligand 
(TRAIL) in an IFNy dependent manner which then migrates to the bladder and kills 
cancerous cells (Simons, ODonnell et al. 2008). In a mouse asthma model BCG induced 
CD4+CD25+ Tregs and FOXP3 expression, accompanied by IL-10 and TGFp production, 
and reduced asthma (Li and Shen 2009). It is therefore not surprising that BCG at birth can 
affect responses to other vaccines in early life (Ota, Vekemans et al. 2002). It was
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unexpected that BCG could promote both Thl and Th2 responses to unrelated antigens. 
This vaccine adjuvant effect has been attributed to the effect of defective DC maturation in 
infants. Under suboptimal conditions of co-stimulation of DCs IL-12 has been shown to 
induce Thl and Th2 cytokines by neonatal CD4+ T cells (Ota, Vekemans et al. 2002). 
However further studies are still needed to understand these mechanisms.
In some areas of the world BCG protection is low but can protect against more 
severe forms of TB as mentioned earlier, such as meningitis and disseminated TB and may 
persist for 10 years after infant vaccination (meta analysis (Colditz, Berkey et al. 1995)). 
More recently there is mounting evidence that BCG effects all-cause child morbidity and 
mortality (Kristensen, I et al, 2000, Elguero, E et al 2005, Stensballe, LG et al, 2005, Roth, 
A et al, 2005, Moulton, LH et al, 2005, Rodrigues, A et al, 2006). This may influence 
decisions regarding infant vaccine schedules in the future. With the beneficial effects from 
severe forms of TB during infancy and the potential for non-specific protection, new 
strategies for TB vaccines are often based on improving the existing BCG vaccine (e.g. 
recombinants BCG) or using BCG as the mycobacterial prime followed by a heterologous 
boost rather than replacing the BCG vaccine completely (reviewed in (Sander 2007)). 
Non-specific effects of BCG in our study are addressed in Chapter 7.
5.1.7 Heritability o f mycobacterial responses
Responses in humans are very heterogeneous necessitating large sample sizes to 
account for the variation in responses. An interesting study from The Gambia found that in 
2 month old, BCG vaccinated infants, IFNy, IL-13 and IL-5 responses to various 
mycobacterial antigens (PPD, Ag85, STCF and KM .W ) varied within a population by 10- 
fold (Finan, Ota et al. 2008). Response patterns of responders and non-responders, based 
on detection levels of cytokine ELISA assays, differed for each cytokine; there were more 
IFNy responders than for the Th2 cytokines as expected. It was suggested that this 
variation within populations might be genetically linked (Newport, Awomoyi et al. 2003;
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Finan, Ota et al. 2008). Newport et al, 2004 showed that responses to BCG were 
predominantly controlled by genes within the human leukocyte antigen (HLA) class II 
locus. Heritability was observed for IFNy and IL-13 responses to PPD but not to Ag85 or 
PHA which may be contributed to the promiscuity of the Ag85 peptide that can be 
presented by multiple MHC class II molecules (Newport, Goetghebuer et al. 2004). 
Although IFNy polymorphisms have been associated with clinical TB disease, in the 
Gambian population IFNy receptor 1 polymorphism was not associated with pulmonary 
TB (Awomoyi, Nejentsev et al. 2004). This area of research needs further investigation to 
understand the contribution genetics plays to BCG responses and protection from TB 
infection and disease.
This chapter investigates the effect of BCG vaccination early (Group 1, at birth) or 
delayed (Group 2, at 414 months of age) on the development of mycobacterial immunity in 
early life. Blood samples were collected at birth (cord blood), 414- and 9- months of age. At 
4/4 months of age comparisons between BCG vaccinated children with BCG naive 
children were assessed.
124
5.2 RESULTS
5.2.1 Reactivity to mycobacterial antigens in cord blood
At birth neither groups had been vaccinated with BCG therefore results were 
analysed collectively to examine cord blood responses. Cord blood memory responses 
were assessed comparing unstimulated background reactivity to antigen stimulated values.
Cord blood is thought to contain predominantly naive T cells and it was therefore 
surprising that cord blood T cells responded to mycobacterial antigens. Reactivity to PPD 
was stronger than to BCQ although similar trends were observed. There was no increase in 
activated T cells when stimulated with each of the mycobacterial antigens tested, but CD4+ 
and CD8+ T cells proliferated and FOXP3+Tregs increased in response to PPD (Figure 
5.1A-C). Proliferation, but not increased Tregs, was also observed with BCG and ESAT-6/ 
CFP-10 fusion protein stimulation. This is most likely to be predominantly due to CD4+ T 
cells since after adjustment for multiple testing CD8+ proliferation was no longer 
significantly increased.
Of the cytokines tested from the supernatants, IFNy and IL-10 were upregulated 
compared to unstimulated control for all antigens (IFNy: PPD and BCG p < 0.0001, EC p = 
0.0292, IL-10: PPD p < 0.0001, BCG p = 0.0021, EC p = 0.0266) although levels produced 
were very low. Figure 5.ID illustrates the production of cytokines in PPD stimulated 
cultures after subtracting the unstimulated controls. Although the levels are low it is 
evident that there are individuals producing IFNy and IL-10. In the case o f IL-10 in 
particular, there are a number of individuals who also downregulated IL-10 production 
(Figure 5.ID). Increased IL-10 production was also observed in response to PPD by flow 
cytometry (p = 0.0154) but not from CD4+ (p = 0.1014) or CD8+ (p = 0.3476) T cells. IL- 
10 is produced from many cell types including B cells, monocytes, macrophages and 
possibly other innate immune cells, but these cells were not analysed in this study. IL-13 
production was very low, with the maximum above background being 10 pg/ml, but it was 
significantly greater than zero (p = 0.0003). Adjustment for multiple testing did not alter
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a n y  o f  t h e s e  f i n d i n g s .
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Figure 5.1: In vitro cord blood responses to PPD. 500 pL whole blood diluted 1: 5 was
cultured with PPD for 5 days. Comparisons between unstimulated (pale green bars) and 
PPD stimulated (dark green bars) o f  CD4 CD25+ (A), CD4 CD25 FOXP3+ (B) and Ki- 
67+ (proliferating) T cells (C) in cord blood. Bars represent means and standard error o f  
the means (SEM) error bars. Unstimulated values subtracted from PPD stimulated values 
were plotted for three cytokines, IFNy, IL-10 and IL-13 from the culture supernatants (D); 
median values are presented as black lines. A Wilcoxon non-parametric paired test was
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applied at 5% significance. Sample number was 76 +/- 4 fo r  flow  cytometry and n =  88 fo r
cytokine data. *  not significant after Bonferroni correction fo r  multiple testing.
It was surprising to find that there were responses to ESAT-6/CFP-10 fusion 
protein (EC) in cord blood above background although the levels were very low. EC 
induced CD4 and CD8 T cell proliferation (Figure 5.2A). In addition, unadjusted values 
would suggest there was also EC specific IFNy and IL-10 production (Figure 5.2B and C); 
the IL-10 production was likely to be from CD4^ T cells (Figure 5.2C) suggesting previous 
priming from these mycobacterial antigens in utero. The EC status of the mothers was not 
studied but it would be interesting to compare these with the children that responded to the 
EC antigen.
CD4+IL-10 CD8+IL-10CD4+Ki-67 CD8+Ki-67
Figure 5.2: Cord blood responses to ESAT-6/CFP-10 fusion protein. 500 pL whole cord 
blood diluted 1: 5 was cultured with EC fo r  5 days. Comparisons between unstimulated 
(pale blue bars) and EC stimulated (dark blue bars) cultures were compared fo r  C D 4K i- 
67+ or CD8+KI-67+ proliferating T cells (A), IFNy and IL-10 cytokine production from  
supernatants (B) and IL-10 production from CD4+ or CD8+ T cells (C). Bars represent 
means and SEM error bars. Wilcoxon non-parametric paired test was applied at 5%
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significance. Sample number was 76 +/- 4 for flow cytometry and n = 88 for cytokine data.
*  not significant after Bonferroni correction for multiple testing.
5.2.2 Reactivity to mycobacterial antigens at 4 V2 months o f age
At 4/4 months there was the opportunity to compare immunity in a BCG 
experienced group (Group 1) with BCG nai've children (Group 2). Vaccination with BCG 
at birth elicited activated immune responses 4/4 months later in response to PPD. The 
pattern of responses to BCG was similar but lower, so much of the subsequent analysis 
discusses PPD reactivity which is consistent with most published work assessing BCG 
immunogenicity.
After adjustment for multiple testing it was evident that the BCG vaccinated group 
exhibited a strong PPD-specific reactivity including increased CD4+CD25+ activated T 
cells and CD4+FOXP3+Tregs in addition to T cell proliferation. In addition there was a 
down regulation of CD3+ and CD4+ expression by T cells following PPD stimulation 
(Table 5.1 and Figure 5.3).
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UNS PPD p  value BCG p  value
CD3 61.52 59.24 0.0012 63.01 *0.0291
CD4 44.65 36.85 0.0012 41.24 0.0058
CD8 13.27 15.19 0.0020 14.14 *0.0203
CD4(CD25) 4.19 19.85 < 0.0001 14.53 < 0.0001
CD4(CD25FOXP3) 0.31 7.47 < 0.0001 4.195 < 0.0001
Ki-67 1.43 7.26 < 0.0001 4.25 < 0.0001
CD4(Ki-67) 1.83 11.53 < 0.0001 6.115 < 0.0001
CD8(Ki-67) 2.65 8.14 < 0.0001 6.82 0.0011
IL-10 2.34 2.8 *0.0136 3.32 *0.0096
CD4(IL-10) 2.955 3.96 *0.0044 4.075 *0.0153
CD8(IL-10) 5.92 9.94 *0.0197 11.34 *0.0221
TGFp 1.37 2.14 *0.0172 1.905 0.2822
CD3CD4(TGFP) 1.08 2.165 *0.0441 1.94 0.3082
CD3CD8(TGFp) 4 6.52 *0.0207 5.705 *0.0221
IFNy 30.57 888.3 < 0.0001 279.5 < 0.0001
IL-6 90.25 12495 < 0.0001 2014 < 0.0001
IL-7 1.16 8.655 < 0.0001 3.325 0.0012
IL-10 3.355 26.12 < 0.0001 8.125 0.0015
IL-13 1.635 297 < 0.0001 3.24 < 0.0001
IL-17 1.065 15.61 < 0.0001 2.945 0.0037
Blue text = significant upregulation compared to unstimulated at 5% significance 
Red text = significant downregulation compared to unstimulated at 5% significance 
* Not significant after Bonferroni correction
Table 5.1: In vitro responses in Group 1 (vaccinated at birth) at 4V2 months. 500 pL
whole blood diluted 1: 5 was cultured with PPD and BCG fo r  5 days. Table represents 
comparisons between T cell phenotypes (%) and cytokine production (pg/ml) from  
supernatants in unstimulated and stimulated cultures in Group 1 (vaccinated at birth). A 
Wilcoxon non-parametric paired test was applied at 5% significance, n = 40 +/- 4.
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Figure 5.3: Flow cytometry plots o f PPD stimulated whole blood. 500 pL whole blood 
diluted 1: 5 was cultured with PPD fo r  5 days. At 4/2  months o f age BCG vaccinated 
subjects (B, D and E) and unvaccinated (A and C) illustrating CD25+ T cells gated on 
CD4+ T cells (A and B) and CD25 FOXP3+ T cells gated on CD4+ T cells (C and D) 
(unstimulated samples on the left and PPD stimulated samples on the right). (F) 
Downregulation o f CD3+ after PPD stimulation compared to unstimulated gated on the 
lymphocyte population.
In response to PPD in the BCG vaccinated individuals, a mean of 23% of all CD4 
T cells expressed the activation marker CD25 (6.5% in unstimulated) and 10.8% of CD4 
T cells were of a CD25 FOXP3 phenotype (1.3% in unstimulated control) (Figure 5.4A
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and B). Interestingly the BCG naive group also had increased activated T cells and Tregs in 
response to PPD stimulation in vitro at 4/4 months (Figure 5.4A and B) but at significantly 
lower levels than the vaccinated group (Figure 5.4C and D).
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Figure 5.4: In vitro flow  cytometry responses to PPD at 4/i months. 500 uL whole blood
diluted 1: 5 was cultured with PPD for 5 days. Comparisons between unstimulated (pale 
bars) and stimulated (dark bars) cultures o f CD4 CD25+ (A), CD4+CD25 FOXP3+ (B), 
bars represent means and SEM error bars. A Wilcoxon non-parametric paired test was 
applied at 5% significance, Group I n = 43, Group 2 n = 38. Comparisons between Group
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1 (vaccinated) and Group 2 (unvaccinated) after subtracting the background for 
CD4 CD25+ (C), CD 4CD25+FOXP3+ (D), median values are presented as black line. A 
Mann Whitney U test was applied to compare the groups, Group I n -  40, Group 2 n = 36, 
*not significant after Bonferroni correction fo r  multiple testing.
In both groups, CD4+ and CD8+ T cells proliferated and produced IL-10 to PPD 
compared to the unstimulated controls although after adjustment for multiple testing this 
was not significant in the BCG vaccinated group (Figure 5.5). IL-10 production after 
subtracting the unstimulated values was comparable between groups suggesting that T cell 
production of IL-10 is due to NTM exposure rather than BCG vaccination. The evident 
production of IL-10 by T cells contrasted to cord blood responses to PPD where IL-10 was 
not T cell derived. Interestingly there was a trend for CD8 T cells to produce more IL-10 
than CD4 T cells, particularly in unstimulated cultures which was consistent in all 
conditions studied and across both groups (Figure 5.5).
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p <  0.0001 p <  0.0001
p = 0.0003p =  0 .0197
= 20
p =  0 .0044
I---------1
p = 0.0001
CD4 CD8 CD4 CD8
vaccinated unvaccinated
Figure 5.5: T cell derived IL-10 production in PPD stimulated cultures by flow
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cytometry. At 4 V2 months o f age 500 juL whole blood diluted 1: 5 was cultured with PPD 
fo r  5 days. Comparisons between unstimulated (pale bars) and PPD stimulated (dark bars) 
for CD4 and CD8 T cell production o f IL-10 and the difference between CD4 and CD8 
production o f IL-10 in the unstimulated cultures in Group 1 (vaccinated, green) and Group 
2 (unvaccinated, blue), bars represent means and SEM error bars. A Wilcoxon non- 
parametricpaired test was applied at 5% significance, Group 1 n = 42, Group 2 n — 37.
In concordance with the activated response described above, all cytokines studied at 
41/2 months were upregulated in response to PPD in both the BCG vaccinated and 
unvaccinated groups including the Thl cytokine IFNy, the Th2 cytokines IL-13 and IL-6, 
the Thl7 cytokine IL-17 and IL-10 (Figure 5.6A - C). IL-10 can be produced by a number 
of T cells including Thl, Th2 and Trl regulatory T cells in addition to non-T cell sources as 
mentioned previously (O'Garra and Vieira 2007). The upregulation of IL-10 in culture 
supernatants was similar in both groups (Figure 5.6E) further supporting the earlier 
suggestion that IL-10 is not induced in response to the BCG vaccine but is probably due to 
exposure to NTM. This is in contrast to IFNy and IL-13 which was induced in BCG naive 
individuals but at much lower concentrations than in the vaccinated group (Figure 5.6D 
and F). IL-17 was upregulated in response to PPD in both the vaccinated and unvaccinated 
groups although this was at a low concentration. A comparison between groups at 414 
months showed greater induction of IL-17 in the BCG vaccinated group (Group 1 median 
14.55 pg/mL) compared to the unvaccinated group (Group 2 median 1.53 pg/mL, p < 
0.0001, data not shown). Thymic function is controlled by IL-7 and neonatal nai’ve CD4+ 
and CD8+ T cells are explicitly responsive to IL-7 therefore production of this cytokine 
was studied. IL-7 was induced in both groups but at very low levels. A high level o f the 
innate cytokine, IL-6 was induced in response to PPD in both groups but was higher in the 
vaccinated infants (median 11,923 pg/mL) compared to the unvaccinated group (median 
1,213, p<  0.0001).
134
A  IFNy B  IL-10 C  IL-13
2000-1 p < 0.0001
1500 -
!<»»■
a
p < 0.0001
500 -
O
unvaccinatedvaccinated
p< 0.000180-1 p< 0.0001
60-
a> 4®' 
a
HL
400'
1 p<  0.0001 
1 1
i p< 0.0001I-  I
vaccinated unvaccinated vaccinated unvaccinated
D IFNy E IL-10 F IL-13
p< 0.0001
5000-.
4000-
3000-
E
z'a.
2 0 0 0 -
1000 -
-1000
vaccinated unvaccinated
1200-1 p < 0.0001
1 0 0 0 -
800-
600-
d  400-
" m”
•••..
200-
0-
vaccinated unvaccinated
p = 0.08162 0 0 -i
100- •••
•••••
--------E
o
■100-
-200
vaccinated unvaccinated
Figure 5.6: In vitro cytokine responses to PPD at FA months. 500 pL whole blood diluted 
1: 5 was cultured with PPD fo r  5 days. Comparisons between unstimulated (pale bars) and 
stimulated (dark bars) cultures o f IFNy (A), IL-10 (B) and IL-13 (C), bars represent means 
and SEM error bars. A Wilcoxon non-parametric paired test was applied at 5% 
significance, Group I n -  46, Group 2 n = 39 fo r  all cytokines. Comparisons between 
Group 1 (vaccinated) and Group 2 (unvaccinated) after subtracting the unstimulated 
background fo r  IFNy (D), IL-10 (E) and IL-13 (F), median values are presented as black 
bars. A Mann Whitney U test was applied at 5% significance to compare the groups.
The BCG naive group also responded in vitro to the BCG antigen compared to 
unstimulated controls even though the children were not vaccinated. Thus a number of
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parameters were upregulated in this group including IFNy (~ 4 fold less than with PPD), 
although this was not the case for CD4+CD25+ activated T cells. Increased TGFp 
production to BCG was demonstrated in vitro, an effect not observed with PPD 
stimulation. However, after adjusting for multiple comparisons the difference seen in 
TGFP was not sustained. Responses to BCG between groups behaved in a similar way to 
PPD reactivity in that the BCG vaccinated group had higher levels o f CD4+CD25+, 
CD4+CD25+FOXP3+, IFNy and IL-13 but comparable levels of IL-10 production.
Since the children in the study were closely monitored for exposure to TB, it was 
not surprising to find low responses to EC at 414- and 9- months of life. However there was 
significant reactivity to EC with an induction of CD4+CD25+ and CD4+CD25+FOXP3+ T 
cells which was comparable between groups and thus unlikely to be related to BCG 
vaccination. Interestingly, at 414 months an EC specific increase in IFNy, IL-6 and IL-10 
cytokine production, compared to background, was confined to the BCG naive group 
(IFNy p = 0.0078, IL-6 p = 0.0013, IL-10 p = 0.0004) (Figure 5.7A). However when 
comparing the two groups directly, based on subtracting the unstimulated control from the 
stimulated values, these differences were not apparent for IFNy (Figure 5.7B and C) and 
IL-6 (Figure 5.7B), but IL-10 was still significantly higher in the unvaccinated group 
(Figure 5.7B and D) suggesting that BCG vaccination could bias away from an 
immunosuppressive IL-10 response and that there is some cross reactivity of ESAT-6/CFP- 
10 expressing NTM, such as M. marinum which has been shown to be present in The 
Gambia (Corrah 1994).
There were no differences in responses to EC between groups at 9 months of age or 
between groups 4/4 months post BCG vaccination (i.e. Group 1 at 414 months and Group 2 
at 9 months).
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AGROUP 1 GROUP2
UNS E SAT-6/ 
CFP-10
p  value UNS ESAT-6/
CFP-10
p  value
IFNy 30.57 53.77 0.0738 67.43 68 0.0078
IL-6 90.25 132.1 0.1424 106.6 199.8 0.0013
IL-7 1.16 1.32 0.9678 1.32 1.32 0.3142
IL-10 3.355 4.305 0.8611 3.4 4.13 0.0004
IL-13 1.635 4.775 0.0535 3.21 7.18 0.071
IL-17 1.065 0.13 0.9569 0 0 0.7943
Blue text = significantly greater values after EC stimulation
Vaccinated
(V)
ESAT-6/ CFP-10 FP
Unvaccinated
(UV)
p  value
IFNy 4.74 12.11 0.3915
IL-6 36.23 94.7 0.2919
IL-7 0 0 0.3572
IL-10 -0.19 1.29 0.0084
IL-13 0.23 0.76 0.8530
IL-17 0 0 0.6974
Red text = significantly lower values in BCG vaccinated group compared to unvaccinated
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Figure 5.7: Cytokine responses to ESAT-6/ CFP-10 fusion protein at 4 V2 months by 
group. 500 pL whole blood diluted 1: 5 was cultured with EC fo r  5 days and cytokines
were measured in the supernatants. (A) Table o f cytokine responses (pg/ml) in unstimualted 
compared with EC stimulated cultures, a Wilcoxon non-parametric paired test was applied 
at 5% significance, Group I n  — 46, Group 2 n = 39. (B) Table o f comparisons o f  cytokine 
responses (pg/ml) between Group 1 (vaccinated) and Group 2 (unvaccinated) assessed by 
Mann Whitney U test. Comparison between Group 1 and Group 2 o f IFNy (C) and IL-10 
(D) cytokine production after subtracting unstimulated control in response to EC.
Since responses to PPD were observed at birth it was important to compare these 
responses to those observed at 4V4 months in the unvaccinated group in order to determine 
how much reactivity might be attributable to exposure to NTM over the first 414 months of 
life. Surprisingly, a number of the responses observed at 4/4 months to PPD, BCG and EC 
were similar to those observed at birth (Table 5.2). These included T cell proliferation and 
IL-10 production by T cells and within the culture supernatant. There was a trend for IL-10 
cytokine production (CD8+IL-10+ and IL-10 from supernatants) to be increased at 414 
months but this was not significant after correction for multiple testing. However,
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mycobacterial induced activated T cells and Tregs, IFNy and IL-13 responses were all 
higher at 4!4 months compared to birth suggesting either there is some NTM exposure at 
birth that influences the T cell proliferation and IL-10 production in response to PPD or the 
responses observed at 4'/2 months were non-specific and too low to regard as true 
responses. In the BCG vaccinated group all responses at 4/4 months o f age were 
upregulated compared to birth (data not shown).
At birth 4Vz months p  value
CD3 -1.69 -5.505 0.1101
CD4 -0.8 -5.55 0.0727
CD8 0.76 0.51 0.4441
CD4(CD25) 0.87 4.93 0.0004
CD4(CD25FOXP3) 0.21 4.77 < 0.0001
Ki-67 1.43 0.53 0.5115
CD4(Ki-67) 1.4 0.94 0.4624
CD8(Ki-67) 2.82 1.08 0.6879
IL-10 0.51 0.87 0.1925
CD4(IL-10) 0.7 1.6 0.1554
CD8(IL-10) 1.01 1.54 *0.0304
TGFP 0.77 -0.015 0.9713
CD3CD4(TGFP) 0.59 0.04 0.5401
CD3CD8(TGFP) 0.98 0.045 0.6567
IFNy 0 142.1 < 0.0001
IL-10 8.13 19.56 *0.0414
IL-13 0 9.26 < 0.0001
Blue text = significant upregulation at 4'A months compared to at birth 
* Not significant after Bonferroni correction
Table 5.2: In vitro responses to PPD at birth and at 4/2 months in Group 2. 500 pL whole
blood diluted 1: 5 was cultured with PPD for 5 days. Table represents T cell phenotypes 
(%) and cytokine production (pg/ml) at birth compared to 4 Z2 months o f age in Group 2 
(vaccinated at 4/2 months o f  age). Values presented are median values in response to 
antigen after subtracting the unstimulated control. A Wilcoxon non-parametric paired test 
was applied at 5% significance, n =30.
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5.2.3 Comparison o f mycobacterial responses after different BCG vaccination schedules 
Since the two groups received BCG vaccination at different time points it was 
important to compare responses between groups in two ways. First, a comparison of 
responses at 9 months of age i.e. 9 months post vaccine in Group 1 and 4‘/2 months post 
vaccine in Group 2. Secondly, reactivity 414 months after BCG vaccination i.e. 414 months 
of age in Group 1 and 9 months of age in Group 2.
Despite the clear differences described between groups in reactivity at 414 months 
of age, it was clear that by 9 months of age measured responses to mycobacterial antigens 
were similar in both groups (Table 5.3). This suggests that delaying the BCG vaccine to 414 
months did not affect mycobacterial specific immunity at 9 months o f age.
Group 1
(vacc. at 
birth)
Group 2
(vacc. at 
AVi m)
p  value
CD3 -5.56 -10.84 *0.0468
CD4 -4.51 -10.03 *0.0085
CD8 0.85 1.345 0.3661
CD4(CD25) 11.43 14.01 0.2099
CD4(CD25FOXP3) 4.87 6.215 0.3475
K.i-67 4.25 5.05 0.4603
CD4(Ki-67) 5.97 6.57 0.7594
CD8(Ki-67) 4.22 7.355 0.1844
IL-10 1.07 2.935 0.0765
CD4(IL-10) 1.17 3.72 0.3939
CD8( IL-10) 2 5.115 0.3372
TGFP 0.34 1.02 0.2630
CD3CD4(TGFP) 0.46 0.9 0.3747
CD3CD8(TGFP) 2.78 2.32 0.4933
IFNy 254.0 214.8 0.9544
IL-10 20.70 13.65 0.2064
IL-13 287.9 374.4 0.5191
* Not significant after Bonferroni correction
Table 5.3: Comparing in vitro responses to PPD at 9 months o f age between groups. 500
pL whole blood diluted 1: 5 was cultured with PPD fo r  5 days. Table represents
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comparisons o f  T cell phenotypes (%) and cytokine production (pg/ml) between Group I 
and Group 2 at 9 months o f age. A Mann Whitney test was applied at 5% significance, 
Group 1 n = 43, Group 2 n =38 . * Not significant after Bonferroni correction.
When comparing the two groups 414 months post BCG vaccine most parameters 
were also similar. However IFNy production was lower in Group 2 (vaccinated at 414 
months) compared to Group 1 (vaccinated at birth) (Figure 5.8A). IL-13 production was 
similarly upregulated in both groups (Figure 5.8B). IL-10 reactivity in response to PPD 
was similar 414 months after vaccine, however the BCG antigen induced IL-10 responses 
that were higher in the delayed vaccine group (Figure 5.8C and D).
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Figure 5.8: Responses to PPD antigen 4 V2 months after BCG vaccine. 500 pL whole
blood diluted 1: 5 was cultured with PPD and BCG fo r  5 days. IFNy (A), IL-13 (B), IL-10 
(C) production in response to PPD and IL-10 production in response to BCG (D). 
Comparisons between Group 1 at 4/2 months o f age and Group 2 at 9 months o f age after 
subtracting the background, median values are presented as black bars. A Mann Whitney 
U test was applied to compare the groups, Group 1 n = 46, Group 2 n = 37.
Despite the lower IFNy production 414 months post vaccination in Group 2 in 
response to PPD, both IFNy and IL-13 were still increased compared to pre-vaccine 
responses at 4!4 months o f age demonstrating that a mixed Thl, Th2 response is induced in 
the delayed vaccine group (Figure 5.9A and B). However, IFNy levels induced in the 
delayed BCG vaccine group were lower than those observed when vaccinating at birth. It 
is evident however, that there were some strong IFNy responders post-BCG vaccine 
although most are poor responders (Figure 5.9A).
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Figure 5.9: Cytokine production over time in Group 2. 500 pL whole blood diluted 1: 5 
was cultured with PPD fo r  5 days. IFNy (A) and IL-13 (B) production in response to PPD 
were compared over time in Group 2 (vaccinated at 4/2 months) after subtracting the
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background, median values are presented as black bars. A Wilcoxon non-parametric paired 
test was applied at 5% significance, Group 1 n — 46, Group 2 n = 39.
As part of the original hypothesis it was suggested that by 4/4 months the infants 
will have been exposed to NTM and this may impair the IFNy response to BCG vaccine at 
9 months of age. Therefore, infants that responded well to PPD at 4/4 months in the 
unvaccinated group might be expected to have a reduced response to PPD or BCG post 
vaccine (at 9 months of age). A scatter plot of correlation between PPD IFNy responses at 
4!4 months compared to PPD IFNy responses at 9 months in Group 2 (Figure 5.10A), 
showed no correlation (Spearman r = 0.07568 p = 0.6609). Indeed most values were low at 
both time points, although a subgroup of 11 of the 36 individuals had increased IFNy 
production at 9 months (> 1,000 pg/ml), thus a good response to the BCG vaccine, 
although they did not correspond to a low IFNy group at 41/2 months. Correlations with 
BCG responses illustrated similar findings.
It was also hypothesised that Tregs may be responsible for the attenuated response 
found in Group 2, however there was no correlation between FOXP3+Tregs at 4/4 months 
and IFNy responses at 9 months suggesting that the reduced IFNy observed at 9 months in 
the delayed vaccine group was not a result of PPD stimulated Tregs present at 414 months 
of age (Figure 5.10B). There was also no association between IL-10 cytokine production at 
414 months in Group 2 and IFNy production at 9 months (Figure 5.10C), suggesting that 
this cytokine is not responsible for the lower IFNy responses.
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Figure 5.10: Scatter plots o f comparisons between IFNy responses to PPD at 9 months to 
immune correlates at 41A  months o f age in Group 2. 500 pL whole blood diluted 1: 5 was 
cultured with PPD fo r  5 days. The relationship between cytokine responses to PPD at 9 
months (4 V2 months after delayed BCG vaccine) to pre-vaccination baseline at 4/2 months 
o f age fo r IFNy (A), FOXP3+Tregs (B) and IL-10 (C) was assessed after subtracting the 
background. Spearman's correlation coefficient suggested there was no correlation 
between responses at 4 V2- to 9- months o f age (p = 0.6609, 0.8970, 0.8907 respectively), n 
-  36. Red dots represent 11 individuals that responded well (> 920 pg/mL) to PPD at 9 
months o f age.
5.2.4 PPD responses waned 9 months after BCG vaccination
An important question both clinically and immunologically is how long does the
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strong Thl memory immune response remain in those vaccinated at birth. Comparing 
responses in group 1 (vaccinated at birth) at 414- and 9- months of age may help answer 
this question. No responses measured were increased in response to PPD over this time 
point. In the majority o f cases the responses were similar suggesting persistence for 9 
months, however some key immune responses were downregulated.
The percentage of FOXP3~Tregs in response to PPD had decreased by 9 months of 
age although the percentage o f CD4~CD25~ cells remained stable. IFNy (the cytokine 
thought to play a major protective role against M.tb) production in response to PPD was 
downregulated at 9 months compared to 414 months (medians of 920.3 and 254 pg/mL 
respectively) (Figure 5.11A) without a simultaneous downregulation of IL-10 or IL-13, 
suggesting that the Thl response to vaccine has reduced by 9 months but the Th2 and 
regulatory responses persisted. There was an overall positive correlation between IFNy 
responses to PPD at 4/4- and 9- months of age (r = 0.4313, p = 0.0039) suggesting those 
that responded well to PPD at 414 months of age were more likely to be good responders at 
9 months of age although the predictive r value was low (Figure 5.1 IB). Nine subjects had 
an IFNy response, greater than 920 pg/ml (median value at 4!4 months) at 9 months o f age 
(Figure 5.11 A). When examining for an association with the IFNy responses in these 
individuals at 414 months, there was no correlation (r = 0.08333, p = 0.8432) suggesting 
the correlation observed previously was not due to the higher responders.
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Figure 5.11: Longitudinal responses within Group 1 comparing 4 V2 months post vaccine 
to 9 months post BCG vaccine in response to PPD. 500 pL whole blood diluted 1: 5 was 
cultured with PPD fo r  5 days. IFNy responses to PPD 4 V2- and 9- months after BCG 
vaccination in Group 1 (A) and the relationship between responses in the same individuals 
over time (B) was assessed after subtracting the background. Red dots and red oval 
represent 9 individuals that responded well (>920pg/mL) to the PPD at 9 months o f age in 
Group 2. Longitudinal data was compared using a Wilcoxon non-parametric paired test at 
5% significance, n = 43. Spearman’s correlation coefficient measured the correlation 
between responses at 4 V2- and -9 months o f age, n = 43.
Table 5.4 illustrates the profile of immune responses to PPD across the three time 
points for Group 1 (vaccinated with BCG at birth). Clearly different patterns emerged for 
the different populations of cells analysed. At 414 most of the subjects exhibited an increase 
in activated T cells in those vaccinated at birth, approximately half of these then had 
responses that reduced at 9 months while half had responses that increased, illustrating 
heterogeneity in the responses. In contrast, the frequency of CD4+CD25+FOXP3+ Tregs 
increased at 414 months but in the majority of subjects the percentage was reduced by 9 
months. Thus at 9 months the responses were more activated and less suppressive, but this 
did not correspond to the IFNy production that was predominantly reduced at 9 months. By 
414 months of age, all individuals upregulated IFNy in response to PPD compared to that 
observed in cord blood, but 82% of individuals had a reduced response by 9 months. IL-13 
fitted a similar profile to the activated T cells where most subjects exhibited an increase in 
IL-13 in response to PPD at 414 months, but half of those had a sustained increase in IL-13 
and half had a reduction in IL-13 by 9 months. IL-10 was the only parameter that, at 414 
months of age, had approximately equal numbers of subjects with an increase or a decrease 
in IL-10 reactivity.
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m onths 0 4 y2 g q 41/, g Q 4 y2 g q 4 y2 g
Group 1
DEC
DEC
(%)
DEC
INC
(%)
INC
DEC
(%)
INC
INC
(%)
CD4 10(31.3) 14(43.8) 7(21.9) 1(3.1)
CD8 6(30) 5(25) 7(35) 2(10)
CD4(CD25) 1(3.1) 1(3.1) 16(50) 14(43.8)
CD4(CD25FOXP3) 3(9.4) 8(25) 18(56.3) 3(9.4)
IFNy 0 0 31(81.6) 7(18.4)
IL-10 6(15.8) 12(31.6) 9(23.7) 11(29.0)
IL-13 0 2(5.3) 20(52.6) 16(42.1)
Table 5.4: Immune response profile to PPD in Group 1 that were vaccinated at birth.
Comparing profiles o f responses over time from birth to 4 V2 months and from 4Vi months to 
9 months in Group I that were vaccinated with BCG at birth. Numbers and percentages (in 
brackets) o f individuals that had immune responses more or less than previous time points 
were calculated, DEC = decrease-, INC  = increase- in responses to PPD compared to 
earlier time point. Therefore DEC DEC is interpreted as numbers o f subjects that had a 
decrease from birth to 4 V2 months AND a decrease from 4/2 months to 9 months.
Figure 5.12A- E summaries the overall longitudinal responses to PPD for activated 
T cells, FOXP3 Tregs, IFNy, IL-10 and IL-13 cytokine production between all three time 
points in Group 1 and 2 that have been discussed in detail throughout this chapter.
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Figure 5.12: Longitudinal responses to PPD over time. Longitudinal CD4+CD25+ (A), 
CD4+CD25+FOXP3+ (B), IFNy (C), IL-13 (D) and IL-10 (E) responses to PPD after 5 
days o f culture in Group 1 (blue) and Group 2 (green). Unstimulated values were 
subtracted from stimulated values. Black bar represents the median value o f the data. 
Wilcoxon paired non-parametric test was applied at 5% significance.
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5.3 DISCUSSION
Young children in The Gambia receive numerous vaccines before the age of 9 
months including BCG, HBV, DTwP, Hib, OPV, measles (MV) and yellow fever (YF). 
BCG is given at birth or at first contact with the child but immunological evidence is 
limited with respect to optimal timing of BCG in infants. Many studies have shown that 
BCG is less effective in developing countries and this study assessed the immunological 
effects of giving BCG vaccine at two different time points to analyse the impact of 
exposure to NTM prior to vaccination.
5.3.1 Mycobacterial responses in cord blood
The findings of in vitro recall responses to mycobacterial antigens in cord blood 
were perhaps unexpected. Increased T cell proliferation and induction of IFNy was 
observed in response to PPD alongside an increased regulatory response of 
CD4+CD25+FOXP3+ Tregs and induced IL-10 (although not from T cells). Previous 
studies have found that mycobacterial responses in cord blood were due to a lipid 
component of mycobacterial lysate. However, in contrast to our results, this study found no 
responses to PPD. The authors found an expansion of gamma delta (y5) T cells and 
proposed that when these T cells in a newborn are confronted by a mycobacterium, they 
respond non-specifically to the lipid component of the organism (Tsuyuguchi, Kawasumi 
et al. 1991). Our results showed similar responses to BCG supporting the idea that a non­
specific component in the mycobacterial antigens used in our study acts as an 
immunostimulatory antigen, however responses to the specific ESAT-6/CFP-10 fusion 
protein would not support this as it does not contain other mycobacterial components.
Limited evidence suggests that cell-mediated immunity could be transferred from 
mother to foetus in atero or through breast milk. Earlier studies have demonstrated this by 
leukocyte migration inhibition assays, where induction of leukocyte inhibitory factor (LIF) 
in antigen stimulated cultures inhibits lymphocyte migration on agar, and
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lymphoproliferative assays using radio labelled thymidine (Gallagher, Welliver et al. 1981; 
Pabst, Godel et al. 1987). Interestingly these studies showed a stimulation index (SI) of > 
2.0 in cord blood cultured with PPD that decreased to 1- 2 by 6 months of age which 
correlated to a reduction in migration inhibition in the LIF assay and to PPD responses 
from the mother. It was thought that maternal antibodies that are known to cross the 
placenta contribute to the cell mediated immunity and suggest that specific factors (e.g. 
Transfer factor) may be responsible for this (Pabst, Godel et al. 1987). Several studies have 
found T cell populations present in breast milk (Schlesinger and Covelli 1977; Girdhar, 
Girdhar et al. 1981; Sabbaj, Ghosh et al. 2005) although this would not contribute to the 
findings in cord blood prior to being breast fed. Foreign antigen exposure in utero was 
originally thought to induce immunological tolerance (Billingham, Brent et al. 1953), but 
many studies have found that transfer of foreign proteins, parasite antigens and even cells 
from mother to the foetus can induce memory pro-inflammatory immune responses 
although the mechanisms involved remain unclear (Gitlin, Kumate et al. 1964; King, 
Malhotra et al. 2002; Adams and Nelson 2004; Malhotra, Mungai et al. 2006) (Malhotra, 
Ouma et al. 1997; Malhotra, Mungai et al. 1999; Brustoski, Moller et al. 2006). Active 
placental malaria at delivery was associated with increased frequencies of Plasmodium 
falciparum (Pf)-specific CD4+IL-10+ T cells and ex vivo CD4+CD25+CTLA-4+ Tregs in 
cord blood (Brustoski, K et al, 2005, Brutoski, K et al, 2006) which is in agreement with 
the increased FOXP3+Tregs that were observed in response to PPD in the cord blood of our 
participants. Malhotra et al also showed that cord blood from 30% of Kenyan neonates 
induced IFNy production after PPD stimulation but with no Th2 cytokines induced. In 
contrast none of the US neonates responded to PPD (Malhoatra, I et al, 1997). Interestingly 
Ben-Smith et al compared T cell phenotypes between Malawi and the UK and found that 
although Malawian adolescents had a lower percentage of naTve, and a higher percentage 
of memory T cells, cord blood T cell populations were similar in both countries (Ben- 
Smith, Gorak-Stolinska et al. 2008). Many studies examining allergen sensitivity in the
neonate have found allergen-responsive T cells in cord blood but these lacked the fine 
specificity of adult memory T cells and were often not CD45RO+ T cells (Yabuhara, 
Macaubas et al. 1997; Thornton, Upham et al. 2004). Interestingly many animal studies 
have observed in utero transmission of M. avium subspecies paratuberculosis (MAP) 
(Sweeney, Whitlock et al. 1992; Judge, Kyriazakis et al. 2006; Alinovi, Wu et al. 2009; 
Singh, Sohal et al. 2009). In cattle MAP was isolated from the placenta, foetus and 
colostrum of infected mothers suggesting vertical transmission of mycobacteria (Sweeney, 
Whitlock et al. 1992; Sweeney, Whitlock et al. 1992). In addition, in 1 day old 
unvaccinated cattle neonates, CD8+CD3" NK-like cells produce IFNy in response to BCG 
infected DCs (Hope, Sopp et al. 2002). It is possible that the IFNy that was observed in our 
studies was produced from NK cells but we could not confirm this.
It is important to recognise the possibility that mature immune responses might be 
due to maternal contamination of cord blood. This could occur in utero (Srivatsa, Srivatsa 
et al. 2003), during labour when the endothelial vessels of the umbilical cord become 
Teaky’ (Masuzaki, Miura et al. 2004) or during blood collection. In some immunodeficient 
circumstances, maternal cells cross the placenta and engraft into human foetal tissues in 
utero, resulting in ‘maternal microchimerism’. A recent study identified human maternal 
cells residing in foetal lymph nodes that induced the development of 
CD4+CD25hlghFOXP3+ Tregs that suppressed foetal anti-matemal immunity, and persisted 
until early childhood (Mold, Michaelsson et al. 2008). The contribution of maternal cells 
was not examined further in this study but HLA typing cellular samples from the mother 
and baby could identify the extent of this problem.
Another possibility that has been well studied in mice, is based on the 
promiscuous low affinity TCR/MHC peptide interactions that occur on the surface of 
functionally immature T cells (Le Campion, Lucas et al. 2002). It has been suggested that 
in neonatal mice this process may be mediated by a subset of T cells with CDR3 regions 
that are shorter than on adult TCRs which interact with the alpha chain of the MHC
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molecule rather than using the peptide/peptide-binding groove (Gavin and Bevan 1995). T 
cell epitope mapping of responses to ovalbumin (OVA) in human cord blood indicated 
reactivity to multiple regions as opposed to an average of < 1 site when peripheral blood 
from 5 year olds was tested (Yabuhara, Macaubas et al. 1997).
The increase in IL-10 production observed in cord blood did not appear to arise 
from CD4+ or CD8+ T cells since by flow cytometry the upregulation of IL-10 was in total 
IL-10 producing cells, but not CD4+ or CD8+ T cells specifically. Many other cells produce 
IL-10 including macrophages (Watkins, Semple et al. 2008) and B cells (Sun, Deriaud et 
al. 2005) (O'Garra and Vieira 2007)) but these were not examined in this study. Watkins et 
al found that cord blood responded to BCG antigen with an induction of IL-10 from 
CD14+ monocytes, accompanied by high IFNy and moderate IL-13 production fromT cells 
(Watkins, Semple et al. 2008). Although the amount of IL-10 produced in cord blood was 
low, DCs have been shown to be extremely sensitive to the inhibitory effects of small 
amounts of IL-10 (Mosser and Zhang 2008). It is possible that the IL-10 production 
observed in cord blood contributes to the defective function of antigen presenting cells 
found in neonates.
In Chapter 4 it was suggested that CD4+ T cells were more susceptible to 
apoptosis. Cord blood responses to PPD showed increased CD4+ proliferation and 
increased IFNy and IL-10 production. It was interesting that both the proportion of CD4+ T 
cells and the proportion of CD4+CD25+ T cells did not increase, but the proportion of 
CD4+CD25+FOXP3+ T cells did. It is possible that there is an increase in CD4+ and 
CD4+CD25+ T cells but these are more susceptible to apoptosis as was suggested in 
Chapter 4. In contrast, the CD4+ T cells that express FOXP3 could be a more resistant 
subset of CD4+ T cells and therefore were increased in response to PPD. This finding is in 
conflict with other studies that suggest Tregs are more susceptible to apoptosis 
(Fritzsching, Oberle et al. 2006; Vukmanovic-Stejic, Zhang et al. 2006). Interestingly 
Fritzsching et al showed that neonatal Tregs possessed a naive phenotype but were more
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resistant to CD95L-mediated apoptosis than adult Tregs which supports our finding. The 
use of apoptotic markers would confirm this idea and ascertain if FOXP3+Tregs in cord 
blood are more or less susceptible to apoptosis.
5.3.2 Mycobacterial responses in infants with respect to the timing o f BCG vaccination
In vitro responses to BCG and PPD were assessed in this study. Since the BCG 
vaccine is a live replicating bacteria, it is likely that processed antigens are presented on 
both MHC class I and II molecules stimulating both a CD4 and CD8 T cell response, 
whereas PPD, a mix of secreted antigens from M.tb, are likely to be loaded onto MHC 
class II molecules and induce a predominant CD4 response. However, most responses 
observed were similar between BCG and PPD which is most likely due to the cross 
reactivity between the immunogenic components of these mycobacterial antigens. RNA 
expression profiles of overnight responses to BCG and PPD in BCG vaccinated infants 
support this finding (Fletcher, Keyser et al. 2009).
Overall the timing of BCG vaccination affected the immune response to PPD in 
the short term but by 9 months of age there was no effect on the parameters tested. As 
reported in the literature, BCG at birth induced a Thl IFNy response to PPD (Marchant, 
Goetghebuer et al. 1999; Vekemans, Amedei et al. 2001; Ota, Vekemans et al. 2002) 
(Sander, Skansen-Saphir et al. 1995). Those vaccinated with BCG at 4!/2 months had much 
less IFNy production to PPD but IL-13 levels were similar to the group vaccinated at birth. 
This was supported by Marchant, A et al where delaying BCG until 2 months of age 
resulted in a trend for reduced IFNy responses 2 months later. It was also reported that the 
unvaccinated group showed no IFNy responses but slightly higher IL-4 responses, although 
they did not look at IL-13. The lack of IFNy response may be due to the sensitivity of the 
assays. Our study utilised the CBA system which is more sensitive than ELISAs and has 
been shown to produce results slightly higher in range than other systems (Elshal and 
McCoy 2006). By 12 months of age the levels of IFNy were similar for all the groups but
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were 10-fold lower than 2 months post vaccination (Marchant, Goetghebuer et al. 1999). 
Our study supports these findings and suggests that the IFNy memory response is transient; 
waning by 9 months of age while the Th2 response is strong and persists longer and also 
supports the widely accepted paradigm that there is a Th2 bias to priming in early life and 
BCG priming is no exception. The loss of the Thl response but maintenance of the Th2 
response may be due to the increased susceptibility of Thl cells to death after re­
stimulation with antigen. In mice experiments, TCR-transgenic CD4+ cells from neonates 
and adults were transferred into a neonatal host and found that the neonatal Thl cells 
underwent apoptosis in response to re-exposure to antigen, whereby the Th2 cells remained 
unaffected (Li, Lee et al. 2004). This process is thought to be due to FAP-1, an inhibitor of 
Fas-related apoptosis which is present in Th2 cells but not Thl cells (Zhang, Brunner et al. 
1997). This may also explain the reduced IFNy response to BCG vaccination in the delayed 
vaccine group after exposure to NTM as the primary stimulus.
Correlates of protection against TB are not well defined although IFNy is a key 
regulator. However studies in mice have shown protection from TB without the need for 
IFNy (Elias, Akuffo et al. 2005). Goldsack and Kirman propose that that IFNy-mediated 
protection is required in the primary response rather than the secondary recall response and 
suggest Thl 7 and Tregs may be involved in overall protection independent o f IFNy 
(Goldsack and Kirman 2007). There are mice studies that support the idea that IFNy is not 
the sole cytokine required for protection. BCG vaccination induced IFNy prior to M.tb 
challenge but the vaccinated and unvaccinated mice induced similar levels o f IFNy post 
challenge even though BCG vaccinated mice exhibited protection (Elias, Akuffo et al.
2005). In addition BCG vaccinated IFNy'7' mice were capable of reducing bacterial burden 
when challenged with M.tb (Cowley and Elkins 2003). This is interesting in light of our 
results where delaying the vaccine reduced the IFNy response compared to BCG 
vaccination at birth. This may not have any relation to protective levels in these infants.
Previous studies have shown that IFNy and IL-10 dynamics in response to PPD
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after BCG vaccination were quite different with IFNy production peaking at 8 weeks post 
vaccination and then declining by 12 months. IL-10 reactivity peaked at 2 weeks and 
declined to its lowest levels peak at 8 weeks i.e. a much earlier intervention than IFNy 
(Nabeshima, Murata et al. 2005). We may therefore have missed the BCG induced IL-10 
response when examining responses 414 months after vaccination. These dynamics are also 
consistent with the waning of IFNy responses by 9 months of age observed in our study.
We hypothesised that exposure to NTM might attenuate the immunogenicity of 
BCG. Our results showed that by 4!4 months of age there were activated responses to PPD 
in the unvaccinated group which suggests mycobacterial priming. The lower IFNy 
production observed in this group post vaccination compared to those vaccinated at birth 
would support this hypothesis. In addition we hypothesised that the attenuation of BCG 
would be associated with induction of Tregs. CD4+ Tregs were defined by FOXP3 
expression as a marker of natural Tregs, and by intracellular IL-10 as an indicator of Trl 
induced Tregs. Induction of CD4+CD25+FOXP3+ T cells in response to PPD was observed 
in both groups, but to a greater extent in the vaccinated group. By contrast IL-10 
upregulation (from CD4+ and CD8+ T cells) was observed in similar concentrations in the 
unvaccinated and vaccinated group. Furthermore it was not enhanced by BCG vaccination 
providing a theoretical causal link between the reduction of IFNy observed in the delayed 
vaccine group and increased T cell production of IL-10. As suppression assays were not 
performed to assess the function of these cells it is difficult to know if these IL-10 
producing T cells are Trl Tregs. One of the strategies that mycobacteria have developed to 
evade the immune system is to downregulate MHC class II molecules which is IL-10 
dependent (Sendide, Deghmane et al. 2005) suggesting this may influence the polarisation 
of the effector memory T cells leading to a reduced Thl mycobacterial response after BCG 
vaccination.
The lack of IL-10 production in response to BCG vaccination is in contrast to a
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recent detailed multiplex study where IL-10 was strongly (1 0 -2 0  fold) induced by BCG, 
along with IL-17 in 6 day whole blood assays (Madura Larsen, Benn et al. 2007; Mendez- 
Samperio, Trejo et al. 2008; Soares, Scriba et al. 2008). Madura Larsen et al also showed 
that BCG matured DCs showed enhanced IL-10 and diminished IL-12 production. These 
DCs primed naive T cells to develop into IL-10-producing T cells with no Thl or Th2 bias. 
It is interesting to note that IFNy and IL-10 had completely opposite effects on increasing 
the dose of BCG with IL-10 increasing with increasing dose (Madura Larsen, Benn et al. 
2007). A study in South Africa showed upregulation of IL-10 but to very low levels (< 
0.01% of CD4+ or CD8+ T cells) (Soares, AP et al, 2008) in 12 hour cultures, whereas our 
cultures were for 5 days and induced IL-10 in the 1.5 - 4% range for CD4+ and CD8+ T 
cells in both the BCG vaccinated and unvaccinated groups.
As a group there was no significant induction of IL-10 in response to PPD at 4/4 -  
or 9- months of age following vaccination at birth, however certain individuals responded, 
in fact 50% elicited increased IL-10 production at 4!4> months and 50% had downregulation 
IL-10 compared to at birth. This heterogeneity in IL-10 responders may be due to the 
highly polymorphic IL-10 gene. In those being treated for bladder cancer with intravesical 
BCG, two particular IL-10 polymorphisms have been identified as risk factors for 
progression (Basturk, Yavascaoglu et al. 2006). IL-10 polymorphisms have also been 
associated with TB disease and progression (Oral, Budak et al. 2006). In the Gambia, large 
natural variations in individual responses was found to mycobacterial antigens after BCG 
vaccination (Finan, Ota et al. 2008) and significant heritability of IFNy and IL-13 
responses to BCG antigens has been illustrated (Newport, Goetghebuer et al. 2004).
In contrast to the cord blood responses, at least part of the IL-10 production 
observed at 4'/4 and 9 months was due to CD4+ and CD8+ production, and in most cases 
there was a larger proportion of CD8+ T cells that produced IL-10 compared to CD4+ T 
cells. This suggests that adaptive IL-10 producing T cell responses are induced in early life, 
and these may have an important immunoregulatory role. Irrespective of the source of IL-
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10, its effects are usually similar in all infections; IL-10 suppresses macrophage and DC 
function, thereby limiting Thl and th2 effector responses. The timing and strength of the 
response may be determined by the stimulus. Infections of low virulence, such as NTM, 
may lead to IL-10 induced regulatory T cells allowing persistence within the macrophage. 
In contrast, a strong stimulus, such as BCG vaccination may induce IL-10 that limits 
immunopathology during early stages of the response and may not be present later 
(reviewed in (Couper, Blount et al. 2008)). If the PPD-induced IL-10 observed at all time 
points, in both groups is due to NTM exposure then maybe this limits the IL-10 producing 
cells that are induced after BCG vaccination as seen in our results.
Although responses to PPD were observed in cord blood, responses at 414 months 
in the unvaccinated group were more robust with increased CD4+CD25+, 
CD4CD25FOXP3+ and higher levels of IFNy and IL-13 after stimulation with PPD most 
probably primed by exposure to NTM over the preceding 4 'A months. By contrast the 
percentage of proliferating cells and IL-10 remained similar between birth and 4/4 months. 
Ki-67 is a measure of proliferating cells at the time of observation which in our case is at 5 
days. We have shown that in unstimulated cord blood cultures 10% of lymphocytes are 
proliferating which is much greater than proliferation observed at 4/4 months (approx 
1.5%), however the percentages of CD4+ and CD8+ T cells proliferating was similar 
between time points at 2% and 4% respectively. We also showed that cord blood cells are 
more susceptible to cell death. It is possible that cord blood lymphocytes are proliferating 
at a greater rate because many of them are dying. Therefore comparing cord blood to infant 
cell responses using pheno typing alone does not fully examine the quality of the responses, 
and it is important to take into account cell numbers and cell death. There was a trend for 
IL-10 responses to increase over 4'/4 months in the unvaccinated group but this was not 
significant after adjustment for multiple testing although it was still significantly higher 
than the unstimulated control. The induction of IL-10 observed at birth may be due to in 
utero exposure to mycobacterial antigens or non-specific induction as mentioned earlier.
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Our results also suggested that different cells are responsible for producing IL-10 in 
response to PPD at birth than at later age groups.
It was not expected that the IFNy response observed at 414 months in the BCG 
vaccinated group would wane by 9 months of age. It was not possible to ascertain what 
effect this has on protection against TB but Black et al proposed that the difference in 
magnitude of PPD response pre- and post- BCG vaccine was likely to be more predictive 
of BCG efficacy than the absolute value post vaccine. This was observed in Malawi where 
the reduced difference between pre- and post- BCG reactivity compared to that seen in the 
UK corresponded to a lack of protection in Malawi and could be due to NTM (Black, Weir 
et al. 2002). This was also illustrated by additional studies comparing Malawi and the UK. 
The responses to NTM antigens were similar in both populations after BCG vaccination 
but were different prior to vaccination (Weir, Black et al. 2006). When comparing the 
different vaccination schedules in our study, the difference between pre-and post­
vaccination was smaller in the delayed vaccine group that would have had exposure to 
NTMs, compared to the group vaccinated at birth and may indicate reduced protection.
It was interesting to observe a sustained IL-13 production in response to PPD after 
vaccination at either time points. IL-13 is a Th2 cytokine more often associated with 
allergic inflammation although also possesses anti-inflammatory properties. It shares a 
receptor subunit with IL-4 (IL-4Ra) and therefore the function of these cytokines is often 
linked. Although the role that IL-13 plays in mycobacterial infection is not clear, BCG has 
been shown to induce IL-13 in cattle in association with anti-mycobacterial activity 
(Endsley, Hogg et al. 2007) and in human studies IL-13 concentrations are increased in TB 
patients that are fast responders to treatment (Djoba Siawaya, Beyers et al. 2009). This 
would suggest that IL-13 has a protective role in mycobacterial infection.
At 4!/2 months of age, IL-6 was upregulated in response to the mycobacterial 
antigens with a 138-fold increase in the BCG vaccinated group and a 16-fold increase in
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the unvaccinated group. It is often stated that neonates have impaired production o f Thl 
cytokines (Adkins, B, 2004) but the IL-6 innate cytokine is often enhanced in these young 
children (Marchini, Berggren et al. 2000; Schultz, Rott et al. 2002). In one report, 
responses o f neonatal (cord blood) monocytes to lipopolysaccharide (LPS;TLR4) were 
biased towards a high IL-6/TNFa ratio in vitro. Compared to adults, neonates produced 
increased levels of IL-6, but lower TNFa which was contributed to a heat stable neonatal 
serum factor(s) (Angelone, Wessels et al. 2006). Innate interaction of mycobacteria often 
involves TLR4 and thus the IL-6 production observed in our study maybe due to an innate 
response to BCG and NTM through the TLR4 pathway. Further investigation is needed to 
determine the role of IL-6 in infants.
The strain of both the NTM and the BCG could have a profound effect on the 
BCG immunogenicity. Aguirre-Bianco et al showed that of the three strains (Danish 1331, 
Glaxo 1077 and Pasteur 1173), it was the Glaxo strain that elicited the most IFNy 
production from CD4+ T cells and highest upregulation of CD25+ on CD4 T cells (Aguirre- 
Bianco, AM et al, 2007). The BCG strain used in our study was independently typed and 
found to be derived from the Russian strain which is the strain closest to the original BCG 
strain ((Mostowy, Tsolaki et al. 2003; Keller, Bottger et al. 2008)). Several studies have 
compared the immunogenicity of the different strains and found that, in addition to BCG 
Glaxo and Pasteur, BCG Russia eliminated recombinant BCG in mice more efficiently 
than the Japanese and Prague strains (Lagranderie, Balazuc et al. 1996). In a separate 
study, BCG Russia and BCG Tokyo induced higher levels of NO than other strains in the 
A549 human lung epithelial cell line but BCG Russia was also more susceptible to the 
effects of NO-induced growth inhibition suggesting BCG Russia may not survive in the 
host as long as the other strains (Hayashi, D et al, in press). However, the protective 
efficacy in a guinea pig model of pulmonary tuberculosis with early- (BCG-Japanese) and 
late- (BCG-Danish, Glaxo, Connaught, Pasteur and Tice) strains of BCG was comparable, 
with the exceptions of BCG-Glaxo that had a relatively poor efficacy and BCG Tice that
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was the most protective vaccine suggesting strain differences are not responsible for the 
variability of BCG protection (Horwitz, Harth et al. 2009). Persistence of antigen could 
result in continued activation and may prevent activated cells from developing into 
memory cells as proposed by Goldsack and Kirman (Goldsack and Kirman 2007) 
suggesting it may be important to consider strain variation when assessing protection from 
BCG vaccination.
The inhibitory effect of NTM on the protective efficacy of BCG depends critically 
on the extent of cross-reactivity of antigens shared with the vaccine. Most studies have 
shown that BCG vaccination on a background of prior exposure to M. avium provided less 
protection than on a background of more distantly related strains such as M. vaccae (Black, 
Dockrell et al. 2001; Brandt, Feino Cunha et al. 2002; Demangel, Gamier et al. 2005; Weir, 
Black et al. 2006; Young, Slobbe et al. 2007). A study in The Gambia using mycobacterial 
skin testing to various environmental mycobacterial antigens showed that M. intracellulare 
is the predominant mycobacterial species (81.2% of BCG nai've 6 - 1 8  year olds had 
induration > 3 mm), closely followed by M  avium (68.3%) present throughout the country, 
although slight geographical differences within the country were observed (Corrah 1994). 
This may account for the reduced IFNy production observed after delaying the BCG 
vaccine in our study. An interesting study illustrated that BCG vaccination following prior 
exposure to mycobacteria elicited a quicker memory recall response within the first week 
of BCG vaccination. Non-sensitised donors exhibited a gradually increasing 
responsiveness to mycobacterial antigens reaching maximum between day 56 and 365 days 
post vaccination (Ravn, Boesen et al. 1997). This may be important to our findings that by 
9 months there were no differences between the groups but differences may occur up to 
this point that were not examined.
Responses to EC (antigen used in the commercial IGRA assays) were very low. 
This is most likely due to a lack of infection in the study participants as was expected in 
this age group. It was possible that the concentration used in the study (chosen from
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previous adult ELISpot assays) was insufficient to induce a detectable immune response in 
infected infants, however responses above background were observed in all age groups. 
IFNy, IL-6 and IL-10 was induced compared to unstimulated cultures in the naive group 
that was not apparent in the BCG vaccinated group at 4% months, however when 
comparing the two vaccine groups IL-10 was the only cytokine found to be increased in 
the unvaccinated individuals. It is possible that young children in this setting are being 
exposed to NTM that contain or are cross primed by EC, such as M. leprae, M. kansasii, 
M. marinum, M. smegatus, M. ulcerans. In a previous study from The Gambia, 30% of 
adult community controls with no known exposure to M.tb responded to ESAT-6 
(Vekemans, Lienhardt et al. 2001). In our study the role of the EC specific IL-10 responses 
in the BCG naive individuals is unclear. IL-10 has also been shown to correlate with 
failure of BALB/c mice to control M. avium infection, whereas IL-10 ablation enhanced 
protection in these mice (Roque, Nobrega et al. 2007). This may suggest that reduced IL- 
10 observed in BCG vaccinated individuals could be linked to protection against M.tb.
Overall our studies suggest that BCG vaccination on the background of exposure to 
NTM is less immunogenic than vaccination at birth eliciting a predominantly Th2 
response. We hypothesise that this may in part be due to mycobacterial induced IL-10 
production from T cells (possibly by Trl induced Tregs). In addition BCG vaccination at 
birth induced a strong Thl and Th2 response but only the Th2 response remains by 9 
months of age suggesting that although BCG can induce a Thl response in early life it is 
transient and the remaining memory response is predominantly Th2 skewed as observed in 
response to many other vaccines in early life.
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CHAPTER 6
Immune correlates of the tuberculin skin
test
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6.1 INTRODUCTION
6.1.1 The tuberculin skin test (TST)
The TST or Mantoux test is used as a standard diagnostic tool to assess for 
infection with M.tb. The test involves the intradermal injection of PPD-tuberculin (PPD-T) 
into the volar region of the forearm and the induration (palpable raised hardened area) of 
the delayed type IV hypersensitivity (DTH) reaction is recorded 48 — 72 hours later. The 
number of T.U. injected varies from 1 - 1 0  T.U. according to national guidelines; making 
it difficult to compare studies across geographical locations (Farhat, Greenaway et al. 
2006). In the UK, 2 T.U. (RT23, SSI, Denmark) are often used in standard Mantoux testing 
(DoH 2006) in immune competent individuals, whereas most of the data from the US are 
derived from 5 T.U. (PPD-S, Tubersol® or Aplisol®, US) (2000), although 1 T.U. was 
found to be sufficient to diagnose TB in neonates in the US (Hoskyns, Simpson et al. 
1994). Generally a positive skin test is defined as an average induration (mean of width 
and length) of > 5 mm, however there are a number of determinants that affect TST 
reactivity necessitating different ‘cut offs’ of induration when assessing for the likelihood 
of M.tb infection.
The TST is highly sensitive but has low specificity. As PPD constitutes a mixture 
of mycobacterial antigens from M.tb, the TST reactivity can be affected by cross reactivity 
with NTM in the environment and by BCG vaccination. Most studies agree that, in adults, 
a higher cut off of > 10 mm increases the likelihood that the individual has TB infection. 
The TST does, however not distinguish between LTBI, i.e. infected but asymptomatic, and 
active TB disease.
6.1.2 Effect o f BCG vaccination on TST
BCG vaccination causes a local immune reaction that results in tissue necrosis and 
long term scarring over the vaccination site. It is not clear if the presence of scarring is 
associated with immune responses or protection from BCG. By 5 years of age
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approximately 54 - 99% of children who received BCG vaccination at birth develop a scar 
(Baily 1980; Fine, Ponnighaus et al. 1989; Vallishayee, Anantharaman et al. 1998). In 
Malawi, at 25 - 36 months post BCG vaccination, the average scar size of infants that were 
vaccinated < 1 month of age was 4 mm, which is lower than those vaccinated at 10-14 
years (average 8.5 mm) (Floyd, Ponnighaus et al. 2000). A correlation between a positive 
TST and BCG scar formation was found in some studies (Sterne, Fine et al. 1996; 
Lockman, Tappero et al. 1999), but not in others (Sedaghatian and Shana'a 1990; 
Lienhardt, Fielding et al. 2003) (Garcia-Sancho, Garcia-Garcia et al. 2006) and no 
association was found between TST and protection against TB (Corrah, Byass et al. 2000), 
(Sterne, Fine et al. 1996). Interestingly, the presence of a vaccinia (from previous 
Smallpox vaccination) and/or BCG scar was found to predict lower all-cause mortality, 
although the mechanism of these non-specific effects is unknown (Aaby, Gustafson et al.
2006).
Tuberculin reactivity after BCG immunisation can vary according to the strain and 
dose of BCG used (Ashley and Siebenmann 1967; Bunch-Christensen 1977; Karalliedde, 
Katugaha et al. 1987; Wang, Turner et al. 2002; Davids, Hanekom et al. 2006), the method 
of vaccine administration (Davids, Hanekom et al. 2006), the time since vaccination 
(Lifschitz 1965; Landi, Ashley et al. 1967; Guld, Waaler et al. 1968; Horwitz and Bunch- 
Christensen 1972; Karalliedde, Katugaha et al. 1987; Ormerod and Garnett 1988; Menzies 
and Vissandjee 1992; Teale, Cundall et al. 1992; Menzies 2000), the number o f BCG 
vaccinations administered (Ildirim, Hacimustafaoglu et al. 1995) and the age, weight and 
nutritional status of the child at the time of vaccination (Marcus and Khassis 1965; Joncas, 
Robitaille et al. 1975; Sinha and Bang 1976; Karalliedde, Katugaha et al. 1987; Menzies 
and Vissandjee 1992; Ormerod and Garnett 1992; Menzies 2000; Okan, Karagoz et al. 
2006; Richeldi 2006) and genetic variation between populations (Sepulveda, Heiba et al. 
1994; Sepulveda, Heiba et al. 1994; Newport, Goetghebuer et al. 2004)).
Although there are many conflicting studies on the effect of BCG on long term
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reactivity o f the TST, BCG vaccination at birth appears to result in TST reactivity > 10  
mm for 6 -  12 months (Lockman, Tappero et al. 1999; Lienhardt, Sillah et al. 2003; 
Santiago, Lawson et al. 2003; Ota, Goetghebuer et al. 2006; Chan, Chang et al. 2008). 
However other studies have suggested that the peak of TST reactivity (>10 mm) occurs at 
about 2 months of age and then gradually decreases to 12 months of age after which a TST
> 10 mm is more specific for TB infection. However, a TST result between 5 and 10 mm 
persists longer after BCG vaccination (Miret-Cuadras, Pina-Gutierrez et al. 1996; 
Bozaykut, Ipek et al. 2002; Reid, Ward et al. 2007). Miret-Cuadras et al showed that even 
20 - 25 years after vaccination at birth a higher proportion of individuals (53%) had a TST
> 5mm compared to non-vaccinated individuals (17.4%), although TST > 1 5  mm was 
more likely to represent TB disease (Miret-Cuadras, Pina-Gutierrez et al. 1996). A 
longitudinal study in Taiwan defined age specific ‘cut offs’ to identify LTBI in children up 
to 7 years of age. The effect of neonatal BCG on TST declined from 3 months to 7 years 
therefore optimal TST ‘cut offs’ for ages 0 - 1 , 2  - 3 ,  4 - 5  and 6 - 7  years were defined as 
21, 18, 13, and 10 mm respectively (Chan, Chang et al. 2008). Interestingly, BCG 
vaccination given after infancy (> 1 year o f age) was twice as likely to result in a TST > 5 
mm 20 years later, than when given to newborns (Menzies and Vissandjee 1992; Wing, 
Ekmark et al. 2002; Farhat, Greenaway et al. 2006).
6.1.3 Effect of NTM on TST
Exposure to NTM in different geographical locations has been shown to affect the 
TST although rarely causes an induration of >10 mm (Edwards, Acquaviva et al. 1969; 
Farhat, Greenaway et al. 2006). A meta-analysis that assessed the contribution of BCG and 
NTM on TST reactivity reported that in Montreal only 0.1% of TST responses >10 mm 
could be attributable to exposure to NTM, M. intracelliilare (prevalence 2-8%) compared 
to 2.3% in India where the prevalence of the same NTM was 86% (Farhat, Greenaway et 
al. 2006). NTM exposure has been assessed in studies in Malawi, by measuring IFNy
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responses to mycobacterial antigens in vitro. Individuals with no evidence of a BCG scar 
exhibited responses particularly to mycobacteria from the MAIS complex (M. avium, M. 
intracellular, M. scrofulaceum) (Black, Fine et al. 2001; Black, Weir et al. 2003). A study 
in The Gambia showed exposure to NTM in BCG nai've children ( 6 - 1 8  years if age) 
throughout the country with a predominance of M. intracellulare (81.2%) and M. avium 
(68.3%) and less prevalence of M. marinum (28.4%) (Corrah 1994). Infants can also 
respond to NTM, 22% (6/27) of BCG naive 4% month old infants in The Gambia had a 
TST > 5 mm suggesting NTM priming (Ota, Goetghebuer et al. 2006).
As discussed in the main introduction (Chapter 1) many studies have assessed the 
contribution of NTM exposure to BCG efficacy and TB protection. Most animal and 
human studies agree that there are interactions between NTM and BCG due to the sharing 
of mycobacterial antigens, but there are conflicting views on whether exposure enhances 
(Pabst, Godel et al. 1989), inhibits (Palmer and Long 1966; Edwards, Goodrich et al. 1982; 
Orme and Collins 1984; Black, Dockrell et al. 2001; Brandt, Feino Cunha et al. 2002; 
Buddie, Skinner et al. 2002; Howard, Kwong et al. 2002; de Lisle, Wards et al. 2005; 
Young, Slobbe et al. 2007) or has no effect (Ravn, Boesen et al. 1997) on the function of 
BCG. This may be due to widespread differences in the load and strain of NTM in 
different populations, but many other reasons may account for these observations.
6.1.4 Alternative diagnostic test for TB
Because of the potential for inaccuracy of the TST, alternative diagnostic tests have 
been developed based on advances in mycobacterial genomics. Two antigens, early 
secreted antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), have been 
found to be present in M.tb but not in BCG (Mahairas, Sabo et al. 1996; Lalvani, Pathan et 
al. 2001). Two commercial tests are now available based on enzyme-linked immunospot 
assay, ELI Spot (T-SPOT.77?; Oxford Immunotec, Oxford, UK) and enzyme-linked 
immunosorbent assay, ELISA (QuantiFERON-TB Gold; Cellestis, Carnegie, Australia)
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based on ESAT-6 or CFP-10 induced IFNy production from T cells. Both these interferon- 
gamma release assays (IGRA) have been shown to be more specific than TST in 
diagnosing TB disease and in LTBI subjects (detected using case contact studies) and more 
sensitive than TST in TB cases (Lalvani 2007; Chun, Kim et al. 2008; Connell, Ritz et al. 
2008; Mandalakas, Hesseling et al. 2008; Stephan, Wolf et al. 2008). These studies have 
also shown that the IFGA tests are not affected by BCG vaccination or NTM exposure 
(Dheda, Udwadia et al. 2005). Nienhaus et al showed that 85% of TST+/IGRA' discordant 
results were due to BCG vaccination (Nienhaus, Schablon et al. 2008). As mentioned 
earlier in the introduction of this chapter, ESAT-6 and CFP-10 are not present in BCG but 
they are present in some species of NTM including M. leprae, M. kansasii, M. marinum, 
M. smegmatis, M. ulcerans (Demangel, Gamier et al. 2005) that could influence the IFGA 
tests in areas where these NTM are prevalent.
Results have varied when analysing correlations between IFNy production in 
response to PPD and the TST although greater concordance was found comparing 
responses to the ESAT-6/CFP-10 antigen with the skin test (Converse, Jones et al. 1997; 
Desem and Jones 1998; Streeton, Desem et al. 1998; Elliott, Hurst et al. 1999; 
Pottumarthy, Morris et al. 1999; Black, Fine et al. 2001; Mazurek, LoBue et al. 2001; Ota, 
Goetghebuer et al. 2006; Martins, Lima et al. 2007). It is however recognised that IGRA 
assays using specific antigens are less prone to the confounder effect of BCG vaccination 
and NTM than the TST.
Immune correlates of protection against TB are unclear, but recent evidence 
suggests that IFNy is not the only cytokine that is involved (discussed in Chapter 1). In 
addition, immune responses involved in the TST are not well studied and therefore this 
chapter aims to examine the immune correlates of TST reactivity at 4 'A months of age and 
to further understand the contribution BCG and NTM have in this reactivity by comparing 
infants who have been BCG vaccinated at birth (Group 1) to BCG naive children (Group
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2). It further analyses the relationship between pro-inflammatory and anti-inflammatory 
cytokines in order to give additional insight into how the TST is controlled and regulated.
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6.2 RESULTS
6.2.1 Reactivity to the TST at 4 V2 months was related to BCG vaccination
All infants were given a 2 T.U. tuberculin skin test at AVi months of age. This 
included the BCG vaccinated group (Group 1, n = 51) and the BCG naive infants (Group 2, 
n = 39). The latter group provided an opportunity to assess for the effect of exposure to 
NTM to TST reactivity. Induration of > 10 mm in either group was treated as suspected 
LTBI or TB disease and investigated further (see Chapter 2: Materials and Methods).
Surprisingly, all the subjects in the unvaccinated group (Group 2) exhibited a 
completely anergic (zero induration) response to the TST (Figure 6.1 A). Within the BCG 
vaccinated group 47% (24/51) of subjects exhibited a positive response (> 5 mm) and the 
remaining 53% were predominantly anergic. Of those that had > 5 mm induration, 58% 
(14/24) had responses > 10 mm and were investigated further for possible TB exposure. It 
was found that two of these children had potentially been exposed to TB in their compound 
and they will be discussed later in this chapter. No child had a TST response greater than 
15 mm (Figure 6.1 A). Skin test induration in Group 1 did not follow a normal distribution. 
Apart from the prominent peak at zero of induration there were three further peaks at 7, 10 
and 13 mm of induration (Figure 6. IB).
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Figure 6.1: Tuberculin Skin Test (TST) results at 4/2 months o f age. 2 T.U PPD was
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injected into the forearm o f each individual at 4 V2 months o f age. The average length x  
width (mm) o f the induration was measured 48 — 72 hours later. (A) Average TST 
induration fo r  each group, red line represents a 5 mm ‘cut o ff’fo r  positive reactivity, (B) 
frequency graph o f TST induration. Vaccinated (Group 1) n = 51, unvaccinated (Group 2) 
n = 39.
6.2.2 PPD and BCG specific cytokine responses and TST reactivity
The Mantoux reaction is caused by a local cell mediated immune response to PPD 
at the site of injection, but it remains unclear as to how Mantoux reactivity relates to 
mycobacterial activity in peripheral blood. Within the BCG vaccinated group, the 
responders (> 5 mm, denoted R) had higher day 5 whole blood IFNy reactivity to PPD than 
the non-responders (< 5 mm, denoted NR) (Figure 6.2A, p = 0.0021). Even the NR in the 
vaccinated group, most of whom were anergic, still exhibited greater IFNy reactivity than 
the anergic BCG naive individuals from Group 2 (p = 0.0002) suggesting that IFNy 
production is upregulated in response to BCG vaccination even if it does not lead to a 
positive TST. IFNy was also increased in the responders after in vitro stimulation with the 
BCG vaccine compared to the non-responders (p = 0.0349). There was a trend for greater 
IFNy production from the non-responders compared to Group 2 but this was not significant 
(p = 0.1575). None of the other cytokines tested (IL-13, IL-6, IL-7 and IL-17) were 
significantly different between responders and non-responders in response to PPD or BCG. 
The borderline significantly higher IL-6 to these antigens in responders (PPD; p = 0.0560, 
BCG; p = 0.0221) was lost after Bonferroni correction for multiple testing (data not 
shown). Although TST responders produced more IFNy compared to non-responders, the 
quantity of IFNy produced and the size of induration of the TST reaction was not 
correlated (Spearmans r = 0.2831, p = 0.2136) (Figure 6.2B).
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The anti-inflammatory cytokine, IL-10 was upregulated in response to PPD in both 
groups (vaccinated and unvaccinated) at 4!4 months compared to unstimulated cultures, 
but there was no difference between the two groups (p = 0.965) suggesting that BCG 
vaccination does not induce PPD specific IL-10. This mycobacterial specific IL-10 in the 
naive group is most likely to be the result of exposure to NTM.
Interestingly, the quantity of IL-10 produced in response to PPD at 414 months of 
age inversely correlated to the induration of the TST (r = 0.4396, p = 0.0358) (Figure 
6.2D) which would suggest that exposure to NTM-induced IL-10 can influence the skin 
test reactivity. If this was true one might predict that those with an anergic TST would 
have the highest levels of IL-10. However, IL-10 production was comparable between 
responders and non-responders and the unvaccinated groups (Figure 6.2C and D). 
However the distribution of data was quite different between groups (Figure 6.2C). Only 3 
BCG vaccinated responders (13.0%) produced greater than 34 pg/ml (3 x SEM) of IL-10 in 
response to PPD whereas 18.2% (4/22) of the non-responders and 26.3% (10/38) of the 
unvaccinated individuals responded with higher levels of IL-10 production to PPD. 
Furthermore, those individuals that downregulated IL-10 production (PPD stimulated 
minus unstimulated control was < zero) in response to PPD stimulation were 
predominantly TST responders; 83% (5/6) compared to none of the non-responders and 
one of the unvaccinated. A similar trend was also observed when comparing in vitro 
reactivity to the BCG imunogen.
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Figure 6.2: Relationship between TST and cytokine production. At 4/2 months o f  age, 
whole blood was incubated with PPD fo r  5 days. IFNy (A and B) and IL-10 (C and D) 
cytokine production was measured in the supernatants o f  the cultures. Unstimulated 
control was subtracted from the PPD stimulated values, black bar represents the median 
value, red line represents 34 pg/ml (3 x SEM). A Mann Whitney U test at 5% significance 
was applied to compare the cytokine production between groups. Correlation between the
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TST induration o f the responders and IFNy (B) and IL-10 (D) was calculated using 
Spearmans correlation coefficient at 5% significance. R = responder n = 23, NR = non 
responder n = 22, unvaccinated n = 38.
Neither IFNy nor IL-10 produced in day 5 BCG culture supernatants correlated 
with TST induration. However there was a trend for the highest cytokine production of 
IFNy to fall between 9 - 1 2  mm induration. In contrast, the lowest IL-10 production was 
observed at this same induration (Figure 6.3A and B). One individual (BCG033) exhibited 
the highest IFNy response alongside the lowest IL-10 production, indicated with an ‘X ’ in 
Figure 6.3A and B. Interestingly this individual corresponded to the high IFNy/ low IL-10 
responder to PPD. This may indicate the different influences that may confound the TST 
reactivity and would be worth examining in more detail in a later study. There were also 
no significant correlations between the other cytokines tested (IL-6, IL-13, IL-7 and IL-17) 
from PPD or BCG cultures and the TST induration.
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Figure 6.3: In vitro responses to BCG vaccine compared to TST induration in Group I 
(vaccinated). At 4 Z2 months o f age, whole blood was incubated with BCG fo r  5 days. IFNy 
and IL-10 cytokine production was measured in the supernatants o f  the cultures. 
Unstimulated control was subtracted from the PPD stimulated values, black bar represents
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the median value. Correlation between the TST induration o f  the responders and IFNy (A) 
and IL-10 (B) was calculated using Spearmans correlation coefficient at 5% significance, 
n = 23. X  = the corresponding results fo r  one subject.
Studies have shown a reduced ratio of IFNy: IL-10 in response to PPD in TB 
patients compared to M.tb exposed but healthy individuals (Hussain, Talat et al. 2007). We 
examined this ratio in the context of BCG vaccination and found BCG vaccinated infants 
had a higher IFNy: IL-10 ratio compared to unvaccinated infants but there were no 
differences in IFNy: IL-10 ratios according to TST reactivity (Figure 6.4A and B). This is 
likely to reflect the increased IFNy but lack of IL-10 induction observed in BCG 
vaccinated individuals.
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Figure 6.4: IFNy to IL-10 ratio in response to PPD stimulation. At 4 lA months o f age, 
whole blood was incubated with PPD fo r  5 days. Unstimulated control was subtracted 
from the PPD stimulated values, black bar represents the median value. The ratio o f IFNy 
and IL-10 cytokine production was measured in the supernatants. A Mann Whitney U test 
at 5% significance was applied to compare the ratio o f IFNy: IL-10 between groups (A) 
and between TST responders and non-responders and between non-responders and
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unvaccinated (B). R = responder n = 23, NR = non responder n = 22, unvaccinated n = 
38.
6.2,3 PPD and BCG specific T cell responses by flow cytometry and TST reactivity
It was hypothesised that the level of Tregs circulating in the peripheral blood may 
influence the reactivity to the skin test, however a comparison of the ex vivo FOXP3 Tregs 
(CD4+CD25+FOXP3+) between responders and non responders in the BCG vaccinated 
group showed similar levels (p = 0.7341) which were also similar to those of the 
unvaccinated group.
Although PPD stimulated IFNy production was greater in the TST responders, this 
did not correspond to greater T cell activation (CD4+CD25+) or proliferation (Ki-67+) 
compared to the non-responders but did remain significantly higher than the unvaccinated 
group (Figure 6.5A and B). However, with respect to in vitro stimulation with BCG there 
was a trend for activated T cells (CD4+CD25+) and Tregs (CD4+CD25+FOXP3+) to be 
upregulated in those that responded to the TST (p = 0.0785 and p = 0.0696 respectively) 
(Figure 6.5C and D).
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Figure 6.5: Relationship between TST and T cell phenotype in response to PPD and
BCG At 4/2 months o f age, whole blood was incubated with PPD (A, B) and BCG (C, D) 
for 5 days. Unstimulated control was subtracted from the PPD stimulated values, black bar 
represents the median value. Activated T cells (CD4 CD25 ) (A, C) and Tregs 
(CD4 CD25 FOXP3 ) (B, D) were measured with respect to TST reactivity. Comparisons
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between responders (R), non responders (NR) and unvaccinated individuals were 
calculated using a Mann Whitney U test at 5% significance. R = responder n — 22, NR = 
non responder n = 21, unvaccinated n = 34.
Interestingly there was an inverse correlation between the size of the TST and 
proliferation of both CD4" and CD8 T cells after in vitro stimulation with BCG, but not 
after PPD stimulation (Figure 6.6A and B). As observed with IL-10 cytokine production, 
this correlation was not reflected by significant differences when comparing R and NR. 
The proportion of proliferating CD8 T cells were, in fact, greater in the R compared to the 
NR (Figure 6.6C and D). When adjusting for multiple comparisons these observations are 
no longer significant but it is worth considering these trends in subsequent studies.
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Figure 6.6: In vitro proliferative responses to BCG correlated with TST. At 4V2 months o f
age, whole blood was incubated with PPD fo r 5 days. Unstimulated control was subtracted 
from the PPD stimulated values, black bar represents the median value. Frequency o f  
proliferating CD4+ T cells (A, C) and CD8+ T cells (B, D) was measured using 
intracellular staining with Ki-67 antibody. Correlation between the TST induration o f  the 
responders and CD4 Ki-67 (A) and CD8 Ki-67 (B) was calculated using Spearmans 
correlation coefficient at 5% significance. Comparisons between responders (R) and non 
responders (NR) were calculated using a Mann Whitney U test at 5% significance (C, D). 
R = responder n = 23, NR ~ non responder n = 21, unvaccinated n = 34.
T cell production of IL-10, as defined by intracellular staining (ICS) did not differ 
between responders and non-responders or compared to unvaccinated individuals both in 
response to PPD and BCG. Furthermore, ICS IL-10 production was not correlated to TST 
induration as was observed with IL-10 production in the supernatant of cultures, 
suggesting a non-T cell source for the latter IL-10 levels (Figure 6.7A -  D). Antigen
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specific TGFp production by intracellular staining o f T cells were very low, in most cases 
< 1% of T cells produced this cytokine. Comparisons between responders and non­
responders did not reveal any significant differences and TGFp production did not 
correlate to TST induration (data not shown).
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Figure 6.7: Day 5 intracellular IL-10 T cells in response to BCG correlated with TST. At
4 V2 months o f age, whole blood was incubated with BCG for 5 days. Frequency o f IL-10
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producing CD4+ T cells (A, B) and CD8 T cells (C, D) was measured by intracellular 
staining. Unstimulated control was subtracted from the BCG stimulated values, black bar 
represents the median value. Comparisons between responders (R) and non responders 
(NR) were calculated using a Mann Whitney U test at 5% significance (A, C). Correlation 
between the TST induration o f the responders and CD4+IL-10+ (B) and CD8+IL-10+ (D) 
was calculated using Spearmans correlation coefficient at 5% significance. R = responder 
n = 23, NR = non responder n = 21, unvaccinated n = 34.
6.2.4 ESAT-6/CFP-10 specific responses and TST reactivity
Many studies have indicated that, in the future, IGRA involving the EC antigen 
complex may replace the TST in determining M.tb infection and TB disease. A comparison 
between in vitro EC responses and the TST would help clarify these conflicting studies.
There were no TST reactors in the BCG naive group therefore it is likely that a TST 
> 10 mm (observed in 27.5% of Group 1 individuals) was due to the BCG vaccination 
rather than M.tb infection.
Immune responses to EC were compared between responders and non-responders 
using the same definitions as before. There were no significant differences between the two 
groups for all the parameters examined including CD4+CD25+, FOXP3+Tregs, ICS Ki-67, 
IL-10, TGFp and production of cytokines (IFNy, IL-6, IL-13, IL-10, IL-7, IL-17) in the 
supernatant. However there was a significant increase in IL-10 production from the EC 
stimulated supernatants in the BCG naive group compared to the non-responders in the 
BCG vaccinated group (Figure 6.8A) supporting the previous results from PPD stimulated 
cultures. EC-specific IFNy production showed a trend for an inverse correlation with 
respect to TST induration as illustrated in Figure 6.8B but with a peak of IFNy production 
between 9.5 and 12.5 mm, which was seen in immune responses to BCG earlier.
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Figure 6.8: Cytokine production in response to ESAT-6/CFP-10 fusion protein compared 
to TST reactivity. At 4/2 months, whole cord blood was incubated with ESAT-6/ CFP-10 
(EC) for 5 days. Cytokine production was measured in the supernatants o f the cultures. 
Unstimulated control was subtracted from the EC stimulated values, black bar represents 
the median value. A Mann Whitney U test at 5% significance was applied to compare the 
cytokine production between responders (R) and non- responders (NR) to the TST (A). R= 
responder n = 23, NR = non responder n = 23, unvaccinated n = 39. Correlation between 
the TST induration o f  the TST responders and IFNy production in response to EC was 
calculated using Spearmans correlation coefficient at 5% significance, n = 23 (B).
6.2.5 Suspected TB exposure
TB exposure was assessed by the monthly TB questionnaire (TBQ) and by the TST 
at 4/4 months. From the skin test results 14 subjects had a TST result > 10 mm which 
could suggest exposure to TB. In all cases all members of the compound were skin tested 
and chest X-ray performed on all those with a TST > 10 mm. Only two children were 
identified from this process as probable TB exposure that might account for the high
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reactivity to the TST (Table 6.1 A).
The TBQ also identified a further two children with potential exposure to TB; one 
was in the delayed BCG vaccine group and identified as at risk at 1 month of age. This 
child was therefore dropped out of the study, assessed by the paediatrician and BCG 
vaccinated immediately. The second child was detected after BCG vaccination and 
therefore remained in the study (Table 6.1 A).
A
Subject
ID
Group Exposure
identified
by
Age
identified
(m)
TST  
at 
4/4 m
TST  
at 
24 m
Details Droppedout
BCG005 1 TST 414 10 4 Member of compound being treated 
for TB
no
BCG016 1 TST 4Vz 13.5 0 Suspected case of child in 
compound but was not confirmed
no
BCG025 2 TBQ 1 N/A N/A Father treated during mother’s
pregnancy
yes
BCG057 2 TBQ 7 0 0 Father currently being treated for 
TB
no
BCG043 2 TST 20-28 0 19.5 Currently being tested for TB no
BCG050 1 TBQ 20-28 0 0 Sister had suspected TB no
B
Number of individuals Number of individuals 
with scar
Anergic (0) 71 (83.5%) 66/72 (91.7%)
1 -4  mm 2 (2.4%) 1/2 (50%)
5 - 9  mm 7 (8.2%) 6/7 (85.7%)
> 10 mm 4 (4.7%) 4/4 (100%)
Table 6.1: TB exposure identified during the study. (A) Details o f individuals identified as 
having potential exposure to a TB case by TST at 4 V2- and 20 months o f age, (B) At 20 
months o f age TST results and scar formation in individuals with specific TST indurations 
(n = 85).
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6.2.6 Repeated TST at 20 months o f age
A repeat Mantoux test of all subjects at 20 - 28 months of age was undertaken. By 
this age the TST response to BCG vaccination would be expected to have waned, and 
reactivity >10 mm would be more likely to be due to M.tb infection.
Seventy two of the 85 children (84.7%) were anergic to the TST (induration of 
zero). Of the 13 individuals that exhibited a response, 4 individuals had an induration of > 
10 mm (Table 6.IB). These individuals were followed up for suspected TB exposure and 
one of them was identified as living in a compound of a possible TB index case (Table 
6.1 A). One individual was also identified through the TBQ that was also completed at 20 
months of age. Only one of the three subjects that were previously identified as being 
exposed to TB at 4V£ months had reactivity to the TST and this was < 5 mm (Table 6.1 A).
When comparing the TST results to those at 4% months, it was obvious the timing 
of the BCG vaccination did not affect the TST at 20 months of age, with similar numbers 
of positive subjects in both groups (Group 1: 13.3%; Group 2: 12.5%) (Figure 6.9A and 
B). Scar formation was recorded at this 20 month visit and was present in 91.8% of 
individuals with a median diameter of 3 mm. Seven out of eighty five (8.2%) children did 
not develop a scar to BCG vaccination. There was no relationship between lack of BCG 
scar and timing of BCG vaccination.
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Figure 6.9: TST results at 4 V2 and 20- months o f  age. (A) Average TST induration fo r  
each group at 4/2 months o f age (vaccinated group n = 51, unvaccinated group n = 39), 
and (B) 20 months o f age (Group 1 vaccinated at birth n = 45, Group 2 vaccinated at 4/2 
months n = 40), red line represents a 5 mm ‘cut o ff fo r  positive reactivity.
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6.3 DISCUSSION
In concordance with the literature, BCG vaccination induced reactivity to the 
tuberculin skin test 4% months later. Studies by Chan et al suggest that the ‘cut o ff for 
M.tb specific reactivity up to 1 year of age was 21 mm and anything below this could be 
attributed to BCG vaccination. By 20 months of age, the proposed ‘cut o ff was 18 mm 
(Chan, Chang et al. 2008). At 414 months of age none of our subjects had reactivity above 
15 mm suggesting that none of the study participants were infected with M.tb. At 20 
months, 4/85 (4.7%) individuals had a TST > 1 0  mm but only one subject reached a 
reactivity of>  18 mm. This child was indeed identified as being exposed to M.tb. However 
there were also children at 4/4 months and 20 months that had an anergic skin test, but 
were deemed to have had a significant TB exposure by TBQ. This would suggest that these 
individuals had not become latently infected even though they had been exposed. All 
children were from the same environment (within a 40 km radius of the Sukuta district) 
and were recruited randomly throughout the different seasons of the year for two years 
(June 2006-M ay  2008).
In a previous Gambian study Ota et al found 22% of BCG naive children at 414 
months of age had a positive TST response (Ota, Goetghebuer et al. 2006). In the present 
study none of the unvaccinated individuals reacted to the TST despite having in vitro 
reactivity to PPD and BCG albeit at significantly lower levels than vaccinated children 
suggesting the skin test may be less sensitive than the 5 day whole blood assays. It may 
also suggest that there is a defect in the ability of T cells to home to the skin. The Th2 
cytokine IL-4 has been shown to downregulate the homing molecule cutaneous 
lymphocyte-associated antigen (CLA) on virus-specific CD8+ T cells. In contrast IL-12 
and, surprisingly IL-10 both increased the expression of CLA (Seneviratne, Jones et al.
2005). In addition differential effects of IL-12 and IL-10 have also been found on 
superantigen-induced expression of CLA where addition of IL-12 augmented the 
expression of CLA but IL-10 strongly decreased it (Sigmundsdottir, Johnston et al. 2004).
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It is possible that the cytokine milieu induced by exposure to NTM downregulates the 
homing molecules on PPD-specific T cells thus reducing the TST reactivity.
It was interesting that more than half (53%) of the BCG vaccinated children had an 
anergic skin test at 4% months of age. The likelihood of false negative results was 
considered. To eliminate the possibility of inactive PPD reagent, the same batch of PPD 
was used and was tested at the start and half way through the study on a known positive 
responder. Training of field staff and using two independent readers reduced false readings 
due to lack of correct skills. False negative TST results can be caused by a number of 
factors including immunosuppression (e.g. by HIV infection) (Pesanti 1994; Raby, Moyo 
et al. 2008), age (reduced TST reactivity has been observed in the very young and the very 
old) (Rodysill, Hansen et al. 1989; Shingadia and Novelli 2003), overwhelming TB 
infection (Boussiotis, Tsai et al. 2000; Magnani, Confetti et al. 2000), other viral (Starr and 
Berkovich 1964; Pesanti 1994), or bacterial infections (Mitchell 1935) and recent viral 
vaccinations (Brody and McAlister 1964; Brody, Overfield et al. 1964; Starr and 
Berkovich 1964). In TB patients Vdelta2+ T cells are thought to play a role in this anergy 
(Szereday, Baliko et al. 2008). As mentioned in Chapter 2: Materials and Methods, the 
prevalence o f HIV in The Gambia is 2.4% in adults (aged 15 -  49) and an estimated 1,200 
children (aged 0 - 1 4  years, 0.1% of population) living with HIV (UNICEF 2005) 
suggesting that it is unlikely that any of the children in this study would be HIV+ and 
therefore would account for a false negative TST. Twin studies have found conflicting 
results as to the inheritability of the TST response and therefore it remains unclear if there 
is a genetic component to the skin test response (Gonzalez, Heiba et al. 1994; Sepulveda, 
Heiba et al. 1994; Sepulveda, Heiba et al. 1994).
A trend of higher levels of IL-10 production was observed in TST non-responders
and BCG naive anergic individuals compared to TST responders (although overall
responses were similar) and within the responders there was an inverse correlation between
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higher IL-10 and lower TST reactivity suggesting that IL-10 plays a role in reactivity to 
TST in relation to BCG vaccination. This was most evident in BCG and EC in vitro 
responses which suggest specificity of the response. The differences observed were mainly 
from IL-10 production measured in the supernatant of the 5 day cultures and did not 
correspond to the IL-10 levels measured in the lymphocyte population of cells by flow 
cytometry, suggesting the IL-10 that influences the TST was produced by non-lymphoid 
sources, such as macrophages. TST anergy occurs in about 25% of immunosuppressed TB 
patients which often correspond to poor prognosis (Boussiotis, Tsai et al. 2000; Delgado, 
Tsai et al. 2002). This anergy has been linked to increased IL-10 production after in vitro 
stimulation with PPD and further supports a link between IL-10 and anergic TST. It has 
also been shown that IL-10 is an important negative modulator of the DTH. Addition of 
anti-IL-10 antibodies prior to BCG vaccination and subsequent skin testing or the use of 
IL-10'7’ mice both enhanced the IFNy response to PPD and the swelling and duration of the 
DTH (Nadler, Luo et al. 2003). In addition, injection of recombinant IL-10 into the footpad 
of mice prior to challenge with antigen prevented the elicitation of contact hypersensitivity 
(CHS) in previously sensitized mice (Ferguson, Dube et al. 1994). These studies add 
further evidence that the skin test anergy observed in our study was regulated through an 
IL-10 dependent mechanism.
IFNy production was higher in the TST responders but the concentration did not
correlate with the induration. This discordance between IFNy and TST induration may
indicate that IFNy is produced to initiate the DTH but the size of the induration that is
recognised by increased swelling and recruitment of macrophages and T cells to the skin,
is regulated by other factors. In support of this hypothesis, Martins et al investigated T cell
function in relation to mycobacterial infections and found that in one subject, strong
erythema to the TST without any induration, correlated with increased IFNy response to
PPD (Martins, Lima et al. 2007). In another study, mice with a disrupted IFNy gene did not
have a reduced DTH response compared to wild type (WT) but did have reduced
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protection from TB in mice (Cooper, Dalton et al. 1993) indicating IFNy is not the only 
pro-inflammatory molecule involved in initiating the DTH. Our results support the 
possibility that non-T cell derived IL-10 regulates the size of the induration. As mentioned 
before, cytokine production in the supernatant can be from many cell types. A study 
showed an association between CD4+CD69+IFNy+ among PBMCs cells and TST 
induration (p = 0.04) but this was not statistically significant when the TST was compared 
to IFNy from culture supernatants (p = 0.07) (Martins, Lima et al. 2007). This is in keeping 
with the lack of correlation between ICS cytokines by flow cytometry and culture 
supernatants in our study. The TST results at 20 months indicated BCG vaccination at birth 
or 4/4 months of age rarely caused a positive response and might be a better test of TB 
infection at this age. It would have been interesting to examine the correlation between 
IFNy and IL-10 responses and TST in this age group.
It has been postulated that Tregs play a role in skin sensitivity to nickel allergy 
(Cavani, Nasorri et al. 2003). An infiltrate of Tregs possessing CLA occurred in anergic 
individuals at the patch site which constituted 20% of all the T cells at this site. When 
removing these Tregs in culture, T cells became more responsive to nickel. In contrast, 
Tregs from the blood of allergic individuals had limited or absent suppressive activity in 
vitro compared to Tregs from anergic subjects indicating the function of the Tregs was 
different (Cavani 2005). From our results CD4+CD25+FOXP3+ Tregs were upregulated in 
response to PPD after BCG vaccination and were not different between responders and 
non-responders. This did not correspond to the nickel study although it is possible that the 
function of these Tregs is more impaired in the responders compared to the non­
responders. The BCG vaccinated but TST anergic subjects exhibited reduced CD8 T cell 
proliferation in response to BCG, however T cell proliferation inversely correlated with the 
TST induration which is counter to what would have been expected. As with most 
immunological studies analysing peripheral blood, the homing of T cells to localised sites 
of disease may cause very different patterns to be seen at these sites that are not reflected
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by changes in the peripheral blood. Previous studies in our lab observed reduced FOXP3 
expression in peripheral blood from TB contacts (Burl, Hill et al. 2007) which in mice and 
monkeys has been shown to correspond to a homing of Tregs to the lung (Shafiana, S and 
Green, A et al, respectively, personal communication).
A peak of IFNy reactivity at 10 mm induration corresponded to a peak percentage 
of skin test reactors at 10 mm. Figure 6.10A illustrates a previous study where three peaks 
were observed in BCG vaccinated individuals (5, 10 and 15 mm) (Wang, Turner et al. 
2002). Our study also showed three distinct peaks at 7, 10 and 13 mm (Figure 6.10B). 
Wang et al did not discuss the relevance of these peaks in his study but they may represent 
different influences on the TST for example, exposure to NTM, BCG vaccination and M.tb 
latent infection or disease respectively. A mathematical approach to establishing ‘cut offs’ 
for LTBI was investigated by Villate et al which concluded that in 7 year old BCG 
vaccinated children there was a 97% probability of LTBI infection at an induration of > 17 
mm and only 35% at > 10 mm and illustrated the distribution of induration that could be 
contributed to NTM, BCG and LTBI (Figure 6.10C)(Villate, Ibanez et al. 2006). 
Combined, these findings suggest that the TST reactivity is not a continuous variable, and 
therefore correlations between in vitro responses and TST induration may need to be 
evaluated differently.
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Figure 6.10: The relationship between frequency and TST induration. (A) Results from a 
large cohort study illustrating three peaks o f percentage o f reactors at 5, 10 and 15 mm 
(Wang, L et al, 2002) using 2 T.U. RT23, (B) results from this study presented in a similar 
way to (A) and also illustrating three peaks at 1, 10 and 13 mm, using 2 T.U. PPD, (C) the 
observed induration distributions derived from a mathematical mixture model suggesting 
more accurate ‘cut offs’fo r TST induration in 7 year old BCG vaccinated children (Villate, 
J l et al, 2006).
There has been an extensive debate regarding the use of TST or the IGRA for 
diagnosing LTBI and TB disease. Largely, the specificity o f the TST and the influence of
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BCG vaccination have been questioned. Previous work in The Gambia suggested that the 
IGRA tests reflect load of M.tb, i.e. acute or recent infection, whereas TST indicated past 
and present infection (Hill, Fox et al. 2005) which may account for the lack of correlation. 
However Hill et al also found that in a Gambian setting the TST specificity was high with 
respect to sleeping proximity to the index case; sleeping closer to the index case was more 
likely to increase the reactivity to the TST (Hill, Brookes et al. 2006). The IGRA tests are 
changing current guidelines for diagnosing TB both in the US and throughout Europe, and 
may eventually replace the TST. However, amongst the many studies illustrating 
discordance between IFGA test and the TST, Fietta et al suggested that by increasing the 
stringency of the QuantiFERON-TB Gold ‘cut o ff, there was correlation between the TST 
and the IFNy production (Fietta, Meloni et al. 2003). Concordance between the TST and 
the IFNy production was also found in patients with inflammatory bowel disease 
(Bartalesi, Vicidomini et al. 2008) indicating that evaluation in different clinical settings 
need to be assessed before discarding the use of the TST. A case contact study in The 
Gambia illustrated that of the contacts that progressed to disease, only 50% reacted to the 
TST or the IFNy ESAT-6/ CFP10 ELISpot assays prior to disease but 71% were positive 
by one or other test suggesting positivity by either test might be the best indication for 
preventive treatment and would therefore not support the replacement of the TST in this 
setting (Hill, Jackson-Sillah et al. 2008). As a practical issue, a delay in processing the 
blood samples from cattle had a direct impact on the IGRA results from PPD stimulated 
samples (Whipple, Palmer et al. 2001; Gormley, Doyle et al. 2004). Although in an animal 
model, this suggests that the timing of blood collection may be crucial in detecting 
accurate results, which is important in many developing country settings. Furthermore, the 
IFNy based tests are more expensive and technically demanding than the TST, which is an 
important consideration in resource-poor settings, where the burden of TB disease is often 
greatest. The use of ESAT-6 as a skin test has been developed recently and shown to be 
reactive in human subjects. Compared to PPD-tuberculin, lpg ESAT-6 showed more
specific results producing reactivity in all TB contacts but not in BCG vaccinated 
individuals (Wu, Zhang et al. 2008) suggesting this antigen could be used in favour of the 
tuberculin skin test.
In summary our results showed that the positive TST observed at 414 months of age 
is likely to be a result of BCG vaccination. This will confound the interpretation o f the 
TST for the diagnosis of M.tb infection in early life but by 20 months of age the TST may 
be more reliable particularly if a higher cut off of 18 mm is used. Our results also suggest 
that BCG vaccination prior to exposure to NTM leads to less EC specific IL-10 compared 
to infants vaccinated on a background of NTM exposure which provides insights into the 
protective effects of BCG. Finally our results suggest that while IFNy is induced by BCG 
vaccination, it is IL-10 that may control the size of the TST induration.
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CHAPTER 7
Gender, CMV and non-specific reactivity
194
7.1 INTRODUCTION
BCG is a strong immune stimulator and has therefore been shown to have many 
non-specific effects (NSE) which have been exploited for therapeutic use. BCG can act as 
an adjuvant to boost the immune response that reduces tumour regression of various 
cancers, in particular bladder cancer where BCG has been used as treatment since 1976 
(Morales, Eidinger et al. 1976). The mechanisms of this adjuvant effect are not clear but 
are thought to be related to Thl cytokine production (e.g. IFNy and TNFa) induced by the 
vaccine, recruiting and activating immune cells to fight the cancerous cells (Patard, Saint et 
al. 1998; Chen, O'Donnell et al. 2007) reviewed in (Herr and Morales 2008).
Given that BCG can induce a mature-like Thl response in neonates (Marchant, 
Goetghebuer et al. 1999), it is therefore not surprising that recent reports have found NSE 
of BCG vaccination early in life. Given at birth, BCG has been found to reduce all cause 
mortality during infancy (Kristensen, Aaby et al. 2000; Breiman, Streatfield et al. 2004; 
Lehmann, Vail et al. 2005; Roth, Gustafson et al. 2005) and influence responses to other 
vaccines in early life (Ota, Vekemans et al. 2002). In an interesting infant study from 
Guinea Bissau, administrating BCG and OPV together in low birth weight children showed 
a reduction in immunogenicity to PPD antigen compared to BCG alone in these children 
(Peter Aaby, personal communication).
Interestingly some of these NSE appear to be gender specific (Aaby, Jensen et al. 
2002; Elguero, Simondon et al. 2005; Moulton, Rahmathullah et al. 2005; Aaby, Ibrahim et 
al. 2006; Aaby, Jensen et al. 2006; Rodrigues, Fischer et al. 2006; Roth, Sodemann et al. 
2006; Valentiner-Branth, Perch et al. 2007). Most of this work has been studied by Aaby et 
al in Guinea Bissau where they found that girls appeared to have lower all-cause mortality 
following BCG and measles vaccine (MV) but increased mortality following DTwP 
vaccine (Aaby, Jensen et al. 2002). This has also been shown in India (Moulton, 
Rahmathullah et al. 2005), Sudan and Democratic Republic of Congo (Aaby, Ibrahim et al.
2006). This work also suggested that the sequence of vaccines administered in early life
195
may have an influence on child mortality (Aaby, Ibrahim et al. 2006; Rodrigues, Fischer et 
al. 2006), and that it is the last vaccine given that dictated outcome (Aaby, Biai et al. 2007; 
Aaby, Gariy et al. 2007). These NSEs are thought to be strongest in the 6 months following 
vaccine administration making our 4Z> month sample time point o f particular interest when 
looking for evidence of NSE.
Many animal and human studies have shown gender related dysfunction of the 
immune system. The incidences of many autoimmune diseases are biased towards females 
but often result in greater severity in males. With respect to infection, female mice have a 
greater Thl response to many viruses thereby reducing the severity of some diseases but 
also increasing pathology in others (reviewed in (Shames 2002)). Immune cell phenotypes 
also differ between adult males and females whereby females have increased numbers o f 
circulating CD4 T cells compared to males (Amadori, Zamarchi et al. 1995). In response to 
vaccination, female adult mice immunised with BCG showed higher levels of IFNy than 
males (Huygen and Palfliet 1984). These gender differences are normally apparent post 
puberty and relate to sex hormones; androgens appear to have suppressive effects whereas 
oestrogens have pro-inflammatory effects. In addition, enhanced B cell function has been 
demonstrated in females which is mediated by oestrogen (Sthoeger, Chiorazzi et al. 1988).
Very few studies have examined gender related pre-pubescent differences but in 
some cases a reverse of the sex hormone difference is evident. A lack of sex hormones 
increases thymocyte development and increases the numbers of circulating immature T 
cells present in peripheral blood (reviewed in (Shames 2002)). Clear gender differences 
exist in the prevalence of asthma with a male preponderance before puberty and a reversal 
of this gender preference after adolescence (epidemiological review by (Chen, Mempel et 
al. 2008). This was also observed in the Gambian study of blood cell indices. The highest 
range for haemoglobin concentration was higher in females compared to males until 15 
years of age where the reverse was true (Adetifa, Hill et al. 2008) indicating there are 
gender differences early in life that are not due to the influence of sex hormones.
196
Culturing conditions can also induce non-specific differences according to age. 
Culture of cord blood cells induced proliferation but the rate of apoptosis was also 
increased compared to adult cells which appeared to be independent of FasL and CD95 
(Tu, Cheung et al. 2000; Yang, Hsu et al. 2001; Canto, Rodriguez-Sanchez et al. 2003) and 
neonatal cells have also been shown to proliferate strongly in response to nominal Ag 
largely by low affinity promiscuous TCR/MHC interactions (Gavin and Bevan 1995; Le 
Campion, Lucas et al. 2002), suggesting possible mechanistic differences between cord 
blood and infant peripheral blood that could influence their responses to specific stimuli.
Immunological studies in The Gambia have shown that CMV infection in early life 
has a profound effect on the immune system, decreasing cell-mediated immune responses 
and altering the phenotype of CMV specific and non-specific CD8 T cells to a more 
differentiated state (Miles, van der Sande et al. 2007; Miles, Sanneh et al. 2008). Measles 
specific antibodies and CD4 IFNy responses were also reduced in CMV infected children 
post measles vaccination suggesting that CMV may affect immunological memory to 
vaccines (Miles, van der Sande et al. 2008). A striking 90% of children in The Gambia are 
infected with CMV by one year of age, and approximately 4% are infected intrapartum or 
during delivery (Miles, van der Sande et al. 2007). This contrasts to a middle-upper 
socioeconomic setting where 50 — 80% of adults are infected by 40 years of age 
(www.cdc.gov/cmv/facts.htm). Clinical evidence has shown hearing and visual loss, 
mental retardation and sometimes death in affected newborns (reviewed in (Hassan and 
Connell 2007)). It was therefore important to examine the impact of CMV infection on 
responses to the BCG vaccination in our study.
Non-specific effects of BCG vaccination were assessed in our study by examining 
the responses to a superantigen, Staphylococcal Enterotoxin B (SEB) that also acted as a 
useful positive control in our study. Superantigens bind to Major Histocompatibility 
Complex (MHC) class II molecules on antigen presenting cells (APCs) without the need
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for peptide processing, and then form a complex with a TCR that possesses a homologous 
VP chain (Hewitt, Lamb et al. 1992). They are thus able to elicit a non-specific T cell 
response.
This chapter analyses the non-specific effects of culture according to age, and then 
analyses for the effect of BCG vaccination status on responses to SEB. Analysis o f gender 
effects are also shown in relation to specific and non-specific stimuli and BCG vaccination 
group. Finally, the effect of CMV infection was considered on the various parameters 
analysed in this study.
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7.2 RESULTS
7.2.1 Age specific differences in T cell turnover and apoptosis during culture
In the ex vivo studies only a proportion of the 100 pL sample o f whole blood was 
required to acquire 500,000 events on the flow cytometer, but after 5 days of culture the 
entire sample (which equated to 140pl of original whole blood) was acquired and the 
average number of events acquired was often < 200,000 suggesting a large amount of cell 
death during culture.
To understand the effect of cell culturing on the distribution of various T cell 
subsets after 5 days of culture, the proportions of T cells in unstimulated cultures was 
compared to those present ex vivo, in the freshly stained whole blood. The lymphocyte 
population and the proportions of CD8^ T cells, CD4CD25 T cells and 
CD4 CD25 FOXP3 Tregs in cord blood and at 41/2 months o f age were reduced 
significantly in culture compared to ex vivo. By 9 months of age culturing had less of an 
effect on the T cell proportions and only the CD4CD25 population was reduced (Figure 
7.1A and B). An increase in CD4" T cells was observed at VA- and 9- months of age after 
culture but not in cord blood, an effect likely to be due to the high rate of CD4^ T cell 
apoptosis at birth (Figure 7.1C).
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Figure 7.1: Comparisons of T cell phenotypes pre- and post- 5 days of culture. 100 pL
whole blood was phenotyped straight after collection (ex vivo) and compared to in vitro 
culture fo r  5 days without antigen. A Wilcoxon non-parametric paired test was applied at 
5% significance. Proportions o f CD4 CD25+ (A), CD4+CD25+FOXP3+ (B) and CD4+ T 
cells populations were plotted fo r  each time point, median values are represented as black 
lines, at birth n = 78 , at 4/> months n = 79 and at 9 months n = 84,* not significant after 
Bonferroni correction fo r  multiple testing.
To further analyse the differences observed in culture with age, longitudinal 
comparisons were analysed. Most differences were apparent when comparing cord blood 
and AVz months, whereas T cell frequencies in unstimulated cultures were often comparable 
at 4'/2- and 9 months of age. Lymphocyte populations (proportion of lymphocytes and 
absolute numbers) were lower in day 5 cord blood (3.36%) compared to infant blood 
(37.96%) (Figure 7.2A - C), and there was a high proportion of cellular debris (probably to 
be due to dead cells) in cord blood which likely contributed to the reduced proportion of 
lymphocytes among total events acquired (green oval in Figure 7.2A and B) in comparison 
to lymphocytes from ex vivo phenotyping (Figure 7.2D).
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Figure 7.2: Lymphocyte populations after in vitro culture fo r  5 days. 500 pL cord blood 
and peripheral blood at 472 months o f  age were diluted 1: 5 and cultured fo r  5 days. The 
profile o f T cells in unstimulated cultures at birth (A), at 472 months o f age (B) and 472 
months ex vivo with 100 pL whole blood (D) were compared, pink oval represents the 
lymphocyte population, green oval represents cellular debris, black oval represents a 
larger and more granular population (possibly macrophages). FSC = refers to size o f event 
acquired, SSC = refers to the density or granularity o f the event acquired by flow  
cytometry. Absolute numbers o f lymphocytes in unstimulated cultures were compared 
across each age group (C). A Wilcoxon non-parametric paired test was used at 5% 
significance, the black bar represents the median value, n = 64.
The reduced number of lymphocytes observed in cord blood corresponded to a
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reduction in percentage of CD3+ T cells (median 51.41%) in this population compared to 
4Vz- (median 64.95%) and 9- months (median 65.26%) of age (Figure 7.3A). This 
reduction was likely to be due to the CD4~ population since the proportion of CD8~ T cells 
within the CD3 T cell subset did not change between age groups but the CD4 T cells 
were reduced (Figure 7.3B). Cord blood also had increased proliferation of lymphocytes, 
as measured by Ki-67 expression, compared to the later time points (Figure 7.3C). Only 
CD8 cells had significantly higher proliferation at birth compared to later so these are 
most likely responsible for the observation (Figure 7.3D). IL-10 production was assessed 
intracellularly by flow cytometry and also in the supernatant of the 5 day cultures. There 
were less IL-10+ lymphocytes in cord blood compared to infants with significant 
upregulation in CD8+ T cells but not CD4" T cells after birth (Figure 7.3E and F). However 
the differences observed in CD8~ T cells were no longer significant after Bonferroni 
correction factor was applied.
CD3 T cells
p < 0.0001
1 0 0 -i
80-
60-
p = 0.0003
o  40-
2 0 -
♦♦♦♦•
»*
:s;t*
••••
&
 1 1 1----
At birth 4 V2 month 9 months
B *p= 0.0281 p = 0.6145
100
CO O
S h  60-
i s™ o  ^c a  5 40-
p = 0.0076 p=0.5757
!!:?•
•••
•u;.,
— 1--------- 1----
At birth 4 'A month 9 months At birth 4 'A month 9 months
CD4 CD8
202
Ki-67 proliferating T cells
p< 0.0001
100
10
0 O
S -t:r- E1 I-
1 -
0 . 1 -
0.01
p< 0.0001
ti
••• ‘35*
At birth 4 Vi m onth 9 m onths
D
100-1
10 -
l {t- S<9 re
— -T
0 .1 -
0.01
p = 0.8833 *p= 0.0164
1
p = 0.9910
I 1
*P = 0.0090
' — 1
• •. •
1
♦ . .
•
• • • • • •
• t
•
• •
• A t• •
M / A  
•  • •
•
• • •
f t
* . . . .
• •
. . . .  
U 5 r
• * . i
#♦
• • •
•
I
• • •
•
»♦ • ♦
\
At birth
i
4 V2 m onth
1
9 m onths
1
At birth
i
4 Vi month
1
9 m onths
C D 4 CD 8
IL-10 secreting T cells
p = 0.0023
100*1 p - 0.0005
2—  in
i l ?e  | = -  
S'
10 -
1-
0 .1 -
0.01
•••
••
•••
^  t i t«.«5* t "  “•
At birth 4 14 m onth 9 m onths
1 0 0 -
10 -
1-
0 .1 -
0.01
p = 0.1561
r
•A**
p = 0.0643
. . . . .
• A * *  • • • • •  t* *. . .  .♦.. . .  •••♦
•••••
 1 1----
At birth 4 Vi m onth
*p = 0.0094
*p= 0.0133
•J .. .•••. . .
AAV.
—i— 1— i—
9 m o nths At birth 4  V4 m onth  9 m o n th s
CD4 CD8
Figure 7.3: T cell populations in unstimulated cultures. 500 pL cord blood and 
peripheral blood at 4 /2- and 9- months o f age were diluted I: 5 and cultured fo r  5 days 
without antigen. The profile o f T cells in unstimulated cultures was compared. The 
proportion o f lymphocytes that were CD3+ (A), C D 3C D 4+/CD8+ (B), Ki-67+ (C), 
CD4+/CD8+Ki-67+ (D), IL-10+ (E) and CD4+/CD8+IL-10+ T cells were compared across 
all three age groups. A Wilcoxon non-parametric paired test was used at 5% significance, 
the black bar represents the median value, * not significant after Bonferroni correction fo r  
multiple testing, n = 64.
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In contrast, there were no significant differences in the production of IL-10 in the 
supernatant of unstimulated cultures between the age groups with moderate production at 
all ages (Table 7.1). With respect to IFNy and IL-13 cytokine production, they were both 
lower at birth than at 4/4 months of age. Cytokine production was often low in 
unstimulated samples but they were generally within the dynamic ranges described by the 
commercial supplier of the assay kits (IFNy, 2.14 -  31,000 pg/mL; IL-10, 1.6 -  26,000 
pg/mL; IL-13, 0.56 -  9,000 pg/mL) and therefore the associations within different age 
groups could be considered genuine.
At birth 4 Vz m 9m At birth At birth 4Vz m
pg/ml pg/ml pg/ml vs vs vs
(range) (range) (range) 4 V2 m 9m 9m
IFNy 0
(0-444.5)
45.92
(0-1 ,575)
7.25
(0-19,819)
< 0.0001 0.0001 0.0739
IL-10 4.87
(0.7-536.8)
3.5
(0 -288 .1 )
5.29
(0.7-624.1)
0.0843 0.0958 0.4989
IL-13 0
(0 -9 .98 )
2.33
(0-368 .4 )
1.96
(0-854.7)
< 0.0001 < 0.0001 0.6273
Blue text = increased cytokine production compared to the earlier age group
Table 7.1: Cytokine production in unstimulated culture conditions. 500 juL cord blood 
and peripheral blood at 4 V2- and 9- months o f age were diluted 1: 5 and cultured fo r 5 
days without antigen. Comparisons o f cytokine production (pg/mL) between age groups in 
unstimulated 5 day whole blood cultures. A non parametric Wilcoxon paired test at 5% 
significance was used to analyse the data, n = 73.
A larger proportion of lymphocytes contained intracellular TGFp compared to IL- 
10 after 5 days of culture, particularly among CD4+ T cells in cord blood. This might be 
because TGFp+ T cells are more resistant to apoptosis or cord blood CD4+ T cells are 
genuinely increased and have a suppressive function. When correcting for multiple testing
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the TGFp and CD8 specific differences were no longer significant.
Interestingly the numbers o f activated T cells (C D 4C D 25) and FOXP3'Tregs 
(CD4+CD25+FOXP3+) in culture were unaltered across all ages.
A summary o f the comparisons between cord blood and 4lA  months o f life in 
unstimulated cultures is found in Table 7.2.
Unstimulated cultures Cord blood 
and 414 months
of age
Lymphocytes +
CD3 +
CD3(CD4) *+
CD3(CD8) =
CD4(CD25) =
CD4(CD25FOXP3) =
Ki-67 -
CD4(Ki-67) =
CD8(Ki-67) *_
IL-10 +
CD4(IL-10) =
CD8(IL-10) *+
TGFp *_
CD3CD4(TGFP) *_
CD3CD8(TGFP) =
IFNy cytokine +
IL-10 cytokine =
IL-13 cytokine +
Table 7.2: Summary o f differences in cord blood immune populations in unstimulated 
cultures compared to 4V2 months. 500 pL cord blood and peripheral blood at 4/2 months 
o f age were diluted 1: 5 and cultured fo r  5 days without antigen. The profile o f T cells (%>) 
and cytokine production (pg/ml) in unstimulated cultures was compared between cord 
blood and 4 ‘A months o f age, ‘+ ’ and dark blue represents higher levels at 4 'A months than 
in cord blood, ‘- ’and light blue represents lower levels at 4‘A months than in cord blood, 
and no highlighted background represents similar levels at 4 'A months and in cord
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blood. A Wilcoxon non-parametric paired test was used at 5% significance, *not
significant after Bonferroni correction fo r  multiple testing, n = 64.
Analysis of unstimulated data with respect to the BCG vaccine schedule at all time 
points did not reveal any differences, suggesting that BCG did not influence the immune 
cells in unstimulated cultures. This further indicates that differences in the antigen- 
stimulated cultures are genuine specific effects.
7.2.2 Responses to SEB
At 4Vz- and 9- months of age almost all the parameters were increased in response 
to SEB compared to background, with the exception of CD3CD4" T cells that were 
downregulation. Thus, CD3+ T cells, CD8+ T cells, CD4+CD25+, CD4+CD25+FOXP3+, Ki- 
67 (both CD4 and CD8+), intracellular IL-10 (both CD4 and CD8+) and intracellular 
TGFp (both CD4+ and CD8+) and supernatant IFNy, IL-10, IL-13 were all significantly 
higher than in unstimulated cultures even after correcting for multiple testing (Figure 7.4 A 
- E). The magnitude o f responses to SEB in cord blood was comparable to 4 'A and 9- 
months of age with the exception of no upregulation of IL-10 production from CD8* T 
cells (Figure 7.4D pink square, p = 0.7311) or TGFp producing T cells (Figure 7.4E pink 
square, p = 0.3255) above background unstimulated levels (Figure 7.4A- E).
CD4CD25 B CD4CD25FOXP3 c CD4Ki-67
9  2 0 -
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Figure 7.4: In vitro T cell responses to SEB superantigen. 500 pL cord blood and 
peripheral blood at 4 /2- and 9- months o f age were diluted 1: 5 and cultured fo r  5 days 
with SEB. The profde ofC D 4+CD25+ (A), CD4+CD25+FOXP3+ (B), CD4+Ki-67+ (C), IL- 
10 produced by T cells (D) and TGFf produced by T cells (E) were compared in 
unstimulated (pale blue) compared to SEB stimulated (dark blue) cultures across all three 
age groups. Pink square represents the lack o f SEB induced response compared to 
unstimulated fo r  the cord blood. A Wilcoxon non-parametric paired test was used at 5% 
significance, bars represent mean values with SEM, at birth n =70, 4/2 months n = 76 and 
9 months n = 80.
After subtracting the unstimulated values and comparing across age groups, there 
was an increased frequency o f activated T cells and overall proliferating cells but also 
greater Th2 (IL-13) and suppressor T cell responses (IL-10, TGF(3) to SEB at 4 / 2- and 9- 
months of age compared to cord blood, but similar Thl (IFNy) and T cell proliferation (Ki- 
67) across all ages (Table 7.3). In particular IL-10 and IL-13 production in culture 
supernatants were increased at 9 months compared to 4 '/2 months (Table 7.3). In addition, 
the level of FOXP3 Tregs was similar across all age groups suggesting that the ability to 
induce Tregs in response to a strong polyclonal stimulus is present and stable from birth
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although the function of these Tregs cannot be elucidated from our results (Figure 7.4B and 
Table 7.3).
At birth 414 months 9 months At birth vs 
414 m
At birth vs 
9 m
414 vs 9 m
CD3 -1.385 6.77 8.295 0.0669 *0.0252 0.5238
CD4 -2.395 -1.66 -0.9 0.9051 0.3541 0.7631
CD8 2.7 4.43 6.225 0.0593 *0.0252 0.1567
CD4(CD25) 22.32 25.64 33.5 *0.0386 < 0.0001 0.1409
CD4(CD25FOXP3) 13.53 12.86 17.50 0.7191 0.2456 0.6794
Ki-67 9.58 14.22 18.5 *0.0484 0.0019 0.3774
CD4(Ki-67) 16.58 16.92 21.89 0.5055 0.1420 0.2908
CD8(Ki-67) 13.95 15.61 18.64 0.6816 0.2726 0.3137
IL-10 0.28 5.565 2.475 < 0.0001 *0.0058 *0.0238
CD4(IL-10) 0.465 1.05 3.725 0.0025 *0.0108 0.8067
CD8(IL-10) -0.145 7.55 6.415 < 0.0001 0.0001 0.7166
TGFp 0.42 0.44 4.285 0.1734 0.0006 0.2646
CD3CD4(TGFP) 0.395 0.58 5.045 0.4917 *0.0055 0.2206
CD3CD8(TGFp) 0.54 2.3 7.805 *0.0292 0.0016 0.4525
IFNy cytokine 7672 9039 7101 0.1416 0.5567 0.411
IL-10 cytokine 148.1 363.1 546.6 < 0.0001 < 0.0001 0.0003
IL-13 cytokine 355.3 1860 2867 < 0.0001 < 0.0001 0.0007
Blue text = increased cytokine production compared to the earlier age group
Table 7.3: Longitudinal responses to SEB. 500 pL cord blood and peripheral blood at 
4/2- and 9- months o f age were diluted 1: 5 and cultured fo r  5 days with SEB. The profile 
o f T cells (%) and cytokine production (pg/ml) was compared across age groups after 
subtracting the background unstimulated responses. A Wilcoxon non-parametric paired test 
was used at 5% significance, at birth n =70, 4/2 months n = 76 and 9 months n = 80.
SEB stimulation induced IL-10 production by both CD4 and CD8 T cells in early 
life. A paired correlation o f IL-10 produced by CD4 and CD8 T cells at 9 months showed 
that those individuals with a high percentage of IL-10 producing CD4 T cells, also had a 
high percentage of IL-10 producing CD8 cells (Figure 7.5A). The same pattern occurred 
for cord blood and at 4/4 months. Generally there was a higher percentage of CD8 cells
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producing IL-10 in response to SEB, although this difference was only significant at 9 
months (Figure 7.5B). Indeed, in cord blood the reverse was true and T cell production of 
IL-10 was predominantly from CD4 T cells (Figure 7.5B).
A
r= 0.8105 
p < 0.0001
40-
2 0 -
-20
CD4
-20-I
B
IL-10 CD4 CD8 p  value
At birth 0.52 -0.15 <0.0001
414 months 3.53 5.93 0.2255
9 months 3.83 6.42 0.0003
Figure 7.5: IL-10 production from T cells in response to SEB. Whole blood was cultured 
for 5 days with SEB and a comparison o f T cell production o f  IL-10 was assessed at 4V2 
months and 9 months. Correlation between CD4 and CD8 production o f IL-10 at 9 months 
o f age (A) illustrating a positive correlation (Spearman’s correlation coefficient r = 
0.8105, p< 0.0001). (B) Comparison between percentage o f CD4+ and CD8+ T cells that 
produced IL-10 after SEB stimulation at birth, 4/2- and 9- months o f  age. A Wilcoxon non- 
parametric paired test was applied at 5% significance, at birth n = 76, at 4 'A months n = 
77, 9 months n = 80. Median values o f unstimulated values subtracted from SEB 
stimulated values are presented. Pale blue text indicates a significant upregulation in CD8
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T cells compared to CD4 T cells and red text indicates a significant downregulation in 
CD8 T cells compared to CD4 T cells.
Analysing the SEB responses by vaccination group showed no significant 
differences at any of the age groups for any o f the parameters studied. In particular there 
were no differences between vaccinated and unvaccinated children at 414 months o f age 
after adjustment for multiple correction, although there was a borderline increase in IL-10 
production in the culture supernatants in the BCG naive group at 414 months but this was 
not significant after adjustment for multiple testing (p = 0.0421). Figure 7.6 illustrates the 
cytokine profiles in response to SEB according to age and BCG vaccination schedule.
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Figure 7.6: Effect o f  BCG vaccination on SEB responses. 500 pL cord blood and 
peripheral blood at 4 ¥2- and 9- months o f age were diluted 1: 5 and cultured fo r  5 days 
with SEB. The supernatant cytokine profile o f (A) IFNy, (B) IL-10 and (C) IL-13 was 
compared between Group 1 (vaccinated at birth) and Group 2 (vaccinated at 4 V2 months) 
at each time point. A Mann Whitney U test was applied to compared between groups at 5% 
significance, the black bar represents the median value, * not significant after Bonferroni 
correction fo r multiple testing, at birth Group 1 n = 45 Group 2 n =42 , at 4/2 months 
Group 1 n = 46 Group 2 n = 38, 9 months Group 1 n =45 Group 2 n = 40.
7.2.3 CMV infection
Urine samples were analysed for cytomegalovirus (CMV) infection on the day of 
bleeding as a surrogate of infection. The CMV nested PCR assay identified a 291 kb 
product from the membrane-associated protein, UL50 sequence of human herpes virus 5 in 
the urine (Figure 7.7A). Congenital infection was defined as infection within the first two 
weeks of life. Overall there were 16.0% congenitally infected neonates which was 
approximately! 0-fold higher than the global average (Hassan and Connell 2007). By 414 
months of age 47.1% of infants were infected and by 9 months of age there was 63.1% 
infected infants (Figure 7.7B).
Infants and children often shed virus for years making it difficult to estimate the 
time of infection when evaluating one time point. In our study persistent shedding was not 
always observed. Thirteen subjects exhibited intermittent shedding over the 9 months 
(Figure 7.7C). These results may indicate that shedding of the virus was not continuous but 
may also indicate that the amount of virus was at the level of detection using our PCR 
assay.
After segregating according to vaccine status the percentage of positive individuals 
was similar in each group at each time point (Fisher’s exact test; at birth p = 1.0, 414 
months p = 0.8284, 9 months p = 0.5005) indicating that the BCG vaccine delay did not
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affect CMV infection status (Figure 7.7D and E).
B
At birth 4V2 months 9 months
positive 15 40 53
total 94 85 84
% positive 15.96 47.06 63.10
At birth
4Yz
months
9
months
Number of
subjects (group 1, 
group 2)
+ - + 4(2 , 2)
- + - 4 (3 , 1)
+ + - 1 (0, 1)
+ - - 3 (1 ,2 )
+ - ND 1 (1 ,0)
D
At birth 4Yz months 9 months
Group 1 2 1 2 1 2
positive 8 7 22 18 26 28
total 51 43 45 40 43 41
% positive 15.7 16.2 48.9 45.0 60.5 68.3
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Figure 7.7: CM V infection status. A nested PCR assay amplified a 291 bp fragment o f 
CMV DNA in the urine o f CMV infected subjects (A). Numbers o f infected children at each 
time point were identified and % positivity (B), numbers o f children with discordant 
infection status over 9 months (C) and numbers o f children in each group at each time 
point were calculated (D). A graphical comparison o f CMV infection over time between 
Group 1 and Group 2 (E).
Ex vivo CD8+ T cell populations are increased in CMV infected individuals
CMV frequently causes a profound expansion of CMV specific CD8+ T cells 
(Marchant, Appay et al. 2003; Gibson, Piccinini et al. 2004; Miles, van der Sande et al. 
2007; Miles, van der Sande et al. 2008; Chidrawar, Khan et al. 2009). Thus it was not 
surprising that CMV infected children had a greater proportion of CD8+ T cells ex vivo at 
both 414- and 9- months of age, irrespective o f vaccine group (Figure 7.8A). Interestingly 
this effect was not observed in those congenitally infected at birth although the number of 
CMV infected neonates is very small (n = 5). There was a borderline significant decrease 
in ex vivo CD4 T cells at 414 months in the CMV infected infants (p = 0.0459) but this 
was eliminated after correction for multiple testing. CD4 T cells were similar across the 
age groups in the uninfected infants (Figure 7.8B).
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Figure 7.8: Ex vivo T cell populations affected by CMV infection over time. 100 pL
whole blood was collected and immediately phenotyped (ex vivo). The proportions o f  
lymphocytes that were CD8+ (A) and CD4+ (B) were analysed according to CMV status 
across all age groups irrespective o f BCG vaccine schedule. A Mann Whitney U test was 
applied at 5% significance, the black bar represents the median value, *not significant 
after Bonferroni correction fo r  multiple testing. A t birth CMVneg n = 76 CMVpos n = 15 
(CD8: CMVneg n = 41 CMVpos n = 5), at 4Zz months CMVneg = 42 CMVpos = 38, 9 
months CMVneg = 30 CMVpos = 52.
The increase in CD8" T cells observed in the CMV infected infants resulted in a 
lower ratio o f CD4: CD8 T cells among the infected infants at 4'/2- (p < 0.0001) and at 9- 
months (p = 0.0043) compared to the uninfected individuals. CD4: CD8 ratios of < 1 are 
considered an ‘immune risk phenotype’ which is well described in relation to chronic CMV 
infection (reviewed in (Koch, Solana et al. 2006). At 414- and 9- months o f age, 8% and 
10% respectively of CMV infected infants had a CD4:CD8 ratio < 1 compared to 2% and 
3% in the uninfected infants at the same time points. No other parameter studied ex vivo 
was affected by CMV status. In addition these findings were not altered by the different 
BCG vaccination schedules of the two groups.
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CMV infection altered superantigen and anti-mycobacterial immunity
Miles et al have shown enhanced CD8” T cell responses to SEB in infants with 
CMV in the same population as our study (Miles, Sanneh et al. 2008). Similarly in our 
study increased IFNy production was observed in response to SEB in cord blood o f 
congenitally infected individuals (n = 14) compared to uninfected infants (p = 0.0162) 
(Figure 7.9A). However CD4+CD25+ activated T cells were significantly reduced in 
response to SEB in the cord blood of CMV infected neonates (p = 0.0024) (Figure 7.9B). 
No other responses to SEB were altered according to CMV infection, including 
CD4+CD25FOXP3~ Tregs and CD8" T cells. Cord blood responses to mycobacterial 
antigens, (PPD, BCG and EC) were unaffected by CMV infection status (data not shown).
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Figure 7.9: Congenital CMV infection alters cord blood responses to SEB. 500 pL cord 
blood was diluted 1 :5  and cultured for 5 days with SEB. IFNy cytokine production in the 
supernatant o f cultures (A), CD4+CD25+ (B), CD4+CD25+FOXP3+ (C) and CD8+ (D) T 
cells were compared according to CMV status. A Mann Whitney U test was applied to 
compared between groups at 5% significance, the black bar represents the median value, 
CMVneg n =55 (CD8: n = 36), CMVpos n =12 (CD8: n = 7).
At 4!A- and 9- months of age, CMV infection had little effect on the immune 
response to SEB and mycobacterial antigens. At 414 months SEB stimulated CD8  T cells 
were greater in CMV infected individuals (p = 0.0093), although not significant after 
correction for multiple testing (Figure 7.10A). Responses to PPD are usually stronger than 
to other mycobacterial antigens, however most CMV related effects were observed in 
response to BCG. The frequency of BCG stimulated CD4+ and CD8+ IL-10 producing T 
cells were reduced in the CMV infected individuals at 414 months (CD4 p = 0.0126, CD8  p 
= 0.0270) and at 9 months of age (CD4 p = 0.0281, CD8  p = 0.0419) although not 
significant after correction for multiple testing (Figure 7.10B and C). However there were 
no significant changes in IL-10 production from the supernatants of cultures stimulated 
with SEB or mycobacterial antigens (data not shown). After adjusting for multiple testing 
there were no CMV related differences within BCG vaccine groups at 41/2- or 9- months o f 
age.
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Figure 7.10: Responses to SEB and BCG in CMV infected infants at 4 V2 and 9 months o f  
age. 500 juL peripheral blood was diluted 1: 5 and cultured fo r  5 days SEB (A) and BCG 
(B and C). CD8+ (A), CD4+ IL-10+ (B), CD8+ IL-10+ (C) T cells were compared
according to CMV status at 4 V2 months o f age (A and B) and 9 months o f age (C). A Mann 
Whitney U test was applied to compared between groups at 5% significance, the black bar 
represents the median value, * not significant after Bonferroni correction for multiple 
testing, 4/2 months, CMVneg n =43 , CMVpos n =33; 9 months, CMVneg n =28 , 
CMVpos n =46.
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7.2.4 Gender specific differences
There were no gender specific effects on the proportions of T cells circulating ex 
vivo at any time point (data not shown). Both sexes responded similarly to SEB for all 
parameters studied, apart from an increase in IFNy in boys at 9 months of age in the 
delayed vaccine group only (p = 0.0199) (Figure 7.11) demonstrating a non-specific pro- 
inflammatory sex difference according to vaccine schedule, however this was not 
significant after correction for multiple comparisons.
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Figure 7.11: Gender specific SEB responses. 500 pL whole blood at 9 months o f age was
diluted I: 5 and cultured fo r  5 days with SEB. At 9 months o f age IFNy responses were 
compared fo r  gender differences in Group 1 (vaccinated at birth) and Group 2 (vaccinated 
at 4 Z2 months). A Mann Whitney U test was applied to compare gender specific differences 
at 5% significance, the black bar represents the median value, *not significant after 
Bonferroni correction fo r  multiple testing, Group I Female n = 22 Male n =21, Group 2 
Female n = 20 Male n = 19.
At birth, there were no gender specific differences in responses to any of the
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mycobacterial antigens tested, apart from a trend for increased IFNy production in 
response to PPD in boys compared to girls that was no longer significant after correction 
for multiple testing (p = 0.0355) (Figure 7.12).
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Figure 7.12: Mycobacterial specific gender differences at birth. 500 pL cord blood was
diluted I: 5 and cultured fo r 5 days with mycobacterial antigens PPD and BCG. IFNy 
responses at birth were compared fo r  gender differences (F = Female, M  = Male). A Mann 
Whitney U test was applied to compare gender specific differences at 5% significance, the 
black bar represents the median value, *not significant after Bonferroni correction fo r  
multiple testing, Female n = 22, Male n =21.
At 4'/2 months of age, BCG induced IFNy was greater in males than in females in 
BCG vaccinated infants (p = 0.0038) with a similar trend but insignificant in response to 
PPD, p = 0.0767 (Figure 7.13A) suggesting boys have a greater Thl response to BCG 
vaccination. Before correcting for multiple testing BCG induced Tregs (but not activated T 
cells) were also increased in Group 1 (vaccinated) in response to PPD and BCG in boys 
compared to girls (Figure 7.13B and C). In the unvaccinated group, males had increased 
levels o f activated T cells and Tregs in response to in vitro BCG, although at low levels, but 
these values were not significant after adjustment for multiple comparisons (Figure 7.13B
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and C). By 9 months o f age there were no gender specific differences after adjustment for 
multiple testing in either group to BCG or PPD, however increased IFNy (p = 0.0142) and 
a trend for increased IL-10 (p = 0.0346) were observed in Group 2 males in response to EC 
although the values were very low (Figure 7.13D).
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Figure 7.13: Gender differences at 4 V2 months o f  age. 500 juL whole blood at 4Y2 months
o f age was diluted 1: 5 and cultured fo r  5 days with mycobacterial antigens PPD and BCG. 
IFNy (A), CD4 CD25+ (B) and CD4 CD25+FOXP3+ (C) T cell responses were compared 
fo r  gender differences (F = Female, M  = Male) in BCG vaccinated and unvaccinated, 
Group I (vaccinated) Female n = 19, Male n =22, Group 2 (unvaccinated) Female n = 18, 
Male n = 18. (D) IFNy and IL-10 production from supernatants in response to ESAT-
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6/CFP-10 fusion protein at 9 months o f age in Group 2, Female n = 21, Male n = 19, (zero 
responses were given the value, 0.01 for illustration purposes). A Mann Whitney U test was 
applied to compared gender specific differences at 5% significance, the black bar 
represents the median value, *not significant after Bonferroni correction for multiple 
testing,
Reactivity to the tuberculin skin test (TST) was not influenced by gender
There was no significant relationship between gender and reactivity to the TST in 
Group 1 at AVz months o f age (Fisher’s Exact test p = 0.580) (Figure 7.14A). The presence 
of a BCG scar was also not related to gender. Only 5/50 (10%) individuals at 4/4 months o f 
age did not scar after BCG vaccination, 3 were female and 2 were male. At 20 months of 
age 7/85 (8.2%) children did not exhibit a scar, 3 were male and 4 were female (data not 
shown). However the median scar size for males was significantly larger (median 3 mm) 
than females (median 4 mm) (p = 0.0118) (Figure 7.14B) which supported a previous study 
in Malawi (Floyd, Ponnighaus et al. 2000).
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Figure 7.14: The relationship between Tuberculin Skin Test (TST), BCG scar formation 
and gender. At 4/2 months o f age, 2 T.U. PPD-T was injected into forearm and induration 
was measured at 48 -  72 hours later, R =  responders > 5mm, NR = non responders < 5 
mm. (A) numbers individuals in each group according to gender and response to TST At 
20 months o f age a second TST was performed and scar size was measured according to 
gender (B). A Mann Whitney non-parametric test was applied at 5% significance.
Gender did not relate to CMV infection
There was no gender specific difference associated with CMV infection at each 
time point (Fisher’s exact test; at birth p = 0.3979, 414 months, p = 0.0836, 9 months p = 
0.4949). When separating into groups the same inference was observed at all time points 
(data not shown).
222
7.3 DISCUSSION
7.3.1 Age specific responses in unstimulated culture
Analysis for differences in the unstimulated day 5 culture across time points and 
according to vaccine group showed that at all ages responses were minimal, and often 
lower than observed prior to culture {ex vivo). It was evident that cord blood lymphocytes 
were highly proliferative and more susceptible to cell death, particularly the CD4+ T cell 
population. This tendency for CD4+ T cells to be more susceptible to apoptosis has been 
observed in studies of lymphocytic malignancies where CD8 + T cells expanded better and 
but CD4+ T cells had a high rate of apoptosis causing inverted CD4:CD8 ratios (Mazur, 
Davis et al. 2008). Previous studies have also observed spontaneous apoptosis in cord 
blood as a result of culture conditions (Tu, Cheung et al. 2000) (Yang, Hsu et al. 2001) 
(Canto, Rodriguez-Sanchez et al. 2003) which was greater than that observed in adult mice 
(Adkins, Chun et al. 1996; Canto, Rodriguez-Sanchez et al. 2003). The mechanism is 
thought to be IL-7 dependent and caspase-mediated (O’Neill, RM et al, 2003). 
Proliferation and increased apoptosis are also characteristics of recent thymic emigrants 
(RTE)(Hassan and Reen 2001). T cell receptor excision circles (TRECs) detected from the 
CD4+ T cell population would help determine the contribution RTE make to the total T cell 
population.
The percentage of CD8 + T cells in the lymphocyte population did not alter in cord 
blood so it is possible that these cells die at the same rate as CD4+ T cells but are 
replenished more quickly in accordance with the higher proliferation rate observed among 
the CD8 + T cell population in cord blood, and in support of the model described above 
(Mazur, Davis et al. 2008).
The total IL-10 production in the supernatant of unstimulated cells was not altered 
with age, however the proportion of IL-10 secreted from T cells was reduced suggesting 
that the source of IL-10 production in cord blood is not the same as in infants, and arises 
from a source other than T cells. Unstimulated day 5 IFNy and IL-13 were produced at
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lower levels than IL-10 at birth, but were significantly increased by 414 months of age. 
This supports our mycobacterial stimulated results where IL-10 production was 
predominantly non-T cell derived.
A higher frequency o f cord blood T cells produced TGFp in unstimulated cultures 
suggesting a bias towards a more suppressive phenotype in culture. Increased in vitro 
TGFp production observed in cord blood has been observed in others studies, particularly 
from CD4+ T cells and has been associated with fish oil supplementation in pregnant 
women (Krauss-Etschmann, Hartl et al. 2008). Interestingly mothers in The Gambia have a 
diet relatively high in oily fish which may have contributed to this observation.
It was reassuring to note that the T cell changes that occurred during unstimulated 
cultures were not affected by the BCG vaccine schedule and could therefore be confidently 
used as background controls when analysing the mycobacterial stimulated responses in 
relation to BCG vaccination.
7.3.2 SEB responses in early life
SEB was found to stimulate T cells at all ages illustrating its ability to act as a 
strong global immune stimulus. CD4 expression on CD3+ T cells was the only parameter 
that was consistently down regulated, an expected finding caused by the interaction 
between the SEB toxin and the TCR receptor leading to endocytosis o f the TCR 
(Niedergang, Hemar et al. 1995). The only difference across age groups was that TGFp 
was upregulated in infants but not in cord blood, although the background (unstimulated) 
levels were higher in cord blood compared to that in the infants as mentioned above. This 
confirms that SEB was an appropriate choice of antigen to be used as a positive control in 
our study. Although similar cells were involved in the immune response to SEB in the three 
age groups, by 9 months of age the magnitude of the response was greater than that 
observed in cord blood. SEB stimulates through the T cell receptor (TCR), suggesting that 
the lower response in cord blood was due to the immaturity of the immune cells and
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dysfunction of interaction of the MHC/TCR complex. However there was an equivalent 
IFNy response in cord blood in response to SEB compared to other time points which 
suggests that, irrespective of the immature immune system at birth, good Thl responses are 
possible to specific stimuli. However it was not possible to identify the cellular source of 
the IFNy and it is possible that innate NK cells may contribute to this production. The Th2 
responses were weaker in cord blood. This supports studies by Chipeta et al that showed 
neonatal T cells were able to respond to TCR-mediated stimulation and to produce both 
Thl (IFNy) and Th2 (IL-4 and IL-13) cytokines compared to adults (Chipeta, Komada et 
al. 2 0 0 0 ).
7.3.3 CMVinfection
Nearly 100% of children are infected with CMV by 12 months of age yet they 
appear to be healthy and normal. The effects of such an early CMV infection are currently 
being investigated.
In this study the numbers o f infants infected with CMV at 4%- and 9- months of 
age were comparable to previous reports in this population (Miles, van der Sande et al. 
2007; Miles, Sanneh et al. 2008) however congenital infection was higher (previous study 
4%, our study 16%). In our study neonates with congenital infection had enhanced IFNy 
response to SEB as previously shown by Miles, et al at 9 and 13 months of age (Miles, 
Sanneh et al. 2008), although this did not correlate with an increase in activated T cells. 
This may indicate the effect is . due to innate production of IFNy, possibly from NK cells.
These previous studies in The Gambia also showed that CMV infection altered the 
differentiation of T cells, particularly CD8 + T cells, and could influence responses to non­
specific antigens (Miles, van der Sande et al. 2007; Miles, Sanneh et al. 2008). A greater 
number of CD8 + T cells in the lymphocyte population of CMV infected infants prior to 
stimulation was observed in this study ex vivo, but less of them produced IL-10 in response 
to mycobacterial antigens compared to CMV negative infants. Mice models have shown
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that low level IL-10 reactivity can lead to resistance to mycobacterial infection. Maybe the 
ex vivo increase in CD8 + T cells and reduced IL-10 production in response to BCG at 4% 
months of age after BCG vaccination provides the added advantage of increased resistance 
to M.tb infection. A study in Malawi suggested that CMV infection may explain why 
adolescents in Malawi (100% CMV infection) have lower naive and higher memory T cells 
in circulating peripheral blood than adolescents in the UK (36% CMV infection) (Ben- 
Smith, Gorak-Stolinska et al. 2008).
7.3.4 Gender specific responses in early life
Associations found with gender suggested stronger immune responses (mostly 
IFNy production) in males compared to females. Increased IFNy production was observed 
at 9 months in the delayed vaccine group, suggesting a non-specific Thl response 4% 
months after delaying the BCG vaccine in boys compared with girls. IFNy production and 
increased FOXP3+Tregs in vitro were also found in males compared to females in response 
to mycobacterial antigens in Group 1 (vaccinated at birth) at 4% months. Thus BCG 
appears to have some gender specific effect on both non-specific stimuli (SEB) and 
mycobacterial stimuli (BCG and PPD) whereby boys elicit a greater Thl and FOXP3+Treg 
response. Reactivity to the TST was not associated with gender which supports some of the 
literature (Floyd, Ponnighaus et al. 2000; Santiago, Lawson et al. 2003; Okan, Karagoz et 
al. 2006). In a TB case contact study in The Gambia the probability of TST reactivity was 
higher in males and increased with age however this study was not restricted to young 
infants (Lienhardt, Fielding et al. 2003). BCG scar size has also shown gender bias with 
larger scars in males than females (Floyd, Ponnighaus et al. 2000), and indeed in our study 
males had larger scars than females. Non-specific beneficial effects of BCG vaccination on 
morbidity and mortality have shown a greater benefit in girls. One explanation for this may 
be that girls have a better ability to control overt inflammation.
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7.3.5 Effects o f  seasonality on immune responses in early life
Recent data has suggested that immune responses may be affected by seasonality. 
Lalor found that both in the UK and in Malawi, infants bom during hotter and drier times 
of the year were more likely to produce a positive IFNy response (> 62 pg/mL) to PPD 3 
months after BCG vaccination (Lalor, Ben-Smith et al. 2009). In a separate study, Miles et 
al found that higher proportions of CD4+ T cells expressing CD154 (CD40L, responsible 
for killing of monocytes and macrophages after mycobacterial infection) at 1 2  months o f 
age was higher in those children bom within the wet season compared to the dry season 
(Miles, van der Sande et al. 2008), however the variation within individuals was very high 
in this study. This study took place within the same community of The Gambia as our 
study and therefore using the same definitions of seasons, wet (June to October) and dry 
(November to May), our study showed roughly equal numbers of children bom in each 
season (wet n = 59 and dry n = 44) and no correlation between season and IFNy responses 
to PPD 4/4 months after BCG vaccination (data not shown). However at the same age, 
BCG naive infants showed a significant increase in IFNy responses to PPD if born in the 
wet season compared to the dry season (p = 0.0146, dry n = 20, wet n = 18). The wet 
season is also very humid and is often associated with increased microbe survival which 
may indicate the NTM exposure is higher in the wet season. A larger sample size is 
necessary to examine this theory in more detail.
In summary, cord blood T cells are highly proliferative but are more susceptible to 
cell death than at subsequent time points. Cord blood T cells are immature but can still 
elicit responses to SEB of a similar magnitude to infant responses. Gender specific 
responses showed a BCG related trend towards males having a greater IFNy response to 
non-specific and mycobacterial specific stimuli.
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CHAPTER 8 
Discussion
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8.1 OVERALL DISCUSSION
BCG vaccine is administered at birth in places that TB is endemic. Although BCG 
is the oldest vaccine and has the widest coverage, TB has continued to be on the increase 
underlining its inadequacy to protect against the disease. Immaturity of the immune system 
of the newborn recipients of BCG and interference of environmental NTM have been the 
major reasons suggested for the inability of BCG to protect against TB throughout life, 
particularly in places where TB is endemic. This study used BCG vaccination to further 
elucidate some of these hypotheses, as well as using it as an immunogen in early infancy to 
further characterise the magnitude and quality of immune responses of newborns and 
factors that could influence them. This study is one of the few longitudinal studies 
assessing BCG immunogenicity at different time points in the first 9 months o f life. The 
strength of this study includes the large number of subjects that were successfully followed 
up, and the detailed characterisation of the T cell responses.
8.1.1 NTM  effect on BCG immunogenicity
Delaying the BCG vaccine to 4Vz months of age compared to vaccination at birth 
made it possible to examine the contribution o f background mycobacterial responses on 
BCG immunogenicity. In vitro PPD reactivity was used as a surrogate for NTM exposure 
since it is a mycobacterial protein containing many antigens present in NTM. Prior to BCG 
vaccination the delayed vaccine group had a significant upregulation of CD4+CD25+ and 
CD4+CD25+FOXP3+ T cells, and increased production of IFNy and IL-13 in response to 
PPD, accompanied by a borderline increase in IL-10 production, suggesting that immune 
priming by NTM in the first 41/2 months o f life leads to pro-inflammatory and regulatory T 
cell responses. All these children were anergic to the TST, suggesting that NTM exposure 
by this age was not able to prime a TST response. Thus, although PPD memory T cells 
existed in the peripheral blood of these children the mechanisms required to home to the 
skin may be impaired. Skin allergy studies have shown that Tregs expressing homing
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markers such as CLA home to the skin (Colantonio, Iellem et al. 2002; Cavani, Nasorri et 
al. 2003), and perhaps this mechanism is responsible for the TST anergy.
IFNy responses to mycobacterial antigens, assessed 41/2 months after BCG 
vaccination, were reduced in the delayed vaccine group compared to the group vaccinated 
at birth. This finding supports our original hypothesis that exposure to NTM prior to BCG 
vaccination attenuates BCG immunogenicity. It is possible that IL-10 is responsible for the 
suppressed IFNy response observed after BCG vaccination in this group (measured at 9 
months of age), possibly by the induction of adaptive (IL-10 producing) Tregs rather than 
naturally occurring FOXP3+ Tregs. Black et al previously found in Malawi, higher IFNy 
responses to PPDs from the MAIS NTM complex prior to BCG vaccination related to 
lower IFNy responses to PPD-T 1 year after immunisation (Black, Dockrell et al. 2001). In 
our study, responses to PPD at 9 months of age did not reveal any correlation to their PPD 
responses prior to BCG vaccination. This included regulatory responses 
(CD4+CD25+FOXP3+ or IL-10 production) that were hypothesised to be involved in 
attenuation of BCG immunogenicity. When comparing geographical locations with 
different BCG protection rates it was suggested that the immunogenicity o f BCG is related 
to the difference between PPD responses pre- and post- BCG vaccination, rather than the 
cross sectional response in isolation (Black, Weir et al. 2002; Weir, Black et al. 2006). Our 
study supported this by comparing the responses to PPD pre- and post- BCG vaccination in 
each group. This difference was less in the delayed vaccine group compared to BCG 
vaccination at birth suggesting the delayed vaccine group may be less protected. The 
strains of local NTM appear to be important in their effect on BCG responses in that those 
closely related are more likely to elicit cross-reactive immunity. Interestingly the most 
common strains of NTM in The Gambia are M. intracellulare and M. avium (Corrah 
1994), and animal studies have shown that exposure to M. avium can limit BCG growth 
and reduce protection levels (Brandt, Feino Cunha et al. 2002; Buddie, Wards et al. 2002; 
de Lisle, Wards et al. 2005).
230
8.1.2 In utero exposure to NTM
It is unknown if mycobacterial antigens can cross the placental barrier or are 
transferred to the infant through the breast milk, but there are several studies that elude to 
this being the case as discussed in Chapter 6 . If  the foetus is exposed to NTM in utero it is 
plausible that responses might even effect BCG vaccination at birth as well as at 4lA 
months of age. There are no published reports of a comparison o f cord blood 
mycobacterial reactivity between high NTM and low NTM geographical settings, but 
preliminary data show slightly higher PPD responses in the cord blood of Malawi neonates 
compared to UK neonates (Hazel Dockrell, personal communication) although still low 
suggesting that in utero exposure might play a role and supports the PPD responses that 
were observed in our results.
8.1.3 Role o f  cytokines in BCG immunogenicity
The Thl cytokine, IFNy is thought to be key in conferring protective 
mycobacterial responses. The opportunity to study cytokine responses in BCG vaccinated 
and naive children was possible at 4'A months o f age. At this age several cytokines were 
examined after mycobacterial stimulation including IFNy, IL-10, IL-13, IL-6 , IL-17 and 
IL-7. The results indicate, as many recent studies have also shown, that although IFNy is 
important, it is possibly not sufficient to understand the mechanisms of BCG immunity and 
protection. It was confirmed that BCG vaccination in early life can induce a Thl response 
at 414 months of age but the results show that the sustained memory response to BCG 
vaccination is Th2 skewed, as often observed in early life to immune stimuli. It was 
interesting that the Th2 cytokine, IL-13 was induced by BCG vaccination when 
administered at either time point and, in contrast to IFNy; reactivity was sustained to 9 
months o f age in those vaccinated at birth. Other studies found similar IFNy results when 
delaying BCG to 2 or 4/4 months of age although, in contrast to our results, the Th2 (IL-4,
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IL-5 and IL-13) responses were low(Marchant, Goetghebuer et al. 1999; Ota, Vekemans et 
al. 2002). IL-4 is often measured as a Th2 cytokine, but IL-4 protein and mRNA levels in 
peripheral blood are usually low (in house communication). IL-13, another Th2 cytokine, 
utilises the same IL-4Ra receptor suggesting that their function is related. Rook et al 
propose that BCG fails in people that have high pre-existing levels of IL-4 because it 
cannot downregulate the subversive Th2 component, and can only boost the Thl response 
which may not be sufficient for protection (Rook 2007). In support of this theory, 
therapeutic vaccine trials in mice that suppress the Th2 response have shown promise 
whereas BCG was therapeutically inactive (Lowrie, Tascon et al. 1999; Hemandez-Pando, 
Jeyanathan et al. 2000). It is possible that the ratio of Thl to Th2 responses is more 
important than absolute concentrations. Increased IFNy: IL-5 ratios after BCG vaccination 
correlated with cytotoxic activity, suggesting that it may be associated with the protective 
activity of BCG (Hussey, Watkins et al. 2002).
Recently IL-17 production from T cells (Thl 7) has been shown to be involved in 
the immune response to mycobacteria, although studies are conflicting as to its role in 
protection against TB. Human TB patients have reduced levels of IL-17 (Scriba, Kalsdorf 
et al. 2008; Sutherland, Adetifa et al. 2009), but mouse studies have shown increased IL-17 
levels in IFNy knockout mice that do not confer protection (Cruz, Khader et al. 2006). 
However IL-17 together with IFNy may be important in the secondary response to TB, as 
suggested in mice that were protected by a peptide based TB vaccine (Khader, Bell et al. 
2007). Our results showed an approximate 10-fold increase in IL-17 production in the 
BCG vaccinated group at 4/4 months o f age, but the levels were low (BCG vaccinated 
median value 14.55, unvaccinated median 1.53). It is not clear what concentration of IL-17 
is needed to confer protection, but it is feasible that such levels are adequate. We did not 
study IL-17 levels at 9 months of age, but it would be interesting to study the effect of 
delaying the BCG vaccine on IL-17 production.
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At 4 V2 months IL- 6  was induced in response to PPD in both groups; BCG 
vaccinated group byl38-fold and unvaccinated group by 10-fold. IL- 6  production suggests 
a role for innate responses in BCG immunogenicity, as may be expected. IL- 6  is dependent 
on stimulation via TLR2 and TLR4 which are common receptors that recognise bacteria, 
including BCG (Jang, Uematsu et al. 2004). It can play a role in T cell activation and 
suppression of regulatory T cells (Pasare and Medzhitov 2003). However production of IL- 
6  from M.tb infected macrophages from mice can inhibit the IFNy responsiveness of 
neighbouring macrophages by selective inhibition o f a subset o f IFNy responsive genes 
(Nagabhushanam, Solache et al. 2003). In this study IFNy itself was unaffected, but IL- 6  
was described to have Th2 polarising effects (Jones 2005). These results are of direct 
relevance to the results of our study in which both IFNy and IL- 6  were upregulated after 
BCG vaccination. In humans increased levels of IL- 6  have been found in the plasma o f TB 
patients, suggesting that induction of IL- 6  is another pathway that M.tb uses to evade the 
immune response. In the case of BCG vaccination IL- 6  induction may be linked to reduced 
protective responses which would not be evident when examining IFNy responses alone. In 
this context it should be noted that the birth process can initiate an acute phase reaction in 
the newborn child including upregulation of IL- 6  (Marchini, Berggren et al. 2000). 
Furthermore, the human newborn has a higher IL-6 /TNFa ratio compared to adults 
(Angelone, Wessels et al. 2006). It is possible that these high levels of IL- 6  initiated at 
birth contribute to that induced by BCG vaccination.
IL-10 has a major immunomodulatory role in that the absence of IL-10 is 
associated with immunopathology and autoimmune diseases, while the enhancement of IL- 
10 reactivity can inhibit the immune response to pathogens (reviewed in (O'Garra, Vieira et 
al. 2004)). The effects o f IL-10 in regulating infection are often due to reduction in TNFa 
which reduces several secondary inflammatory mediators such as chemokines and 
prostaglandins, and enhances anti-inflammatory molecules. IL-10 can also inhibit antigen
presentation and downregulation of TLR4 (as reviewed in (Moore, de Waal Malefyt et al.
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2001)). In addition the reciprocal relationship between IFNy and IL-10 seems critical in the 
clearance of M.tb. This was shown in a prospective case contact study in Pakistan where 
contacts that developed disease 12 months after exposure had lower IFNy/ IL-10 ratios 
compared to contacts that did not develop disease (Hussain, Talat et al. 2007). The IL-10 
may act via inhibition of antigen presenting cell (APC) activation, therefore reducing the 
Thl pro-inflammatory effects however direct inhibitory effects on T cells have also been 
demonstrated (O'Garra, Vieira et al. 2004). Our results indicate that it may have a 
prominent role in controlling the strength of the immune response to vaccination and in 
particular, help regulate tuberculin skin test induration. However it is also evident that IL- 
10 can be produced from many different cell types including T cells, (CD4+ and CD8 +, 
Th2, Trl, Thl, Thl7), macrophages, dendritic cells, B cells, some granulocytes and non- 
immune cells (keratinocytes, epithelial cells and tumour cells) making it difficult to 
understand the specific role IL-10 plays in controlling infection. The source of IL-10 may 
also differ according to age. In our study it was found that CD8 + T cells produce more IL- 
10 than CD4+ T cells at 9 months of age in response to SEB but the reverse was true in 
cord blood. The IL-10 producing T cells were not assessed for suppressive activity but it is 
possible that the CD4+ IL-10 producers represent Trl cells. The CD8 + IL-10 producing T 
cells could relate to the original suppressor cells observed in the 1980s (Jiang and Chess 
2004).
It was interesting to find that in cord blood, basal IL-10 production (from the
supernatants of unstimulated cultures) was greater than both IFNy and IL-13, but remained
similar when compared to the later time points. This is in contrast to basal levels o f IFNy
and IL-13 that were both increased significantly at 414- and 9- months o f age compared to
at birth suggesting IL-10 production at birth is robust. Interestingly lymphocyte production
of IL-10 is low at birth, particularly from CD8 + T cells, suggesting that the source of IL-10
is non-T cell derived at this time. This agrees with data from South African neonates where
IL-10 production in cord blood in response to BCG was produced predominantly by
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monocytes and the IFNy was produced by NK cells (Watkins, Semple et al. 2008). It is 
possible that differences in the cytokine milieu influence the polarisation o f the T cell 
responses at different ages. IL-10 was induced in the supernatants of EC stimulated 
cultures in unvaccinated but not vaccinated children at 4% months. In fact down regulation 
of IL-10 was only seen in the BCG vaccinated group suggesting BCG vaccination may 
override the IL-10 regulatory effects to mycobacterial exposure.
Our lack of BCG-induced IL-10 did conflict with many other BCG vaccination 
studies in both animals and humans that found BCG induced a strong IL-10 response 
(Gagliardi, Teloni et al. 2005; Sendide, Deghmane et al. 2005; Soares, Scriba et al. 2008). 
However a lack of unvaccinated controls in many human studies means it is not possible to 
attribute all IL-10 induction to BCG vaccination where some may be due to NTM exposure 
prior to vaccination (Soares, Scriba et al. 2008). If NTM induces IL-10, this could suppress 
antigen presentation and TLR4 and thus reduce the response to subsequent BCG 
vaccination.
Since the correlates of BCG protection are still unknown, we cannot say whether 
the cytokine findings in this study are related to protection, but it is becoming more evident 
that IFNy may not be the only cytokine responsible for protection. With the advancement 
of new technologies, a cytokine profile or signature consisting of a combination of 
cytokines is more likely to be used as a biomarker to predict protection and susceptibility 
to M.tb.
8.1.4 Tuberculin skin test (TST)
In the vaccinated group, 50% of the children did not respond to the TST at 4 '/2  
months of age. These TST anergic children produced less IFNy in response to PPD and 
showed a trend for higher levels of IL-10 compared to the TST responders. It is possible 
that these children had a stronger response earlier and that it had already waned by 4/4
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months of age. Adult studies have shown that IFNy responses peak at 4 weeks post BCG 
vaccination and decline by 12 weeks (Nabeshima, Murata et al. 2005). Interestingly IL-10 
inversely correlated with TST induration, whereas IFNy bore no correlation. We propose 
that IFNy initiates the skin test, but IL-10 controls the induration possibly via production 
from macrophages that home to the site of challenge. Our study used 10 mm as a ‘cut o ff 
as indicating potential M.tb infection, however 50% of TST responders were >10 mm at 
4% months of age and only 2 of these children were suspected as being exposed to TB. We 
therefore suggest that a higher ‘cut o ff is required in early life for BCG vaccinated 
children when being used as a diagnostic indicator of potential M.tb infection. This is in 
agreement with the study by Chan et al that suggested using TST ‘cut offs’ for ages 0 —1, 
2 -  3, 4 -  5 and 6 - 7  years of respectively 21, 18, 13, and 10 mm respectively (Chan, 
Chang et al. 2008). Use of these values in our study would suggest that no one was 
infected with M.tb, which is the likely scenario. A ‘cut o ff for the skin test at 20 months o f 
age, of 18 mm would, also indicate that only one subject was M.tb infected, which in fact 
was later confirmed to be the case.
It is possible that peaks of TST induration predict the type of exposure where 5 — 
9 mm indicates exposure to NTM, 10 — 12 mm predicts BCG vaccination and > 13  mm 
indicates exposure to M.tb, however this would be determined by the age of the subject and 
the timing of the BCG vaccination.
8.1.5 Non-specific effects o f  BCG
The changes in the timing of BCG vaccination in our study had no effect on cross 
sectional ex vivo, unstimulated and SEB stimulated cell populations at each time point. 
This agrees with others who analysed circulating immune cell subsets in infants pre- and 7 
months post- infant vaccinations (Berrington, Barge et al. 2005).
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It was not clear from our results if there are gender differences in BCG 
immunogenicity. There was a trend for males to have greater pro-inflammatory responses 
to BCG, but this finding was only statistically significant at 4!/2 months o f age in the BCG 
vaccinated group in response to the BCG vaccine in vitro.
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8.2 LIMITATIONS OF THE STUDY
The project was designed as a prospective observational study assessing BCG 
immunogenicity in the context of pre-sensitisation from NTM. Although the results have 
shown many interesting concepts, there were certain financial, technical, time, and 
personnel limitations that are addressed below.
Blood collection
As with most infant studies a restriction on blood collection of 1 mTV kg weight is 
generally thought ethically acceptable which meant that only 5 mL (or less in some cases) 
of venous blood was collected from the children, thus limiting the numbers of experiments 
that could be performed. The timing of the follow up bleeds was determined by what was 
considered an acceptable frequency that a child should be bled. This was discussed with 
the community fieldworkers and the ethics committee and chosen accordingly. It is 
possible that measuring responses prior to 4'A months o f age would have provided more or 
different information about immune responses to BCG in early life.
Treg definition
The assays were designed when the only available flow cytometer was the 
FACSCalibur which detects only four fluorochromes thus limiting the number o f cell 
markers that could be measured. This limited our definition of Tregs according to surface 
and intracellular markers. At the commencement of the study the most appropriate Treg 
definition was CD4+CD25+FOXP3+. Recently the addition of low CD 127 expression has 
been proposed as a more precise phenotype for Tregs. It was not possible to measure 
certain antibodies in the same assay due to differences in staining protocols; for instance 
the anti-FOXP3 antibody protocol from e-Bioscience had a tendency to increase 
background staining of other intracellular markers (including, Ki-67, IL-10 and TGFp) if 
used in the same assay.
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Although FOXP3 has been used as a marker of Tregs, it is still not apparent if all 
FOXP3+ T cells are functionally suppressive. Assays involving the separation o f T cell 
subsets and culturing with and without Tregs require large volumes of blood, and was not 
possible in our study. Furthermore it was not possible to purify FOXP3+ cells without a 
phenotypic cell sorter which is not available in The Gambia. The use of Ki-67 as a marker 
of proliferation was assessed but it was not possible to add this antibody to the FOXP3 
panel for the reasons described above. The limitation of this marker is that it only indicates 
cell cycle division at the end of the culture period.
With the recent purchase of the CyAn (Dako, CA, US) it is now possible to stain 
for 9 different markers within each panel. This would have allowed us to identify other 
populations of cells that might be involved in BCG immunogenicity, such as macrophages, 
NK cells and dendritic cells.
Efficacy o f BCG vaccination
As with all human studies in the field of TB, without the identification of 
correlates of protection, observed immune responses can only indicate how the immune 
system is reacting to a stimulus. Although we found differences in responses to the BCG 
vaccine administered at different times, the relationship to protection against TB could not 
be determined.
RNA expression profiles
The study design described in the Materials and Methods mentioned analysis of 
RNA expression profiles from 100 pL of the 5 day cultures. Extraction of the RNA from 
about 50% of these cultured samples yielded low concentrations and in some cases RNA of 
poor quality as assessed by the Agilent 2100 Bioanalyser (Agilent, Santa Clara, CA, US) 
by our collaborator, Dr Roger Buxton at National Institute for Medical Research, London,
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UK. It was thought that this may be due to the small quantity of samples or the presence of 
haemoglobin in the samples degrading the RNA during the collection and/or thawing of 
the samples. For this reason, microarray or real time PCR analysis was not performed on 
these samples and therefore not presented in this thesis.
Genetic heterogeneity
The heterogeneity of the responses illustrates that although there may be an 
overall pattern of reactivity observed, not all individuals behave in a similar way 
(illustrated in Chapter 5, Table 5.4). IL-10 responses were particularly heterogeneous in 
our study. Natural variation in The Gambian population has been observed in responses to 
several mycobacterial antigens 2 months of age after BCG vaccination at birth (Finan, Ota 
et al. 2008). This becomes increasingly important when analysing responses using small 
numbers of subjects, as the statistics may miss important findings. Furthermore, those 
individuals who behave differently may be of particular interest.
Time constraints
Finally, one big limitation of this type of work is the time constraints of 
performing very labour intensive immunological assays on fresh samples every day. As a 
result the number of samples collected each day was limited and sample collection took 24 
months to complete.
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8.3 FUTURE STUDIES
This study has generated a number of new ideas that warrant further study. 
Furthermore, a number of the limitations discussed above could be overcome in future 
studies due to newer technology and additional published literature in this area. Despite 
this few immunological studies have examined the development of the immune system in 
early life and therefore this is an exciting field with much more work to be done.
8.3.1 Effect o f  BCG on responses to other E P I vaccines
Plasma samples were collected at each time point from the study participants. 
Antibody responses to other vaccines delivered as part of the EPI schedule could provide 
data on the effect delaying BCG has on responses to these vaccines. BCG has previously 
been shown to increase the antibody response to hepatitis B vaccine (HBV) and oral polio 
vaccine (OPV), dependent on the timing of the vaccines; delaying the BCG vaccine to 2 
months of age reduced the HBV antibody enhancement but increased the OPV antibody 
production (Ota, Vekemans et al. 2002). In addition non-specific effects of BCG 
administered at the same time or prior to OPV were observed in Guinea Bissau (Aaby et 
al, unpublished). Financial and logistical constraints have delayed this work but it is 
expected that it will be completed within the next year.
8.3.2 Role o f  IL-10 in mycobacterial immunity
The contribution of IL-10 to immune responses in early life is not clear but our 
studies suggest it may play an important role in the control of pro-inflammatory responses. 
It is therefore important to establish what cells are involved in producing the observed IL- 
10 at the different time points. Access to 9 colour staining would allow us to assess for ICS 
IL-10 production among monocytes, macrophages, dendritic cells and T cells in one 
sample. Functional assays could also be carried out using neutralising anti-IL-10 antibodies
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and examining in vitro effects to understand the underlying mechanisms by which IL-10 
exhibits its immunoregulatory role.
8.3.3 Novel CD4CD8 double positive T cell population
While analysing the data two populations of CD4CD8 double positive (DP) T cells 
were evident both ex vivo and after 5 days of culture. Ex vivo the DP population was 
mainly CD4hlCD8int and consisted of approximately 1 -  2% of lymphocytes (Figure 8.1 A), 
whereas after 5 days o f SEB stimulated culture it was predominantly CD4mtCD8hl (Figure 
8.IB) among approximately 2 - 4% of the lymphocyte population. This DP population 
appeared to be highly proliferative after stimulation with SEB (27 — 37% of lymphocytes at 
all ages) and a considerable proportion of these cells expressed FOXP3 (median 18 - 25% 
at all ages) and IL-10 (median -7 - 3.75%). This population is rare in human peripheral 
blood due to the efficient selection process in the thymus whereby the DP population loses 
either CD4 or CD8 expression before entering the periphery (Blue, Daley et al. 1985; Blue, 
Daley et al. 1986; Patel, Wacholtz et al. 1989; Kay, Bone et al. 1990; Sala, Tonutti et al. 
1993). However this population is abundant in pigs (in the adult pig 60% of T cells are DP) 
where they mainly express IL-10 (Hernandez, Garfias et al. 2001). These DP cells have 
been found in individuals with chronic viral infections (Macchi, Graziani et al. 1993) 
including HIV (Lusso, De Maria et al. 1991) and malignancies (Mizuki, Tagawa et al. 
1998). An extrathymically-derived DP ySTCR cell population has also been found to be 
associated with intestinal epithelium (reviewed in (Kagnoff 1998)). The proportion o f 
y8TCR cells that are DP in humans is not known. A recent study has shown T cell clones 
developed from cord blood in an IL-2-independent manner and co-express CD25 and 
FOXP3, suggesting that they are another subset of regulatory T cells (Nakamura, Suzuki et 
al. 2007). DP Tregs have been postulated in the MHC class II KO mouse, whereby 
CD4+CD8aP+CD25+ a(3 T cells attenuate CD4+ T cell-induced transfer colitis (Krajina, 
Leithauser et al. 2004). Further studies to characterise this population in our setting are
proposed, including identifying if these are more common in young children and related to 
recent thymic emigrants (RTE).
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Figure 8.1: A representative plot illustrating the CD4CD8 DP T cell populations. The
proportion o f lymphocytes that possess the phenotype CD4"l,CD8fu ex vivo (A) and 
CD41"CD8"" and after 5 days o f culture with SEB (B) showing the percentage o f  these DP 
cells that express FOXP3 (left), IL-10 (middle) and Ki-67 (left).
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8.3.4 Innate immunity in infants
Modifying the innate response may increase the strength of the longer lasting, more 
specific adaptive memory response and vaccination is no exception to this. Microbial 
products activate the host cells via TLR present on cells of the gut, respiratory system and 
in blood. When triggered by the microbial product, TLR activation initiates cell 
maturation, translocation of NF-kB, transcription of multiple genes and production of 
cytokines including IFNy and TNFa which are associated with a strong Thl inflammatory 
response (Barton and Medzhitov 2003). Indeed a number of studies show that 
polymorphisms in human TLRs and their adaptor molecules cause increased susceptibility 
to a broad range of bacterial, viral, fungal and protozoan pathogens (Misch and Hawn 
2008).
Despite normal basal expression of TLR and associated signalling intermediates, 
neonatal responses to a range of TLR agonists are characterised by impaired production of 
pro-inflammatory cytokines, such as TNFa (Levy, Zarember et al. 2004; Angelone, 
Wessels et al. 2006). Studies of newborns based in the US have shown very poor reactivity 
to all TLR agonists except for TLR8, raising the possibility that TLR8 might be suitable 
for development as a vaccine adjuvant in this age group (Levy, Zarember et al. 2004; Levy, 
Suter et al. 2006). This is thought to be due to the distinct neonatal adenosine system, 
including relatively high adenosine concentrations in neonatal blood plasma which also 
leads to preserved IL-6 production (Levy, Coughlin et al. 2006). However there are no 
such studies in African children where improved vaccine schedules are urgently required, 
and who may also give a different response profile to a Western population.
In collaboration with Dr Ofer Levy, Harvard Medical School we proposed to carry 
out a cross-sectional prospective study that will examine cytokine immune responses to a 
panel of TLR agonists in different age groups; cord blood, 1-, 2-, 3-, 4-, 6-, 9- and 12- 
months of age, using the CBA multiplex system. We hypothesise that while the responses
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to TLR agonists are limited at birth, increased reactivity to a broader range of agonists will 
occur within the first few months of life in this setting of high exposure to pathogens. This 
work will provide vital information for those developing TLR agonists as adjuvants for 
infant vaccines.
8.4 CONCLUDING REMARKS
The final conclusions of this study support the original hypothesis that delaying 
BCG vaccination to 4/4 months o f age reduced the post-vaccination pro-inflammatory Thl 
response, which may in turn cause reduced immunogenicity o f the vaccine. It was 
hypothesised that Tregs are responsible for the attenuated response. Our results suggest 
that while FOXP3+ naturally occurring Tregs may not be involved, IL-10-producing Tregs 
induced in response to NTM exposure may be responsible for the reduced IFNy response 
after vaccination. It was not determined if this was from Trl regulatory T cells, or other IL- 
10 producing T cell subsets.
BCG is administered at birth in countries with a high risk of TB, however there is 
no immunological evidence to suggest that this provides better protection against TB 
compared to immunising later in infancy. Our study could not determine the effect of 
delaying the BCG vaccination on protection against TB, but does provide immunological 
evidence that supports vaccinating at birth, since it induced a stronger Thl IFNy 
production 4/4 months post vaccination compared to delaying the vaccine. However 
responses by 9 months of age were comparable in the two vaccine groups suggesting that 
long term protection may not be affected by delaying the vaccine.
This study therefore provides valuable insights into BCG immunogenicity in early 
life and the effect of delaying the vaccine. This is the most comprehensive analysis to date 
of how this relates to regulatory T cell activity and interestingly to Thl 7 responses. It has 
provided new information into the mechanisms behind the control of TST reactivity, and
245
concurs with the suggestion o f others that ‘cut o ff values need to be higher in these young 
age groups. It has opened up a number of questions and future avenues of research. In 
particular, the role of CD4CD8 DP regulatory T cells in early life, and the nature of the IL- 
10 producing Tregs that seems to play a regulatory role in mycobacterial immunity in this 
age group. This clearly demonstrates the importance of studying the immune system in this 
young age group in whom the majority of vaccines are administered.
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APPENDIX I: Study Information Sheet for BCG Study
Infant BCG study SCC1009 
Study information sheet
We would like to start by thanking you for helping us with the study that you are already 
enrolled on. However, we would like to ask you to accept a few changes in the sampling 
schedule that will help us to learn about one of the vaccines your baby receives called 
BCG.
We would like you to help us better our understanding of BCG vaccination and prevention 
of TB (tuberculosis). We would like to inform you about the study and how you can help 
us.
What are vaccinations?
Most children in The Gambia, including your child, receive vaccinations through the EPI 
programme. These vaccines protect them from diseases that may be dangerous when they 
are young but also later in life. Sometimes our body cannot control an infection on its own 
and that is why vaccinations are administered. Vaccinations work by teaching cells to 
recognise and fight an infection the next time you come into contact with it.
Why are we interested in BCG vaccination? BCG vaccine is the only vaccine against 
TB but it isn’t very effective in African countries therefore better vaccines are required. TB 
is a disease caused by bacteria that infects the lungs. TB is transmitted from person to 
person through breathing the air that is infected with these bacteria. One-person in every 
ten infected people progress to disease during their lifetime, leading to two million deaths a 
year worldwide. In the Gambia, BCG vaccination is given at birth and provides some 
protection against developing serious forms of TB, although in adults the protection may 
be very low. The reason for this is unknown but we think it may relate to how specific cells 
develop in the infant at an early age in The Gambia, and this is what we would like to 
investigate.
What is the aim of the study?
Our aim in this study is to understand the regulation of the immune responses to BCG early 
in life so that we can we can help develop a vaccine that will be able to protect children 
and adults in The Gambia.
Guidelines for BCG vaccination suggest it should be given within the first year of life to 
protect against childhood TB and therefore we would like to look at two different times of 
vaccination to see what effect vaccinating at different times has on immunity to TB. Your 
baby will either be part of group 1 and be vaccinated at birth, or part of group 2 and 
vaccinated at 4.5 months. This will enable us to study the development and regulation of 
TB immunity before or after BCG vaccination.
What happens if you agree to participate? Your participation in this study is entirely 
voluntary. We will continue to provide vaccines for your child according to the EPI 
programme and your child will receive free healthcare throughout the duration of the 
study.
We would like to collect 50ml of cord blood at birth and then we would like you to bring 
your baby back to the clinic twice more at 4.5-, and 9- months of age to collect a maximum 
of one teaspoon (5ml) of blood from them. At 4.5 months we would also like to perform a
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standard skin test on your child for their reaction to the vaccination. At all time points we 
would like to collect a urine sample to test for current CMV infection (a common infection 
that may influence your response to vaccines). If you have been told that your child is part 
of group 1 then they will be vaccinated with BCG at birth, and if they are part of group 2 
then they will be vaccinated at 4.5 months.
We will monitor your child on monthly visits as part of a routine health check and also for 
TB exposure.
Problems
If there is any reason to suspect your child has been exposed to TB then we will assess 
your child thoroughly before allowing your child to continue in the study.
BCG vaccination has been widely used for many years and therefore we do not expect any 
problems with BCG vaccination at either time points. One teaspoon of blood will be 
replaced in the body within a few hours and therefore the child will not be affected by 
collecting 1 teaspoon of blood. We guarantee this blood will not be used for anything other 
than this study without consent from you.
MRC Contacts. If you are unable to attend the clinic on the designated times then please 
call the Sukuta Health clinic or Katie Flanagan or Sarah Burl on the telephone numbers 
below and inform the person on duty. We will try and arrange for blood to be collected at 
an alternative time.
Please feel free to ask any questions you like at any time during the study. You may ask 
the field worker that visits you, or the MRC doctor in the health centre. You can also 
phone Dr Katie Flanagan or Ms Sarah Burl at MRC (4495442 ext.314 or 379 respectively).
Your rights. All information that you give us will be treated as confidential. You are free 
to leave the study at any time you wish, which will not affect your access to normal 
medical care. We will compensate your travel costs to the clinic during this study. If your 
child is part of group 2 that is scheduled to be BCG vaccinated at 4.5 months it is 
imperative that you bring your child back for BCG vaccination even if you do not 
wish to participate in the study any longer. It is also VERY IMPORTANT that you 
inform us of any travel plans before the 4.5 months to help us ensure your child is 
vaccinated with BCG.
This study (SCC1009) is funded by MRC and has been approved by the MRC and LSHTM 
Ethics Committees.
If you are willing to help us with this study, please sign the consent form.
Thank you very much.
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APPENDIX II: Consent Form for BCG Study 
Infant BCG study SCC1009 
CONSENT FORM
I have read the information sheet fully, and/or it has been read and explained to me and I 
have had a chance to ask questions about the study and had them answered.
I willingly and voluntarily agree to allow my child to participate in this study.
I understand my child is free to leave the study at any time, and that this will not affect our 
access to standard normal medical care.
Name of child..................................................................... (add)
Study number: SUK |__|__|__|__|
Project number: BCG |__|__|__|
Name of Parent or Guardian.....
Mother/Father/ Guardian
Signature or thumbprint Date |__|__|-|__|__|-[2|0|0|_
I , .............................................................................................................................. (name),
field worker, declare that I have explained the study to the above participant, that as far as I 
am aware they have understood well what participation entails and that they freely and 
willingly give their consent to participate.
Signature Date |__|__|-|__|__|-|2|0|0|__|
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APPENDIX III: Tuberculosis Information Sheet
Infant BCG study SCC1009 
What is TB?
Tuberculosis (TB) is a bacterial disease that most commonly infects the lungs and often 
causes cough. People who have TB but have not been treated release TB bacteria into the 
air when they cough. If you breathe in this infected air then you can catch TB.
What are the symptoms of TB?
There are many symptoms of TB and it is often difficult to diagnose. The main symptoms 
that you should look for are:
Cough > 3 weeks 
Fevers
Night sweats / cold clammy perspiration 
Anorexia / loss of appetite
Failure to gain weight (children) / progressive weight loss
What to do if you suspect that the child has been exposed to TB?
If you suspect that the child may have been exposed to someone with TB then contact the 
Sukuta clinic or your field worker as soon as possible so that a home visit can be arranged.
What to do if you suspect that the child has TB?
If your child has any of the above symptoms during the study period then please visit the 
Sukuta clinic for a medical assessment as soon as possible.
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APPENDIX IV: TB Exposure Questionnaire 
Infant BCG study SCC1009
TB EXPOSURE QUESTIONNAIRE
Name of child________________________________
Study no: SUK M i l l  
Project number: BCG | | |__|
Name of interviewee_______________________________________________ _
Status (mother / father / guardian / compound head / other)____________________
Name of Interviewer__________________________ Date | | |-|_|__ |-|2|0]0|_|
In the last 9 months have you, anyone in the household, or any close contacts with the mother / 
child been:
Diagnosed with TB? Yes [_| No |__ | DK [_|
Taking TB medication? Yes |__ | No | | DK |__|
Taking a long course of medication (>4 weeks)? Yes_[__ | No |_| DK |__ |
Had any of the following:
Cough > 3 weeks Yes |_| No |__ | DK j_|
Fevers Yes |__l No |_ l DK L I
Night sweats / cold clammy perspiration Yes |_| No |__| DK |_|
Anorexia / loss of appetite Yes |_| No | | DK |_|
Failure to gain weight (children) /
progressive weight loss Yes_|__| No | | DK | |
If yes to any of the above questions then the child has suspected exposure:
Suspected Exposure Yes | | No | |
Please give details of exposure below and refer child to Dr Adetifa or Dr Flanagan for further 
action:
Clinical Opinion
Name of clinician Pate I |__|-|__|__|-|2|0J0|__|
Comments & Action taken
Continue on study | | Remove from study |__|
If removed from study has the child received BCG?
If not, give BCG and confirm BCG given
Yes | | No L I
Date BCG given 
Given by_____
LU-I_LH2|0|0U
Signature:
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APPENDIX V: Information Sheet for TST Extension Study
TST extension study L2008.54 
Understanding the tuberculin skin test reactivity
We would like to start by thanking you for helping us with the BCG study that you 
enrolled in previously. We would like to ask your child to have a repeat skin test to 
compare the results to when the child was younger.
We would like to inform you about why we would like to repeat this test.
What is the Tuberculin Skin Test (TST)? A TST is a test to see if you have had contact 
with the bacteria that causes tuberculosis {Mycobacterium tuberculosis, M.tb). It is a small 
amount of liquid injected under the skin on the forearm. If your body reacts to the 
substance in the liquid it will produce a lump on the arm. The size of the lump will be 
measured by the fieldworkers at 48 - 72 hours after the test. A size greater than 5 mm in 
average is regarded as positive.
What does a positive test mean? The TST is used to diagnose TB infection but can be 
positive for the following reasons:
The child is ill with TB disease
The child has been exposed to TB
The child has been vaccinated with BCG
The child has been exposed to bacteria in the environment that look like M.tb but are 
harmless
Why are there so many reasons for a positive TST? The mycobacterium that causes 
tuberculosis is made up of many small parts, some of these parts are harmless and are 
contained in lots of other bacteria that are in the environment and are in the BCG vaccine. 
These harmless parts are contained in the substance that is used in the TST test and that is 
why your body will react to the skin test when you may not be infected with TB.
What happens if you agree to participate? Your child already had a TST at 4/4 months 
but we would like to repeat the test to see if the results are different when your child is 
older. We will ask you to come to the Sukuta clinic to receive the test and assess if there is 
any TB exposure to the child and then come back 48 - 72 hours later to measure the results. 
Your participation in this study is entirely voluntary.
We will continue to provide vaccines for your child according to the EPI programme and 
your child will continue to be part of the Sukuta cohort for the following year as stated in 
the original study SCC1009, regardless of whether you decide to participate in this 
extension to the study.
What is the aim of the study? To understand how the reactivity to the TST changes over 
time. We predict that by 20 months the influence of the BCG vaccine on the TST would 
have reduced and that the test will be more specific to TB exposure or bacteria in the 
environmental.
Problems. The tuberculin skin test has been widely used for many years and therefore we 
do not expect any problems with this test. If you have any questions you can come to the 
MRC clinic at Sukuta at any time to discuss any issue relating to the study with Dr Jane
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Adetifa and Ebrima Touray.
Your rights. All information that you give us will be treated as confidential. We will 
compensate your travel costs to the clinic during this study.
MRC Contacts. If  you are unable to attend the clinic on the designated time then please 
call the Sukuta Health clinic, MRC clinician Dr Jane Adetifa (7700328), fieldworker 
supervisor Ebrima Touray (7795635), study investigators Sarah Burl (4495442 ext 3021) 
or Katie Flanagan (4495442 ext 5003). Please feel free to ask any questions you like at any 
time during the study.
This extension to the SCC1009 BCG study has been approved by the MRC/ Gambian 
Government Ethics Committees.
If you are willing to help us with this study, please sign the consent form.
Thank you very much.
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APPENDIX VI: Consent Form for TST Extension Study
TST extension study L2008.54 
CONSENT FORM
The information sheet has been read to me and I understand it / 1 have read and understood 
the information sheet.
I understand what participation in the study means for me.
I understand that the information regarding me that is collected in the course of this study 
will remain confidential.
I understand that if I get sick during the 1 year following recruitment, I can go to the clinic 
where study staff are providing care, and be examined and treated for free.
I understand that I am free to take part in the study or refuse, and that I can withdraw from 
the study at any time, and without giving any reason. Deciding not to take part or to 
withdraw from the study will not affect the care that I am normally entitled to.
I have had a chance to ask questions and have them answered.
Signature or thumb print of parent/guardian:_________________________
This form has been read by / 1 have read the above t o ______________________
(write name of parent/guardian)
in a language that he/she understands. I believe that he/she has understood what I 
explained and that he/she has freely agreed for their child to take part in the study.
Signature of field w o r k e r :________________________________
Name of field worker: _______________________________
Date: | _ | _ J  / |___ | | / | _ J _ J _ _ | _ |
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APPENDIX VII: Defining Tregs
Regulatory T cells have received a great deal of attention recently, however the 
definitive phenotype of Tregs remains controversial, particularly since several markers are 
also present on activated T cells. The use o f FOXP3 expression has improved the 
classification o f Tregs, however not all human FOXP3~ T cells are Tregs. CD4CD25~ T 
cells were shown to be Tregs in mice, but in humans only the CD4 CD25hl population have 
regulatory activity (Baecher-Allan, Brown et al. 2003). Unfortunately this population is 
difficult to gate accurately because there is no clear distinction between CD25int and 
CD25hl populations, and gating is thus highly subjective. With the advent of FOXP3 as a 
marker o f a Treg cell, a number of different phenotypic subsets have been used in the 
literature to define Tregs including FOXP3+ T cells as a percentage of all lymphocytes / 
CD4+ / CD4+CD25+ or CD8+ T cells; or CD25+FOXP3+ as a proportion o f  CD4+ T cells. 
The further use o f CD127low has recently been added to refine Treg definition, but was not 
used in this thesis.
Our study defined Tregs as the proportion of CD4~ T cells that were CD25~ and 
FOXP3 . We further analysed for Tregs using a number of different published definitions 
in order to see whether this would change our results. The variability between Tregs using 
our definition, and FOXP3+, CD4 (FOXP3 ) and CD4~CD25"(FOXP3) Tregs was low 
(Figure 1A -  C). Indeed, the most divergent subset was the CD 4CD 25hlFOXP3~ 
population which is probably due to the gating difficulties described above. CD25hl T cells 
also correlated poorly with the other subsets, and showed the greatest within group 
variation at all time points (Figure 2A -  C). This suggests that using the CD25hl definition 
is likely to give different results to most of the other definitions, and it was not used in this 
study.
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Figure 1: Comparisons between different subsets o f  Tregs defined by FOXP3 expression 
at birth (A), 4 V2- (B) and 9- months o f age (C).
1 %FOXP3 expressing lymphocytes (FOXP3),
2 %FOXP3 expressing CD4+ T cells (CD4 FOXP3+),
3 % CD25+FOXP3+ expressing CD4+ T cells (CD4+(CD25 FOXP3')) *
4 %FOXP3 expressing CD4+CD25+ T cells (CD4+CD25+(FOXP3+)),
5 % FOXP3 expressing CD4+CD25hi T cells (CD4+CD25hi(FOXP3)),
*population used in our study
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ELymphocytes CD4 CD4CD25+ CD4CD25hi
(FOXP34) (FOXP3) (FOXP3+) (FOXP3+)
CD4(FOXP3+) r = 0.8052
p < 0.0001
CD4CD25+(FOXP3+) r = 0.2889
p = 0.0081
r = 0.6045
p < 0.0001
CD4CD25hi(FOXP3+) r = 0.2180 r = 0.1503 r = 0.3447
p = 0.8449 P = 0.1749 p = 0.0014
CD4(CD25FOXP3+) r = 0.7727 r = 0.9173 r = 0.5206 r = 0.2113
p < 0.0001 p < 0.0001 p < 0.0001 p = 0.0599
Figure 2: The relationship between the Treg phenotype used in this thesis 
(CD4^(CD25 FOXP3 )) and other published Treg phenotypes. Results shown fo r  the 9 
month time point in response to SEB stimulation. FOXP3+ (A), CD4+(FOXP3+) (B), 
CD4+CD25+(FOXP3+) (C) and CD4CD25hi(FOXP3+) (D).Correlations were analysed 
using Spearmans Correlation coefficient at 5% significance. Table o f correlation (r) and p  
values corresponding to the associations between the different Treg subsets, n = 83
In conclusion, it is clear that the Treg definition used in our study 
(CD4+(CD25+FOXP3+)) correlates well with those definitions based on FOXP3 
expression, but the use of CD25hl as a marker of Tregs is not appropriate due to high inter­
individual variability and a lack of correlation between other subsets.
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